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ABSTRACT OF DISSERTATION

THE METABOLOMIC EFFECTS OF METFORMIN ON COLON CANCER
Metformin is an oral biguanide that is prescribed to over 120 million people
worldwide for the treatment of conditions including type II diabetes mellitus,
polycystic ovarian syndrome, and gestational diabetes. This hypoglycemic agent
is rapidly emerging as a potential cost-effective anti-oncogenic agent. Over the
past decade multiple epidemiologic studies have consistently associated
metformin with decreased cancer incidence and cancer-related mortality. More
recently numerous preclinical and clinical studies have demonstrated anti-cancer
effects of metformin, leading to the proposal of numerous clinical trials to better
understand this drug and its mechanisms of action.
Previously experts believed metformin primarily targeted AMP-activated
protein kinase (AMPK), a crucial cellular energy sensor, but more recent data
suggest the impact of metformin has a multi-faceted impact on various metabolic
pathways. Current understanding of the potential anti-cancer effects of metformin
raises the intriguing possibility of a duality of action, suggesting that metformin
has the ability to act directly on a tumor while also indirectly lowering insulin
levels in the host. This complexity creates challenges in determining the true
impact of this drug in the clinical and translational setting.
Despite an increase in investment, only one in every 10 new molecular
therapeutic agents that enters clinical development receives approval from the
Food and Drug Administration. This warrants a demand for better designed
clinical trials with more elegant and robust analyses of relevant primary endpoints
to determine which targeted therapies are cost-effective, and more importantly
which agents will provide the best care for our patients. Stable isotope resolved
metabolomics (SIRM) is a powerful tool capable of robust analyses that can
address these questions. Using these capabilities we have determined that
metformin does significantly impact cellular metabolism by shifting colon cancer
cells into glycolytic overdrive, ultimately leading to decreased proliferation and
protein synthesis in cancer cells. This study contributes to the literature and
implores that we continue to elucidate the full potential of this drug, especially in
the setting of personalized medicine where select patients may receive maximal
benefit from this agent.
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CHAPTER ONE: INTRODUCTION
1.1 Colon Cancer
Colon and rectal cancers are the second leading cause of cancer related
death in the United States with an estimated 150,000 new diagnoses to occur in
2015. Colon cancer is an insidious, ruthless process that takes advantage of our
own genetic and cellular pathways and wreaks havoc to create an environment
conducive to tumor growth and development. Colonic mucosa is deemed to be at
risk for the development of malignancy in the setting of genetic instability which
sets the stage for a precursor lesion (1). Cell proliferation increases due to
altered metabolism, decreased apoptosis, and unlimited replication which leads
to a cancer in situ and more developed adenomas. Later activated protease
systems, immune modulation, and angiogenesis or blood vessel development to
supply these tumors, leads to all the requirements for the development of an
invasive disease and ultimately a metastatic cancer (2). Risk factors for the
development of colon cancer include genetic predisposition, dietary factors such
as a diet high in red meat and animal fat, low-fiber diets, and low overall intake of
fruits and vegetables. Obesity and lifestyle choices such as cigarette smoking,
alcohol consumption, and sedentary habits have also been associated with
increased risk for colorectal cancer (3-5).
1.1.2 Development and Diagnosis of Colon Cancer
Initial symptoms of colon cancer frequently include abdominal and or
pelvic pain, blood in the stools, unintentional weight loss, and eventually sepsis if
obstruction and/or perforation of the intestine occur (6). Diagnosis of is often
made prior to the development of severe symptoms based on screening and
surveillance, especially in high risk populations. It is estimated that full
implementation of screening guidelines could cut mortality rate from colorectal
cancer in the United States by an estimated additional 50% (7). Other studies
such as fecal occult blood testing, carcinogenic embryogenic antigen (CEA), and
tissue biopsy aid in the initial diagnosis of colon cancer. Patients may also be
evaluated for the presence of metastatic disease, or spread of cancer to distant
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organ sites, using computer tomography (CT) imaging of the chest, abdomen,
and pelvis, and positron emission tomography (PET) scanning to assess for
distant hypermetabolic disease processes.
1.1.3 Staging and Current Treatments of Colon Cancer
Five year survival rates for colon cancer are largely dependent on the
stage of disease at the time of diagnosis and treatment. Stages of colon cancer
are classified as Stage I-IV. These stages are developed based on the disease
burden present in the primary tumor (T), lymph nodes (N), and metastasis (M),
which is referred to as TNM staging (8). Stage I disease is defined as T1 (tumor
invades submucosa) or T2 (tumor invades muscularis propria), without evidence
of nodal or metastatic disease. Stage II is defined as tumors described as T3,
(Stage IIA- tumor extends through the muscularis propria), T4a (Stage IIB- tumor
penetrates to the surface of the visceral peritoneum), or T4b (Stage IIC-tumor
directly invades or is adherent to local organs or structures), but still does not
have disease burden in the lymph nodes or at distant organ sites. Stage III is
defined as cancer that has spread to the lymph nodes and Stage IV describes
metastatic disease that has spread to a single distant organ (Stage IVA, M1a), or
is present in multiple different organs and/or the peritoneum (Stage IVB, M1b)
(9).
Patients diagnosed with Stage I disease have an average survival of over
90%, whereas patients diagnosed with Stage IV disease have a more dismal
prognosis with five year survival rates of around 5% (10). When considering the
prognosis for all-comers with this disease, which includes patients with Stages I,
II, III, and IV colon cancer, the five year survival rate is 65.9% with an estimated
50,000 deaths to occur this year (11). When broken down by stage at
presentation and year survival rates, the prognosis actually sounds much more
dismal. 39% of patients present with localized disease which has that higher 90%
survival rate previously mentioned, while 36% of present with regionally
progressive disease with a 5 year survival rate of 70.8%. With consideration to
patients with distal disease, which compromises 20% of this population, survival
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drops to 13.1% at five years (12).
Current recommendations for the treatment of colon cancer include
surgery and chemotherapy. Depending on the location and extent of the primary
tumor, surgical options include right colectomy, extended right colectomy, left
colectomy, sigmoid colectomy, and total abdominal colectomy with ileorectal
anastomosis (13). These procedures may be performed with a minimally invasive
approach (i.e. laparoscopic or robotic) in select patients (14, 15). Patients with
stage IV disease limited to the liver and/or lung may benefit from resection of
these distant metastatic tumors (16, 17). Patients with residual disease or
advanced stage colon cancers are treated with chemotherapy adjuvantly
(postoperative) which commonly include 5-fluorouracil (5-FU) with leucovorin or
capecitabine, either alone or in combination with oxaliplatin (18, 19). Advances in
targeted therapies and personalized medicine has prompted treatment with
biologic agents such as Bevacizumab (Avastin), Cetuximab (Erbitux) (20-22).
These agents are effective at reducing tumor burden and increasing both disease
free and overall survival, but frequently have significant side effects such as
severe nausea, vomiting, weight loss, and risk of infectious complications due to
immunosuppression.
Recent studies have suggested using off label agents in combination with
traditional chemotherapy and biologic agents (23, 24). Metformin, which is an
oral hypoglycemic agent traditionally used to treated Type II diabetes mellitus,
offers an alternative that will allow decrease doses, and therefore toxicity, of
aggressive traditional chemotherapy. We also speculate using this drug during
the pre-surgical and immediate post-surgical interval when no other therapeutic
intervention such as chemotherapy can safely be offered could potentially lead to
decreased micro-metastatic disease which results in later recurrences.
Furthermore, patients who cannot tolerate aggressive chemotherapy due to age
or other medical conditions could significantly benefit from this safe and less toxic
alternative.

3

1.2 The History and Development of Metformin
Metformin was first described in the scientific literature in 1919, by Emil
Werner and James Bell, as a product in the synthesis of N,N-dimethylguanidine,
however it had been in use since medieval times in Europe (1). In the 17th
century a English botanist determined the extracts of Galega officinalis, also
known as French lilac or goat’s rue, could be used to treat polyurea (i.e.
increased frequency of urination) associated with the development of diabetes
mellitus (2). The active ingredient in the French lilac that produced the lowering of
blood glucose was shown to be galegine or isoamylene guanidine, but
guanidines alone are too toxic for routine use at high doses (3). The
development of biguanides (two linked guanidine rings) were effective and safer
than traditional botanicals. Metformin and other oral biguanides such as
phenformin and buformin gained popularity in the early 1920’s as effect oral
hypoglycemics used to treat diabetes mellitus. Within a decade the use of these
agents was discouraged due to ready availability of subcutaneous insulin which
was fast- acting and easier to titrate, as well as the increased risk of renal and/or
liver failure with increasing doses of biguanides (4-7). Renewed interest in oral
biguanides emerged in the 1950’s when scientists began studying the
pharmacokinetic effects of the drug and determined previous studies were flawed
based on a misunderstanding of the mechanisms and dosing of biguanides (1).
Unfortunately as a number of lactic acidosis and cardiac related deaths
increased, phenformin was removed from the market in the United States (US) in
1977. Despite concerns in the US, endocrinologists in France and Scotland felt
comfortable continuing to use it cautiously. In 1995 the benefits of metformin
were rediscovered in Europe during the United Kingdom (UK) Prospective
Diabetes Study which was a randomized, multicenter clinical trial that followed
3867 patients over 10 years (8). Independently of blood glucose control,
metformin reduced the risks of myocardial infarction and mortality of all causes
and is considered to be safer than other biguanides because it is less lipophilic
due to its structure containing two methyl substitutes as opposed to a large
phenylethyl side chain, which is seen in phenformin (3, 9) (Figure 1.1).
4

Figure 1.1. Metformin is less lipophilic because it has two methyl side
groups.
Metformin is less lipophilic than because of the two methyl substituents on
metformin compared to the larger phenylethyl side chain in phenformin.
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Metformin was approved by the Food and Drug Administration (FDA) in 1994
and Glucophage (i.e. “glucose eater”) was the first branded formulation
marketed by Bristol-Meyers Squibb (10). It is now prescribed to over at least 120
million people worldwide and is the most commonly used drug for type II
diabetes (11).
Since then metformin has also been approved to treat polycystic ovarian
disease, non-alcoholic fatty liver disease, and gestational diabetes (12-15). In
1924, the Nobel laureate Otto Heinrich Warburg first hypothesized the existence
of a connection between cellular metabolism and malignancy (16). In 1971,
Dilman et al. suggested that oral biguanides hold promising potential as potent
anti-aging and anti-oncogenic agents (17). Over the past three decades
substantial data has surfaced suggesting that metformin may exert cancer and
chemopreventive effects by suppressing the transformative and
hyperproliferative processes that initiate carcinogenesis (18). Metformin has
been shown to have anti-proliferative and anti-metabolic effects against cancer
in many different types of cancer including breast, prostate, lung, colon, liver,
and ovarian, but there is scarce data describing the specific mechanism
metformin utilizes to target these oncogenic cells, notably colon cancer cells (1924). Furthermore, although metformin has been studied as a molecular inhibitor,
there currently is scant literature describing specifically which patients may
benefit most from this therapy (25, 26). These issues highlight the need for
further of the precise mechanism of this drug and which patients may receive the
most benefit from, specifically those with colon cancers.
1.3 Metformin: Mechanisms of Action
Metformin is considered to be a hypoglycemic agent because it lowers
blood glucose concentrations in patients with type II diabetes without causing
physiologically overwhelming hypoglycemia. Metformin is also frequently
described as an insulin sensitizer leading to reduction in insulin resistance and
significant reduction of plasma fasting insulin level (27). Metformin is also
responsible for inhibiting hepatic gluconeogenesis, however multiple
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mechanisms including enzymatic variations in glucose-6-phosphatase (G6P),
pyruvate carboxylase-phosphoenolpyruvate carboxykinase (PC-PEPCK), and
inhibition of mitochondrial glycerophosphate dehydrogenase (28-31). Metformin
also increases anaerobic glucose metabolism in the intestine and decreases
gluconeogenesis, glycogenolysis, and fatty acid oxidation in the liver. It is
responsible for insulin-mediated glucose uptake, decreases glycogenesis, and
decreases fatty acid oxidation in skeletal muscle (11) (Figure 1.2). Central to the
understanding of the molecular mechanisms of metformin is the traditionally
accepted target 5' adenosine monophosphate-activated protein kinase (AMPK)
(Figure 1.3).
AMPK is a crucial cellular energy sensor because it promotes adenosine
triphosphate production (ATP) by increasing the expression of catabolic proteins
while conserving ATP by switching off biosynthetic pathways (32). AMPK is
activated by increases in AMP:ATP or ADP:ATP ratios, which occur when cellular
energy status has been compromised. This frequently occurs in response to
metabolic stresses, such as oncogenesis, that either interfere with ATP
production or that accelerate ATP consumption. AMPK and its orthologues exist
universally as heterotrimeric complexes comprising a catalytic α-subunit and
regulatory β- and γ-subunit (33). The function of the catalytic subunits of AMPK
is very important to its relationship with tumor biology. For many decades AMPK
has been thought to be the main target of Metformin in both its direct and indirect
metabolic functions. It consists of three protein subunits that together make a
functional enzyme, conserved from yeast to humans. Triggering the activation of
AMPK can be carried out when the γ subunit of AMPK undergoes a
conformational change so as to expose the active site (Thr-172) on the α subunit.
AMPK is activated by increases in AMP and ADP as the cellular concentrations
of ATP, ADP and AMP change. In the basal state, sites 1 and 3 in the γ-subunit
are occupied by ATP. Replacement of ATP by ADP or AMP at site 3 during
moderate stress promotes phosphorylation of Thr172. Replacement of ATP by
AMP at site 1 during more severe stress causes a further tenfold allosteric
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Figure 1.2. Metformin impacts metabolism in the intestine, liver, and
skeletal muscle.
Metformin increases anaerobic glucose metabolism in the intestine and
decreases gluconeogenesis, glycogenolysis, and fatty acid oxidation in the liver.
It also increases insulin-mediated glucose uptake, decreases glycogenesis, and
decreases fatty acid oxidation in skeletal muscle. All of this results in systemic
hypoglycemia (Adapted from Bailey, Diab Vasc Dis Res, 2009).
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Figure 1.3. 5' adenosine monophosphate-activated protein kinase (AMPK)
is an enzyme that plays a role in cellular energy homeostasis.
Triggering the activation of AMPK can be carried out when the γ subunit of
AMPK undergoes a conformational change so as to expose the active site (Thr172) on the α subunit. AMPK is activated by increases in AMP and ADP as the
cellular concentrations of ATP, ADP and AMP change (Hardie et al. Nat Rev Mol
Cell Biol 2012;13:251-262; used with permission).
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activation. As cellular energy status returns to normal, AMP at site 1 and ADP or
AMP at site 3 are progressively replaced by ATP. This promotes the
dephosphorylation of Thr172 and a return to the basal state (33). The major
upstream kinases of AMPK are the LKB1–STRAD–MO25 complex and the
Ca2+/calmodulin-activated protein kinase kinases (34, 35). The LKB1–STRAD–
MO25 complex provides a high basal level of phosphorylation at Thr172 that is
modulated by the binding of AMP to the AMPK γ-subunit, which promotes
phosphorylation and inhibits dephosphorylation. In tumor cells that have lost the
tumor suppressor LKB1 owing to somatic mutations, treatments that increase
AMP and ADP levels do not normally activate AMPK because basal activity is too
low for the effects of nucleotide binding on phosphorylation status to become
evident. This emphasizes that the effects of AMP and/or ADP on Thr172
phosphorylation status are a result of their binding to AMPK, and such effects are
independent of the upstream kinases and phosphatases that phosphorylate or
dephosphorylate Thr172 (32).
Although metformin activates AMPK, this may not explain all of the
therapeutic effects of the drug. Metformin, at least in part, does exert its
therapeutic effects by activating the AMPK. However, the site of its action, as
well as the mechanism to activate AMPK, remains elusive. Other mechanisms of
action have been proposed for metformin such as inhibition of mitochondrial
complex I, inhibition of glucagon-induced elevation of cyclic adenosine
monophosphate (cAMP), and consequent activation of protein kinase A (PKA),
inhibition of mitochondrial glycerophosphate dehydrogenase (31, 36, 37). The
exact mechanism of metformin has not been fully elucidated and warrants further
review.
1.3.1 Indirect Mechanisms of Action
The indirect insulin-dependent effects of metformin are mediated by its
ability to activate 5' adenosine monophosphate-activated protein kinase AMPK
and inhibit gluconeogenesis in the liver and stimulate glucose uptake in muscle.
The resulting reduction in circulating insulin alleviates activation of

10

PI3K/AKT/mTOR pathway signaling in cancer cells. The indirect effects of
metformin are due to decreased blood glucose primarily by suppressing glucose
production by the liver, or hepatic gluconeogenesis (Figure 1.4). The direct
effects of metformin include increased insulin sensitivity, enhances peripheral
glucose uptake (by inducing the phosphorylation of GLUT4 enhancer factor),
decreases insulin-induced suppression of fatty acid oxidation, and decreases
absorption of glucose from the gastrointestinal tract (38, 39). Increased
peripheral use of glucose may be due to improved insulin binding to insulin
receptors, but this theory also applies to its role as an anti-cancer agent (40, 41).
Metformin diminishes hepatic glucose output leading to lower systemic glucose
and insulin levels, which could impair malignant growth indirectly without
requiring accumulation of metformin in the tumor. High insulin levels associated
with obesity, insulin resistance and type 2 diabetes may promote tumorigenesis.
Insulin-like growth factors, insulin, IGF-1 and IGF-2, secreted by visceral or
mammary adipose tissue have significant paracrine and endocrine effects. These
effects can be exacerbated by increased steroid hormone production (41). The
insulin receptor lies upstream of a number of growth-promoting pathways
including the PI3K/AKT/mTOR signaling network which are implicated in
oncogenesis (42, 43).
1.3.2 Direct Mechanisms of Action
The direct insulin-independent effects of metformin are mediated by
activation of AMPK and a reduction in mammalian target of rapamycin (mTOR)
signaling and protein synthesis in cancer cells (44). The tumor suppressors liver
kinase B1 (LKB1) and TSC2 are important in mediating the effects of metformin
on AMPK and mTOR respectively; however, metformin may also inhibit mTOR
independently of LKB1, AMPK and TSC2 (45). Metformin can act directly on
cancer cells by inhibiting cell progression by suppressing mTOR signaling,
mitochondrial glucose oxidation, and/or reducing stability of hypoxia inducing
factor (HIF) under hypoxic conditions.
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Metformin: A Potential Anti-cancer Agen

Metformin

Figure 1.4. Metformin has direct and indirect effects on cellular and
molecular signaling.
The indirect effects of metformin are due to decreased blood glucose primarily by
suppressing glucose production by the liver, or hepatic gluconeogenesis. The
direct effects of metformin include increased insulin sensitivity, enhances
peripheral glucose uptake (by inducing the phosphorylation of GLUT4 enhancer
factor), decreases insulin-induced suppression of fatty acid oxidation, and
decreases absorption of glucose from the gastrointestinal tract (Adapted from
Luengo et al. BMC Biol 2014;12:82).
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1.4 Metformin’s Impact as an Anti-Cancer Agent
Insufficient activity of AMPK allows uncontrolled cell growth, despite the
conditions of cellular stress such as those occurring during tumorigenesis,
making AMPK an attractive target for anti-cancer therapy. Although numerous
AMPK-activating drugs have been described, only metformin is widely used
clinically and available in cost-effective generic formulations. Other AMPK
activators are currently less suitable for routine clinical use due to the higher
rates of lactic acidosis (phenformin) or low specificity and potency (5aminoimidaz-ole-4-carboxamide ribonucleoside). Novel, more specific AMPK
activators are still in preclinical development (46). A rapidly increasing body of
preclinical and clinical evidence argues for the use of metformin as an antioncogenic agent.
1.4.1 Molecular and Cellular Signaling Targets of Metformin
Protein synthesis is one of the most energy-consuming processes in the
cell and, as such, is a major target of AMPK signalling under conditions of
cellular energy stress. Upon activation by metformin, AMPK phosphorylates
TSC2, stimulating its GTPase-activating protein (GAP) activity towards the small
GTPase RHEB, which causes a reduction in mTOR signaling. mTOR controls
protein synthesis by regulating the phosphorylation of key proteins involved in
mRNA translation, such as the 4E-BPs and S6Ks (Figure 1.5). Inhibition of
mTOR signaling leads to a reduction in phosphorylation of downstream effectors
like 4E-BPs and S6Ks, therefore resulting in decreased protein synthesis and
subsequent cancer cell proliferation (47). As indicated earlier, LKB1 is the
immediate AMPK activator in response to cellular energy stress and
phosphorylates a key AMPK residue (Thr172) obligate for catalytic activity (22,
33, 48). Cells lacking LKB1 exhibit decreased AMPK activation and elevated
mTOR signaling even under conditions of cellular energy stress or treatment with
AMPK agonists (49). LKB1 is also required for metformin-mediated AMPK
activation. A variety of cells lacking LKB1, are resistant to the growth inhibitory
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Figure 1.5. Multiple molecular mechanisms have been proposed to explain
how metformin decreases cell metabolism and proliferation.
Although AMPK is thought to be the main mediator of the potential anticarcinogenic effects of metformin, the molecular mechanism of metformin is
incompletely understood: metabolic inhibition of the mitochondrial respiratory
chain (complex I) results in increased glycolysis and acetyl-CoA carboxylase
(ACC) activation results in decreased lipid synthesis and increased oxidation.
Activation of AMPK is also thought to result in decreased proliferation by cell
cycle arrest and protein synthesis inhibition via decrease of CD1/CDK and
inhibition of mTOR complex I, respectively (Habibollahi et al. J Nucl Med
2013;54:252-258).
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effects of metformin in vitro LKB1 and TSC2 represent key factors in determining
tumor sensitivity to the effects of metformin (22).
AMPK phosphorylates p53, a tumor suppressor responsible for regulating
cell cycle arrest (50, 51). AMPK activation induces phosphorylation of p53 on
serine 15, and this phosphorylation is required to initiate AMPK-dependent cellcycle arrest. AMPK-induced p53 activation promotes cellular survival in response
to glucose deprivation, and cells that have undergone a p53-dependent
metabolic arrest can rapidly reenter the cell cycle upon glucose restoration.
However, persistent activation of AMPK leads to accelerated p53-dependent
cellular senescence. Thus, AMPK is a cell-intrinsic regulator of the cell cycle that
coordinates cellular proliferation with carbon source availability (52).
Metformin also exerts its downstream therapeutic effects such as
regulating lipid synthesis by inhibiting Acetyl-CoA carboxylase (ACC) and
regulating mTOR signaling by activating TSC2 (38, 53). Uptake of fatty acids into
mitochondria, which seems to be the rate-limiting step in β-oxidation, is promoted
by AMPK via phosphorylation and in activation of the ACC2 isoform of ACC (33).
This results in a drop in concentration of the ACC product, malonyl CoA, an
inhibitor of fatty acid entry into mitochondria mediated by the carnitine O palmitoyltransferase 1 (CPT1) system (54, 55). Malonyl-CoA is a critical bifunctional molecule, i.e., a substrate of fatty acid synthase (FASN) for acyl chain
elongation (fatty acid synthesis) (56). Since ACC is a rate-limiting enzymes in de
novo fatty acid synthesis as it catalyzes ATP-dependent carboxylation of acetylCoA to form malonyl-CoA. Loubiere et al. determined metformin does not alter
the concentration of malonyl-CoA and that the inhibitory effect of metformin on
lipogenesis in prostate cancer cell lines is primarily due to a cellular energy
deficit (57). Furthermore, they determined metformin decreases ATP in a dosedependent manner, and this diminution is significantly correlated with the
inhibition of lipogenesis.
1.4.2 Metabolic and Bioenergetic Changes Initiated by Metformin
Altered cellular metabolism is a hallmark of cancer cells (16, 58). Tumor
15

cells adapt their metabolism to provide the necessary substrates to continue to
immortally proliferate (59, 60). Sensitivity to the anti-tumoral effects of metformin
may also be governed by expression levels of the organic cation transporters
(OCT1). Metformin enters the cell by OCT1, where it then accumulates in the
mitochondria (Figure 1.6). There, metformin inhibits complex I of the electron
transport chain and mGDP, resulting in decreased NADH oxidation. One of the
best described mechanisms of metformin is by inhibition of complex I, the first
component of the mitochondrial electron transport chain (58). Complex I
inhibition by metformin interrupts mitochondrial respiration and decreases
proton-driven synthesis of ATP, causing cellular energetic stress and elevation
of the AMP:ATP ratio. Decreased electron chain activity suppresses tricarboxylic
acid (TCA) cycle flux and decreases mitochondrial ATP synthesis, and these
actions result in increased AMPK signaling, decreased cAMP/PKA signaling,
decreased gluconeogenesis and increased glycolysis (28).
Madiraju et al. determined metformin non-competitively inhibits the redox
shuttle enzyme mitochondrial glycerophosphate dehydrogenase, resulting in an
altered hepatocellular redox state, reduced conversion of lactate and glycerol to
glucose, and decreased hepatic gluconeogenesis by using whole- body
mitochondrial glycerophosphate dehydrogenase knockout mice (31). Acute and
chronic low-dose metformin treatment effectively reduced endogenous glucose
production, while increasing cytosolic redox and decreasing mitochondrial redox
states. mGPD transports cytosolic reducing equivalents from NADH into the
mitochondria via the glycerol-phosphate shuttle. Interestingly, inhibition of mGPD
and complex I both compromise the ability of mitochondria to oxidize cytosolic
NADH and decrease the entry of these reducing equivalents into the electron.
Mitochondria are highly sensitive to stress and are susceptible to oxidative
damage which accompanies inflammation and subsequently an ideal
environment for tumor establishment and proliferation (61). The sensitivity of
measuring mitochondrial stress may offer novel insight into translational
questions regarding mitochondria as an energy sensor and targeted molecular
therapies for cancer like metformin (26) (Figure 1.7).
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Figure 1.6. Metformin inhibits mitochondrial metabolism.
Metformin enters the cell by organic cation transporter 1 (OCT1), where it then
accumulates in the mitochondria. There, metformin inhibits complex I of the
electron transport chain and mGDP, resulting in decreased NADH oxidation.
Decreased electron chain activity suppresses tricarboxylic acid (TCA) cycle flux
and decreases mitochondrial ATP synthesis. These actions result in increased
AMPK signaling, decreased cAMP/PKA signaling, decreased gluconeogenesis
and increased glycolysis (Luengo et al. BMC Biol 2014;12:82).
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Figure 1.7 XF Extracellular Flux Analysis can be used to determine the
bioenergetic health index.
The specific metabolic downstream effects Metformin causes by mitochondrial
inhibition can be determined by performing a mitochondrial stress test using
measurements of cellular oxygen consumption rate (OCR) (Chacko et al., Clin
Sci (Lond) 2014;127:367-373).
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1.4.3 Epidemiologic Evidence of Metformin as an Anti-Cancer Agent in Colon
Cancer
Evans et al. were the first to report a potential association of metformin
use with reduced cancer incidence. In diabetics receiving metformin (as opposed
to other therapies), overall cancer incidence was lowered (odds ratio (OR) 0.86
and 95% confidence interval (95% CI) (0.73–1.02) and there was evidence of a
dose response in relation to the total duration of use or number of prescriptions
dispensed (62). Landman et al. showed that metformin use was associated with
lower cancer mortality compared to no metformin use (hazard ratio 0.23–0.80)
and that the effect was dose dependent (63). Specifically to colon cancer, Cho et
al. recently reported that in patients taking metformin independently associated
with decreased adenoma incidence (OR=0.738, 95% CI=0.554-0.983, P=0.03)
(64). Table 1.1 reviews epidemiologic studies specific to colon cancers.
Although epidemiological studies have fairly consistently reported reduced
cancer incidence and/or mortality in diabetic patients who receive metformin in
standard clinical doses (1500–2250 mg/day in adults), these studies have
important methodological limitations. Most were conducted retrospectively and
many sampled their cases from hospital or clinical registries rather than
population-based registries, thereby limiting external validity and introducing
potential selection biases (62, 64). Inclusion criteria varied (65). Some studies did
not exclude individuals with prior diagnosis of cancer, thus introducing a possible
reverse causation bias (65). Many studies included patients exposed to a variety
of treatments for diabetes complicating the analysis of metformin associations
(62, 65-67). However, despite the flaws in the epidemiologic data there is valid
evidence to support that this drug potentially has anti-oncogenic capabilities.
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Table 1.1. Recent epidemiologic studies evaluating metformin colon
cancer.
Study type

Outcome

Sample Comparison
size

Results

Reference

(HR/OR/RR,
95% CI)

Retrospective

Incidence

62,809 Sulfonurea

cohort

Prospective

Incidence

cohort
Retrospective
cohort
Retrospective
cohort

(1.29-2.53)

al. (2009)

HR-1.43

sulfonurea

(1.05-1.94)

480,984 Any vs. no
595 Any vs. no
metformin

Incidence

Currie et

Metformin +

metformin
Mortality

HR-1.8

995,843 Any vs. no
metformin

HR-0.36

Lee et al.

(0.13-0.98)

(2011)

HR-1.45

Lee et al.

(1.08-1.93)

(2012)

RR-0.643

Tseng

(0.490-

(2012)

0.845)
Retrospective

Adenoma

12,186 Any vs. no

cohort

incidence

metformin

OR-0.738

Cho

(0.554-

(2014)

0.983)
Abbreviations: Hazard ratio (HR), Odds ratio (OR), Confidence Interval (CI).

20

1.4.4 Pre-clinical Evidence of Metformin as an Anti-Cancer Agent in Colon
Cancer
Despite extensive funding in research and development to cure colon
cancer, few agents pass preclinical trials to demonstrate efficacy in humans.
These advancements most often rely on murine models to screen for efficacy
before progressing to clinical trials. Previously there has been little focus on the
validation of these models, even in the era of targeted therapy where
understanding the genetic signatures of tumors under study is critical. Table 1.2
represents recent animal models used to evaluate metformin in colon cancer.
Each of these models provides valuable information regarding metformin.
Li et al. determined with either vitamin D3 or metformin alone, combined use of
vitamin D3 and metformin showed more pronounced effect in reducing the
numbers of aberrant crypt foci (ACF) and tumor in the colon and was associated
with downregulation of S6P expression, via the AMPK (IGFI)/mTOR pathway
(68).
Algire et al. determined administration of metformin led to the activation of
AMPK, the inhibitory phosphorylation of ACC and increased apoptosis as
estimated by poly (ADP-ribose) polymerase (PARP) cleavage in mice fed a highenergy diet on growth of an in vivo colon cancer model in mice injected with
MC38 colon carcinoma cells (23). Zafaar et al. evaluated the effects of induced
diabetes with metformin treatment in combination with or without oxaliplatin and
determined that metformin did have anti-proliferative effects with this murine
model (69). Buzzai et al. determined that metformin is selectively toxic to p53
deficient cells. They used paired isogenic colon cancer cell lines HCT116
p53(+/+) and HCT116 p53(-/-) treatment with metformin selectively suppressed
the tumor growth of HCT116 p53(-/-) xenografts (50). Hosono et al. used an
azoxymethane (AOM) model with a 6 week intraperitoneal injection of metformin
(250mg/kg/d) and determined that metformin suppresses colonic epithelial
proliferation via the inhibition of the mTOR pathway through the activation of
AMPK (70).
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Table 1.2. Recent murine models using metformin to study colon cancer.
Gender Animal

Model

Dose

Route Effect on

Reference

pathways
Male

Wister rat DSS

120

i.p.

mg/kg/d
Male

C57BL/6

5×105

50 mg/kg

Male

p53 WT

s.c.
HCT116

vs KO

s.c.

Swiss

DMH

albino
Male

BALB/c

250mg/kg
100 or

d.w.
i.p.
d.w.

200
AOM

mg/kg
(250

Li, 2015

PI3K/mTOR

MC38
Male

decrease

i.p.

mg/kg/d)

decrease

Algire,

FASN, Akt

2010

p53(-/-) less

Buzzai,

autophagy

2007

decrease

Zafaar,

angiogenesis

2014

aberrant crypt

Hosono,

foci

2010

Abbreviations: DMH-dextran sodium sulfate (DSS), azoxymethane (AOM),
intraperitoneal (i.p.), drinking water (d.w.), subcutaneous (s.c.), mTOR
mammalian target of rapamycin, fatty acid synthase (FASN), 1,2dimethylhydrazine (DMH).
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Although each of these recent models contributes to the literature,
collectively there is such a profound variety in available models with regard to
cancer induction model, delivery of treatment, doses of treatment, and varieties
and combinations of treatments it is difficult to draw substantial conclusions
which would warrant proceeding with performing a clinical trial. The need for
translational data prompts researchers to seek more clinically applicable models
by reviewing human data obtained through clinical and translational programs.
1.4.5 Clinical Evidence of Metformin as an Anti-Cancer Agent in Colon Cancer
Gaining access to human and clinical specimens is a priority to better
understand the true mechanisms of metformin and other molecular inhibitors that
act in a multi-faceted manner. Baba et al. used immunohistochemistry data to
determine that phosphorylated AMPK expression in colorectal cancer is
associated with superior prognosis among p-MAPK3/1-positive cases,
suggesting a possible interaction between the AMPK and MAPK pathways
influencing tumor behavior (71). Julien et al. obtained and implanted 54 human
colorectal tumors in immunodeficient mice and rats, representing 35 primary
tumors, 5 peritoneal cancers and 14 metastases (72). Furthermore, they
determined through extensive in vivo analysis they were able to compare the
molecular profile with the drug sensitivity of each tumor mode and found that the
key role of KRAS mutation in cetuximab resistance. Using patient derived
xenografts (PDX) Nunes et al. IGF2 upregulation (16%), which was mutually
exclusive with IRS2, PIK3CA, PTEN, and INPP4B alterations, supporting IGF2
as a potential drug target (73). Development of targeted therapeutics required
translationally relevant preclinical models with well-characterized cancer genome
alterations. Colorectal PDXs are appropriate tools to identify both new targets
and predictive biomarkers of response/resistance to targeted therapies.
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1.5 The Challenges of Moving Metformin from the Bench to the Bedside for
Cancer Treatment
1.5.1 Review of Previous Clinical Trials Using Metformin as an Anti-Cancer
Agent in Colon Cancer
Prospective randomized clinical trials designed to use metformin for the
treatment of breast and prostate cancers are just now reaching accrual and/or
offering relevant data regarding the efficacy of using this treatment as a
molecular inhibitor to target cancer (74-76). Most of the breast cancer trials that
have met accrual and finished data collection or have evaluated initial data
determined there was no difference in mortality or proliferative biomarkers when
comparing their treatment groups (77-80). A couple of recently performed trials
did show significant decreases in proliferative markers such as Ki67 (81, 82).
Interestingly in their recent randomized placebo controlled trial Bonanni et al.
determined that the metformin effect on Ki-67 change relative to placebo was not
statistically significant, with a mean proportional increase of 4.0% (95% CI, 5.6% to 14.4%) 4 weeks apart, but did show significantly different effects
according to insulin resistance, particularly in luminal B tumors (19). Kalinsky et
al. determined that although there was no reduction in ln(ki-67) after metformin
(p=0.98) or compared to controls (p = 0.47) that there was a significant reduction
in BMI, cholesterol, and leptin (83).
Thus far there is little data regarding completed clinical trials observing the
effect of metformin on colon cancer. Table 1.3 offers a brief overview of the
current clinical trials on available on the National Cancer Institute (NCI) site
(www.clinicaltrials.gov). Multiple trials are currently ongoing while others had
difficulty reaching accrual. Hosono et al. performed a prospectively randomized
trial on 26 nondiabetic patients with aberrant crypt foci to treatment with
metformin (250 mg/d, n = 12) or no treatment (control, n = 14) (84). They
examined proliferative activity in colonic epithelium (via proliferating cell nuclear
antigen labeling index) and apoptotic activity (via terminal deoxynucleotidyl
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Table 1.3 Recent and ongoing clinical trials using metformin for colon
cancer.
Trial

Institute

Design

Trial Arms

number

Inclusi

Primary

on

End

Criteria

Point
DFS, OS

NCT0192

Gachon

Non-

1. FOLFOX6 +

Advan-

6769*

University

random-

Metformin

ced

ized

2. FOFIRI +

CRC

Metformin
NCT0193

Barretos

Non-

1. Irinotecan

Refrac-

Non-

0864+

Cancer

random-

350mg/m² q21d

tory to

progres-

Hospital,

ized

+ metformin up

oxali-

sion

Gil Medical

to 2500mg/d

platin,

at 12

Center

2. Irinotecan

5-FU,

weeks

alone

iritoecan

NCT0163

University

Random-

1. Metformin

StageI-

Prolifer-

2020#

of

ized,

850mg PO BID

IV colon

ation

Arkansas

double-

14-21 days

or rectal

status of

(Slow

blinded

2. Control

cancer

CRC

accrual)

placebo

tumor
and
adjacent
normal
tissue
following
Metformin
therapy
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NCT0181

M.D.

Random-

1. Metformin

Stage I-

Compare

6659#

Anderson

ized,

850mg PO BID

IV colon

Ki67

Cancer

double-

14-21 days

or rectal

biopsy vs.

Center

blinded

2. Control

cancer

surgery

(Slow

placebo
FAP

Speci-

accrual)
NCT0172

Yonsei

Random-

1. Metformin

5490*

University

ized,

500mg PO

men

double-

Qday

number

blinded

2. Metformin

and size

placebo

1500mg PO

of polyps

Qday
3. Control
NCT0220

Health

Pro-

1. Atorvastatin

Stage

1381!

Clinics

spective

80mg Qday

IV

Limited

(QOL

2. Metformin up

(Pending

measure /

to 1000mg once

discus-

form)

a day

sions with

3. Doxycycline

regulatory

100mg day for 1

ethical

Qday month

bodies

4. Mebendazole

PFS

100mg Qday
NCT0131

National

2467©

Single arm

1. Metformin

Colon

Change

Cancer

500mg PO

cancer,

in

Institute

Qday

Colon

activated

adeno-

S6serine

ma,

235 over

Obesity

12 weeks

(NCI)

Abbreviations: Disease free survival (DFS), Overall survival (OS), Colorectal
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cancer (CRC), per oral (PO), twice daily (BID), Familial Adenomatous Polyposis
(FAP), every day, (Qday), Quality of life (QOL).
*Recruiting +Not recruiting #Terminated !Suspended ©Completed.
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transferase dUTP nick-end labeling). At 1 month, the metformin group had a
significant decrease in the mean number of ACF per patient (8.78 +/- 6.45 before
treatment versus 5.11 +/- 4.99 at 1 month, P = 0.007), whereas the mean ACF
number did not change significantly in the control group (7.23 +/- 6.65 versus
7.56 +/- 6.75, P = 0.609). To date this is the first reported trial of metformin for
inhibiting colorectal carcinogenesis in humans provides preliminary evidence that
metformin suppresses colonic epithelial proliferation and rectal aberrant crypt foci
formation in humans, suggesting its promise for the chemoprevention of
colorectal cancer.
1.5.2 Elucidation of the Metabolomic Impact of Metformin in Colon Cancer
Most of the clinical trials that have been completed thus far must combine
different tumor biology, patients with variable health backgrounds, and off-target
primary outcomes in order to meet accrual and continue to secure funding (8587). Evaluating molecular end points can be hindered by difficulties in procuring
tumor tissue before and after drug administration and by heterogeneity in
previous exposure to cancer therapies.
To determine the true effects of metformin on colon cancer cells will
require differentiation of the relative importance of indirect (insulin-mediated) and
direct (insulin-independent) effects. The currently accepted mechanisms of action
give rise to a broad range of therapeutic targets, leading to a large number of
potential clinical markers of metformin benefit, so clinical and translational
scientists must choose wisely and aim well when choosing which drugs to use
and which molecular pathways to target (88). Recently developed highthroughput experimental technologies, summarized by the terms genomics,
transcriptomics, proteomics and metabolomics provide for the first time ever the
means to comprehensively monitor the molecular level of disease processes
(89). These advances can characterize a drug target's physiology and improving
the overall efficiency of pharmaceutical research processes. Fendt et al. used
treated prostate cancer cell lines with metformin and performed labeled 13Cglucose and 13C-glutamine to measure the incorporation of labeled carbon from
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either nutrient into the tricarboxylic acid cycle metabolite α-ketoglutarate by gas
chromatography - mass spectrometry (90). They determined that metformin
Inhibition of glutamine anaplerosis in the presence of metformin further
attenuated proliferation while increasing glutamine metabolism rescued the
proliferative defect induced by metformin (Figure 1.8).
The Warburg effect describes the biochemical anomaly that occurs when
a shift in glucose metabolism occurs from mitochondrial oxidative
phosphorylation to glycolysis, therefore the tumor is phenotypically exhibiting the
effects of anaerobic metabolism (i.e. increased lactate production) (91). These
metabolic hallmarks can be readily assessed either in vitro or in vivo by
metabolic technologies to monitor responsiveness and resistance to novel
targeted drugs.
1.5.2a Stable Isotope-Resolved Metabolomics (SIRM)
Metabolomics can be defined as a “systemic interrogation of the
metabolome in terms of metabolite concentration, structure, and transformation
of pathways” (92). One of the most reliable methods of measuring the complexity
of oncogenic metabolomic abnormalities, namely of glucose metabolism and
phospholipid turnover, is by SIRM (93). Isotopes are different forms of a
respective element. The atoms have the same number of protons, but different
numbers of neutrons. For example, when considering the isotopes of carbon, the
“most common” carbon is 12C, as it is stable and quite abundant in the
environment (98.89%). It is important to point out that 12C is balanced in the
sense that it has 6 protons and 6 neutrons, therefore the term “isotope” has no
impact on the nuclear stability. Similarly 13C, which has 6 protons and 7
neutrons, is a staple isotope, is not radioactive, but is much less abundant
(1.11%) than 12C. 13C, if it has 6 protons and 8 neutrons, is a radioisotope and is
not considered to be a stable isotope; however, this isotope is extremely rare.
Although stable isotopes do have the potential to become unbalanced,
and therefore unstable, this generally does not happen as the difference
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Figure 1.8 Metformin specifically blocks glutamine from contributing to
glycolytic metabolism in prostate cancer cells.
Previous authors determined that metformin attenuates proliferation in prostate
cancer cells by inhibiting complex I of the respiratory chain and that metformin
increases the dependency of the prostate cancer cell lines on reductive
glutamine anaplerosis of the tricarboxylic acid (TCA) or Kreb’s cycle Therefore
they suggest a combination therapy between metformin and inhibitors of the
glutamine pathway might have a therapeutic benefit in prostate cancer (Fendt et
al. Cancer Res. 2013; 73:4429-4438; used with permission).
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between 12C and 13C is very small and it does not have the ability to participate
in the bond- breaking step in the metabolic sequence (94). Finally, isotopomers
should not be confused with isotopes. Isotopomers are compounds of identical
chemical structure but are different in isotopic composition at individual atoms
(92). This important concept is how different structures can be identified once
they are labeled (Figure 1.9).
Sample Processing
From a clinical and translational, as well as ethical, standpoint it is
imperative to note that 13C is naturally occurring in the environment and does not
pose a health risk to animals or humans (95). Animal or human tissues may be
labeled by various methodologies. In vivo labeling generally requires access to
either a intravascular compartment (intravenous) or a body compartment
(intraperitoneal, subcutaneous) so the 13C may be ultimately absorbed and
circulated throughout the body in order to effectively label the tissues. Once the
tissues are adequately labeled the clinical and translational scientist must take
extreme caution to produce excellent precision and accuracy during sample
collection and processing to ensure high quality, structured data (96). The
ultimate goals of excellent sample processing are as follows: 1) to maintain
biochemical integrity during sampling; 2) to efficiently and reproducibly recover
metabolites from biospecimens with high throughput; 3) to increase the coverage
of the metabolome on limited quantities of biospecimens; 4) to determine trace
level and/or labile metabolites in the presence of stable and abundant species,
with high throughput; 5) to enable large-scale metabolite identification and
automation of metabolite assignment; 6) to identify de novo or obtain crucial
structural information of unknowns, with or without the use of metabolite;
databases; 7) to facilitate metabolite quantification without the need for authentic
standards (93).
Briefly, sample processing involves sample homogenization and sample
extraction. During homogenization samples must be broken into very fine
particles (i.e. <10µm) without compromising their biochemical integrity (96).
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Figure 1.9 13C-6 Glucose labeling identifies specific components of the
citric acid cycle.
Stable Isotope-Resolved Metabolomics (SIRM) refers to the labeling of stable
isotopes which are different forms of a respective element (i.e.

13

C versus 12C).

The atoms have the same number of protons, but different numbers of neutrons.
An isotopomer is a compound of identical chemical structure but differs in
isotopic composition at individual atoms which allows for the analysis and editing
of different metabolites after SIRM (Image courtesy of Teresa Fan, PhD).
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Typical homogenization techniques may include manual grinding with a pestal
(liquid N2 compatible) or mechanical liquid N2 homogenizers. For very small
samples (i.e. biopsy samples, small ex vivo labeled tissues), in order to maximize
the amount of sample retrieved, it may be necessary to homogenize these
samples with glass beads using a micro ball mill directly in solvents that denature
and precipitate the proteins without affecting their biochemical integrity.
Sample extraction includes separation of the polar fraction metabolites
from the lipid fraction and protein fractions using acids or solvents. Lyophilization
should be employed after polar extraction in order to remove water,
trichloroacetic acid (TCA), and ammonium bicarbonate. Sixty percent acetonitrile,
acetone, or chloroform/methanol/water are ideal solvents for extraction because
they are compatible with acid-labile metabolites (i.e. fructose-2,6-bisphosphate,
UDP-N-acetylglucosamine) and the solvent extraction method can be integrated
with the solvent quenching steps (96). Of note, TCA extraction is an excellent is
superior with regard to sample throughput because the removal of the volatile
TCA can be done with lyophilization, but it can lead do degradation of some
metabolites like glutamine.
One of the benefits of metabolomic analysis is that a robust amount of
data can be gained from careful attention to ensure quality labeling and precision
sample preparation, however if this standard is not respected then 13C labeling
will not occur on all of the appropriate positions and the sample will be
compromised. This error will likely require re-analysis or re-extraction, and will
not yield the robust statistical analysis that is standard when samples are
prepared with care and precision.
1.5.2b Nuclear Magnetic Resonance (NMR)
NMR is a powerful tool that can be used to identify and quantify
metabolites in an unfractionated mixture like serum or media samples or crude
cell/tissue extracts (97). When SIRM is used, NMR can determine the positional
isotopomer distributions of metabolites derived from a precursor enriched in
stable isotopes such as 13C and 15N via metabolic transformations. NMR readily
33

determines each positional isotopomer as a distinct species without the need for
fragmentation, however one disadvantage of NMR is its relatively low sensitivity
(97). With regard to 2D experiments, as 13C is a magnetic nucleus, whereas 12C
is not, a 13C NMR experiment recorded at natural abundance with proton
decoupling will consist of a series of singlets (i.e. one for each carbon atom), but
if a molecule is enriched with 13C, adjacent carbons will couple and also “split”
like what is seen in the 1H spectrum observed in homonuclear scalar
experiments. For screening purposes 1 D HSQC (heteronuclear single quantum
coherence) can help select metabolites that are 13C enriched, but sometimes this
is an overestimation of labeling since also takes into account additional 13C
atoms (98). When combined with mass spectrometry, NMR provides a very
accurate measurement of complementary information.
1.6 Purposes and Aims of Studies
Although the exact mechanisms of metformin are not entirely understood,
there is robust literature that defines the hallmarks of cellular and molecular
signaling in colon cancer cell lines with regards to protein synthesis, fatty acid
oxidation, and cell cycle arrest (23, 51, 99). Approaching this project, the primary
research questions is what exactly are the metabolomic effects of metformin on
colon cancer cells, especially since this has already been determined in other
cancers such as breast and prostate (90, 100)? Furthermore, additional
questions stem from the tremendous phenotypic and genotypic variability seen
when comparing individuals within our patient population. How can we expect
one drug to work exactly the same way as a molecular inhibitor for every
patient? The world of metabolomics opens amazing opportunities to analyze
each patient’s cancer and potentially find personalized targeted therapies for
responders and potentially elucidate more beneficial therapies through pathway
discovery for non-responders (74, 92, 101) (Figure 1.10).
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Figure 1.10 Specific impact of metformin on the citric acid cycle in colon
cancer cells.
Previous data suggests that metformin does decrease colon cancer cell
proliferation and metabolism, especially when used in combination with
chemotherapeutic agents. However, the current literature lacks information
regarding exactly how and where metformin impacts colon cancer metabolism in
vitro patient derived cell lines, patient derived xenografts in murine models, and
in ex vivo human tissues studies. The aim of our multi-faceted study is to
determine the specific glycolytic mechanisms of how metformin impacts human
colon cancers and to determine if certain molecular inhibitors may be more
beneficial than other for select patients.
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The hypothesis is that each colon cancer cell line and collected human
tissue will have its own unique metabolic profile. I also hypothesize that a newly
created colon cancer cell line from a PDX that was originated from a locally
invasive cancer will be less responsive to metformin treatment and provide a
more realistic concept of human patient tumor biology. I anticipate there will be
notable changes through the citric acid cycle, and it is very likely that metformin
will increase lactate production since it forces most cells into a more glycolytic
form of metabolism. Furthermore, we anticipate that a newly created PDX will
provide an excellent and reproducible background on which we can treat
samples with in vivo murine models for future drug discovery models.
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CHAPTER TWO: MATERIALS AND METHODS
2.1 Cell lines
Colon cancer cell lines SW480, KM20, HT29, and HCT116 were
authenticated November 2011 (Genetica DNA Laboratories, Cincinnati, OH).
Cancer cell line PDX was created from human tissues collected (Appendix A) at
the University of Kentucky after three generations of tumor implantation into
(severe combined immunodeficiency SCID) mice (Appendix B). Table 2.1
contains specific information for cell lines.
2.2 Animal studies
All animals were housed in a specific pathogen-free animal facility (060immunodeficient animal room) at the University of Kentucky BioPharmacy
Complex with 12 hour light-dark cycle. Animals received water and chow ad lib.
All animal procedures were reviewed and approved by the University of Kentucky
IACUC (Appendix B).
2.2.1 Implantation of PDX
SCID mice underwent implantation of human derived tissues obtained
from consenting patients with colon cancer undergoing surgical resection at the
University of Kentucky. Interaction with these patients and the collection of these
tissues was approved by the University of Kentucky IRB (Appendix A).
The general procedure for the subcutaneous implantation of involves
preparation of the tumor by washing it with 2% Penicillin/Streptozosin/Fungizone
in phosphate buffered saline (PBS) at least three times for all colon samples.
Original patient derived tissue is flash frozen in liquid nitrogen (LN2) for protein
analysis and additional tissue is placed in 10% formalin for 24 hours, the 70%
ethanol to later be paraffin blocked and prepared for immunohistochemistry
(IHC). Next the tumor is cut into very small pieces (i.e. tumor slurry) and a portion
is placed in 100µL of Matrigel (Corning, Bedford, MA) and remains on ice while
transported to the animal facility for implantation.
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Table 2.1. Colon cancer cell line properties.
SW480

KM20

HT29

HCT116

PDX

Culture

DMEM+10% EMEM +

McCoy's

McCoy's

DMEM+10%

media

FBS

5A+10%

5A+10%

FBS

FBS

FBS

additives*

Organism Human

Human

Human

Human

Human

Tissue

Colon

Colon

Colon

Colon

Colon

Morpho-

Epithelial

Epithelial

Epithelial

Epithelial

Epithelial

Adherent

Adherent

Adherent

Adherent

Adherent

Duke's B,

Stage IV

Stage I,

Colon

Colon

adeno-

well-

adeno-

adenocarCA

carcinoma

differen-

carcinoma

logy
Culture
properties
Disease

tiated
Age

50

N/A
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Adult

63

Gender

Male

N/A

Female

Male

Male

Ethnicity

Caucasian

N/A

N/A

N/A

Caucasian

Genetic

mutation

Chemo-

CEA

CEA

increased

infor-

codon-12;

resistant

ras proto-

Gemcitabine, expression expression KRAS

oncogene

5-FU

MSI

mation
negative

c-myc, K-

TGF-1,

*recurrent

ras, H-ras,

TGF-2

cancer

N-ras
myb, sis, fos
oncogenes
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Abbreviations: (DMEM), (FBS), carcinoembryonic antigen (CEA), transforming
growth factor (TGF), cancer (CA).
Additives: sodium pyruvate, non-essential amino acids, multivitamins
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The animal facility is reserved and sterile equipment is prepared and
covered to ensure sterility. The animal is anesthetized with isofluorane and
oxygen at 2L/min. The skin is prepped with betadine and alcohol and covered
with sterile towels. The skin is incised with an 11” scalpel and a subcutaneous
flank pocket is developed using an 18” gauge blunt needle. The tumor slurry is
pipetted into the pocket, ensuring there is no spillage of contents. The skin is
gently grasped while a buried subcuticular stitch using 5-0 absorbable suture
(Ethicon, Somerville, NJ) to approximate the skin edges. The skin is cleaned with
alcohol and the animal is allowed to gently wake up. Further details regarding
this procedure can be found in Appendix B.
2.2.2 Randomized trial of intraperitoneal metformin injection
Ten 8-week old SCID mice, all weighing over 25.0 grams were implanted
with a single third generation PDX as described above. All implanted tumor
volumes were from an equally divided second generation PDX and mixed with
1.5mL of Matrigel (Corning, Bedford, MA). Each mouse received 100µL of the
3rd generation tumor/Matrigel slurry delivered subcutaneously to the left flank by
strict sterile technique. After 22 days all ten mice developed subcutaneous
tumors. Mice were randomized into two groups. They were weighed and tumors
were measured on days 1, 7, and 14. The control group received a daily
intraperitoneal injection of 30µL of sterile normal saline for 14-16 days of
treatment. The metformin group received a daily injection 30µL of Metformin
(200mg/kg/day) for 14-16 days. The mice received water and regular chow ad lib.
2.2.3 13C-glucose tissue and plasma labeling
Prior to sacrifice, in order to achieve 13C-glucose tissue and plasma
labeling a 20% solution of 13C -Glc in PBS (1.075 M) was sterile-filtered and 100
µL of this solution (i.e. 20 mg of 13C -Glc) were injected into the lateral tail vein
while the mouse was under intermittent anesthesia. Mice were injected with three
sequential injections of 100 ul of 20 % glucose 15 minutes part (i.e. at 0, 15, 30,
with sampling at 45 minutes post injection). Approximately 50 µL of blood
samples were taken intraorbitally at timed intervals, chilled on ice 5 minutes after
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standing at room temperature and separated into plasma and blood cells by
centrifugation at 4°C at 3,500 g for 15 minutes. Plasma was immediately flashfrozen in liquid N2 for storage prior to metabolite extraction.
2.2.4 Tissue harvest
Mice were sacrificed humanely by cervical dislocation at different times
post 13C -Glc injection, and the following xenograft was resected. Dissected
tissue was blotted, washed with water, blotted and flash-frozen in liquid N2
within 3 minutes of euthanasia. Additional tissues were flash frozen and placed
in 10% formalin for 24 hours followed by 70% ethanol for Western blotting and
paraffin blocking prior to sectioning for immunohistochemical staining.
Mice were sacrificed over the course of three days. The mice were
“evenly” sacrificed (sacrifice day 1- 1 control, 1 metformin; sacrifice day 2- 2
control, 2 metformin; sacrifice day 3- 1 control, 1 metformin).
2.3 Collection of human tissues
The clinical and translational scientist is responsible for identifying and
contacting potential patients for the gastrointestinal tissue protocol which
received IRB approval in November 2013 (Appendix A). If the patient agrees to
participate in the study the clinical and translational scientist obtains consent
which is secured in locked cabinet and all electronic patient identifiers are
maintained in a password and firewall protected secure file. The biospecimen
core and/or operating room circulator is requested to call or page when the
specimen is available. The clinical and translational scientist retrieves tissues
with ice and distributes and stores the tissues accordingly to other lab personnel.
2.4 Ex vivo tissue labeling/incubation
Tissues intended for labeling were collected and glucose-free DMEM +
0.45% 13C 6 –Glucose + 10% dialyzed FBS +antibiotics was prepared. Tissues
were washed with antibiotic/antifungal PBS x 3 and then resuspended tissue
pieces were placed in 5-10 mL of freshly made and pre-warmed tracer medium in
a T25 flask. Next, 0.2 mL of aliquot of tracer medium was removed from the flask
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and stored in a 1.5 mL microfuge tube and flash-frozen and store at -80C. The
T25 flask was placed on shaker x 24 hours in 37C, 5% CO2 incubator. At the end
of the tracer treatment, it was removed from shaker and record the weight of the
flask. Next the medium was transferred into a 15 mL centrifuge tube and
centrifuge at 3500xg or higher speed for 10 minutes at 4C. Immediately after
medium removal, transfer the tissue pieces to a microcentrifuge tube. Wash the
tissue pieces on ice with ice-cold PBS 3 times. Remove supernatant and place
tube in LN2.
2.5 Cellular and molecular signaling
2.5.1 Proliferation analysis
All cell lines (Table 2.1) were plated in a 6 well dish at 1.0x106 cell
number and allowed to seed for 12 hours. Conditions were treatment control,
1mM metformin, and 5 mM metformin at time points of 24 hours, 48 hours, and
72 hours. At each time point the cells were washed with PBS and 500µL of the
crystal violet staining solution (0.5% crystal violet in 20% methanol) to the cells in
the 6-well dish. These cells were fixed and stained for 20 minutes at room
temperature. Next plate was generously rinsed and allowed to dry overnight. The
next day the dried and stained cells were stained with 500 µL of 1% SDS and
placed on a shaker for 20 minutes to dissolve the stain. The 200 µL of SDS/cell
solution was added into a 96 well plate and measured at an absorbance of
570nm.
2.5.2 Western blotting analysis
All cell lines (Table 2.1) were plated in a 6 well dish at 5.0x106 and
allowed to seed for 12 hours. Then the cells were treated with varying doses of
metformin (control, 1mM, 5mM) for 24 hours. The cells were then collected and
lysed with TNN buffer [50 mM Tris-HCI (pH 7.5), 150 mM NaCl, 0.5 mM NP40,
50 mM NaF, 1 mM sodium orthovanadate, 1 mM DTT, 1 mM
phenylmethylsulfonyl fluoride, and 25 µg/ml each of aprotinin, leupeptin, and
pepstatin A] at 4°C for 30 min. Lysates were clarified by centrifugation (10,000 ×
g for 30 min at 4°C), and protein concentrations were determined using the
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Bradford method (102). Briefly, total protein (100 µg) was resolved on a 10%
polyacrylamide gel and transferred to Immobilon-P nylon membranes. Filters
were incubated overnight at 4°C in a blocking solution (Tris-buffered saline
containing 5% nonfat dried milk and 0.1% Tween 20), followed by a 1-hour
incubation with primary antibodies. Primary antibodies analyzed were p-ACC
(Cell Signaling #11818) ACC (Cell Signaling #3676), p-AMPK (Cell Signaling
#2535), AMPK (Cell Signaling #5831, p-S6 (Cell Signaling #2217) and β-actin.
Filters were washed three times in a blocking solution and incubated with
horseradish peroxidase-conjugated second antibodies for 1 h. After three
additional washes, the immune complexes were visualized by the enhanced
chemiluminescence detection system.
2.5.3 Immunohistochemistry
All 10 animals from the randomized trial of intraperitoneal metformin
injection and all collected human tissues (immediate post resection and ex vivo
incubated) were analyzed for expression of proliferation marker Ki67 (Cell
Signaling #9027) and apoptotic marker cleaved caspase-3 (Cell Signaling
#9661). Aperioscope digital imaging was used to determine a quantitative score
for nuclear staining (Ki67) and positive pixel count (cleaved caspase-3). The
extent of expression score was assessed on a scale of 0 to 3 the intensity score
was also measured on a scale of 0 to 3 (negative = 0, weak = 1, moderate = 2,
strong = 3). Multiplication of the values for intensity and extent of expression
provided a score for immunoreactivity.
2.6 Metabolic studies
2.6.1 Seahorse analysis
Cellular OCR was used to measure basal respiration, non-mitochondrial
respiration, ATP-linked respiration, and proton leak. ECAR was used to monitor
glycolysis. Each cell line was plated in specialized XF96 plates (Seahorse
Bioscience, North Billerica, MA). Each cell line was plated at a concentration of
3.0x104 cells/well. Twelve hours after seeding cells were treated with control
(ddH20) or 1mM of metformin (Sigma-Aldrich, St. Louis, MO). Plated cells were
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maintained for 24 hours in a 37°C/5% CO2 incubator. One hour prior to assay,
cells were equilibrated with bicarbonate-free low buffered DMEM medium without
any supplement, or supplemented with glucose or glutamine as indicated, in a
37°C non-CO2 incubator. Reagents required for the experimental protocol were
prepared in assay medium, loaded into reservoirs and automatically injected into
plates as required for each assay.
2.6.1a Oxygen consumption rate (OCR)
Experimental design followed the protocol provided by Seahorse
Bioscience. Briefly, cells were metabolically perturbed by the addition of three
different compounds in succession and the OCR was measured prior to and after
injection of each compound. First, cells were injected with oligomycin (1 µM
working concentration), which inhibits ATP synthesis and identifies the
percentage of OCR devoted to ATP synthesis. The second compound, carbonyl
cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP) (0.6 µM working
concentration), an uncoupling agent, collapses the mitochondrial membrane
potential; a rapid consumption of energy and oxygen without ATP generation
follows. FCCP was used to calculate the maximum and spare respiratory
capacity of cells. Finally, cells were exposed to a combination of rotenone, a
complex I inhibitor, and antimycin A, a complex III inhibitor (1 µM working
concentration). This combination inhibits mitochondrial respiration and allows
calculation of the mitochondrial and non-mitochondrial fractions contributing to
respiration.
2.6.1b Extracellular acidification rate (ECAR)
For the first ECAR assessment, non-glycolytic acidification was obtained
in the absence of extracellular glucose and pyruvate. Next, cells were exposed to
three compounds, with measurements after each injection. The first injection, a
saturating concentration of glucose (10 mM), causes an increase in ECAR and
defines the rate of glycolysis under basal conditions. The second injection,
oligomycin (1 µM working concentration), inhibits mitochondrial respiration and
shifts energy production toward glycolysis, revealing the maximum glycolytic
44

capacity of the cells. The final injection, 2-deoxy-D-glucose (2-DG; 100 mM), a
glucose analog, inhibits glycolysis. The difference between glycolytic capacity
(Measurement 2) and glycolysis (Measurement 1) defines the glycolytic reserve.
2.6.2 Metabolomic analysis
2.6.2a Cell and media experiments
SW480 and PDX cells were plated at 60-70% confluency in 10 cm dishes.
The conditions for both cell lines were as follows: unlabeled control, unlabeled
treated with 1mM metformin, 13C-glucose labeled control, 13C-glucose labeled
treated with 1mM metformin. Prior to placing labeled medium on the cells all cell
lines were was twice with PBS. Each plate was weighed before and after
extracting 100µL of media (0 hour time point) which was immediately flash
frozen. Cells were allowed to incubate in 37C/C02 for 24 hours. Each plate was
weighed before and after extraction of 100 µL of media (24 hour time point) and
this was also flash frozen. The remaining media was transferred into a 15 ml
conical tube and centrifuged at 3,500xg for 20 minutes at 4C. Supernatant was
removed and 100 µl was aliquoted in a 2 ml screw top tube (USA Scientific 14208700) for metabolite extraction. 5 mL of cold non-sterile PBS buffer was added
onto the plate, and gently rotated on the plate to wash all surface of the plate
prior to being suctioned off. Remove PBS by vacuum-suction and repeat.
2.6.2b Cell quenching and collection
1 mL of cold acetonitrile was added to cover the whole plate and allowed
to stand for 5 minutes. Next 0.55 mL of nanopure water + 0.2 ml 0.2 mM TrisHCl pH 8 was added as an internal standard for NMR to the plate. Then the cells
were scraped and placed into a 15mL tube for a final acetonitrile to water ratio of
2:1.5 (v/v).
2.6.2c Cell and media experiments using acetone extraction
One lyophilized NMR aliquot of the polar fraction resulting from CH3CNH2O-CHCl3 extraction of tissue sample on ice and the sample is dissolved in
100 µL of nanopure water and mixed. Then 400 µL of ice cold 100% acetone was
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added to perform protein precipitation and vortexes prior to being placed in -80C
for 30 minutes to after a second centrifugation for 20 minutes @ 14,000 rpm in
4C the supernatant may be transferred to a 2mL screw top tube and the protein
pellet is further extracted with 100 µL of 60% acetonitrile and repeated to
preserve as much sample as possible. The samples are flash frozen and then
transferred to the lyophilizer. Then the dry samples are dissolved in 55 µL of 50%
D2O with 50 nmoles DSS (With EDTA) per 0.1 mL and vortex to mix the buffer
with the extract and centrifuge for 20 minutes @ 14,000 rpm, 4C before loading
into 1.7 mm NMR tubes to attain a minimum column height of 36 mm.
2.6.2d Tissue extraction for animal and human samples
Frozen tissues were ground in liquid N2 to < 10 µm particles in a 6750
Freezer/Mill (Retsch, Inc., Newtown, PA) and extracted simultaneously for
soluble and lipidic metabolites as follows. Up to 20 mg of frozen tissue powder in
15 ml polypropylene conical centrifuge tube (Sarstedt, Newton, NC) containing
three 3 mm diameter glass beads was vigorously shaken in 2 mL of cold
acetonitrile (mass spectrometry grade, stored at -20 C) to denature proteins,
followed by addition of 1.5 mL nanopure water, and 1 ml HPLC-grade chloroform
(Fisher Scientific). The mixture was shaken vigorously until achieving a milky
consistency followed by centrifugation at 3,000 g for 20 minutes at 4 C to
separate the polar (top), lipidic (bottom), and tissue debris layers (interface). The
polar and lipidic layers were recovered sequentially and the remaining tissue
debris (mainly denatured proteins) was extracted again with 0.5 ml
chloroform:methanol:butylated hydroxytoluene (BHT) (2:1:1 mM) and centrifuged
at 4C, 22,000xg for 20 min to separate the three phases again. The residual
polar and lipid fractions were pooled with respective main fractions. All three
fractions were vacuum-dried in a speedvac device (Vacufuge, Eppendorf, New
York, NY) and/or by lyophylization. The dry weight of tissue debris was obtained
for normalization of metabolite content. The polar extracts were redissolved in
100 % D2O containing 30 nmol perdeuterated DSS (2,2’-dimethyl-2-silapentane5-sulfonate, Cambridge Isotope Laboratories, Andover, MA) as internal chemical
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shift and concentration reference for NMR measurement.
2.6.2e NMR Spectroscopy
NMR spectra were recorded at 14.1 T on a Varian Inova spectrometer
equipped with a 5 mm inverse triple resonance cold probe, at 20 °C. 1-D 1H
NMR spectra were recorded with an acquisition time of 2 s and a recycle time of
5 s to minimize peak saturation. 1-D 1H Spectra were typically processed with
zero filling to 131 k points, and apodized with an unshifted Gaussian and a 0.5
Hz line broadening exponential. Concentrations of metabolites and 13C
incorporation were determined by peak integration of the 1H NMR spectra
referenced to the intensity of DSS methyl groups, with correction for differential
relaxation, as previously described (103-105).
13

C profiling was achieved using 1-D 1H-(106) HSQC experiments

recorded with a recycle time of 1.5 s and 13C GARP decoupling during the
proton acquisition time of 0.15 s. 1-D HSQC spectra were processed with zerofilling to 16 k points and apodized using an unshifted Gaussian function and 6 Hz
line broadening.
TOCSY and HSQC-TOCSY spectra were recorded with an isotropic
mixing time of 50 ms, a B1 field strength of 8 kHz, and acquisition times of 0.341
s in t2 and 0.05 s in t1. The free induction decays were zero-filled once in t2, and
linear predicted and zero filled to 4096 points in t1. The data were apodized
using an unshifted Gaussian and a 1 Hz line broadening exponential in both
dimensions. Positional 13C incorporation into labeled metabolites was quantified
as previously described (104, 107).
2.7 Statistical analysis
Proliferation data was normally distributed and was therefore compared
with a paired two-tailed t-test comparing the control condition to each of the
treatment conditions within the respective time point. Statistical analyses were
performed with SAS 9.3 (Cary, NC) and a p-value of <0.05 was the standard for
statistical significance. Seahorse data was analyzed using a Wilcoxon signed
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rank test because the data was not normally distributed and required statistical
analysis with a non-parametric test to ensure statistical significance was valid
when present. Paired tests using the Wilcoxon signed rank test were employed
to assess differential expression of ordinal biomarker immunoreactivity scores
between matched normal versus tumor and normal versus metastatic tissues as
this data did not appear to be normally distributed based on histogram and
required analysis with a non-parametric test. The correlations between
biomarkers were measured using Spearman’s correlation coefficient nonnormally distributed data. All results are expressed as mean ± SE.
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CHAPTER THREE: RESULTS
Introduction
Reprogrammed energy metabolism is a hallmark of cancer cells and is
rapidly emerging as a potential target for therapeutic intervention (108). To
overcome metabolic stress, cancer cells activate several pro-survival pathways.
Activation of AMPK, an established metabolic stress sensor, occurs with even
modest decreases in ATP production. This activation promotes enhanced activity
of catabolic pathways that generate more ATP and inhibits anabolic pathways
(32). AMPK is certainly implicated in the decreased proliferation, lipid synthesis,
and protein synthesis observed in human colon cancers, but alone it cannot
explain why colon cancer cells exhibit such a significant increase in glycolysis
when under metabolic stress.
Madiraju et al. demonstrated that non-competitively inhibits the redox
shuttle enzyme mitochondrial glycerophosphate dehydrogenase, resulting in an
altered hepatocellular redox state, reduced conversion of lactate and glycerol to
glucose, and decreased hepatic gluconeogenesis. Acute and chronic low-dose
metformin treatment effectively reduced endogenous glucose production, while
increasing cytosolic redox and decreasing mitochondrial redox states (31). While
this novel mechanism certainly contributes to the effect of metformin on whole
body energy metabolism, it is likely one of many mechanisms that contributes to
metformin’s actions as an anti-cancer agent.
Fendt et al. determined that metformin decreased glucose oxidation and
increased dependency on reductive glutamine metabolism in both cancer cell
lines and in a mouse model of prostate cancer. Inhibition of glutamine
anaplerosis in the presence of metformin further attenuated proliferation,
whereas increasing glutamine metabolism rescued the proliferative defect
induced by metformin. These data suggest that interfering with glutamine may
synergize with metformin to improve outcomes in patients with prostate cancer
(90). Corominas-Faja et al. showed that certain breast cancer cells treated with
metformin had an accumulation of 5-formimino-tetrahydrofolate, one of the one-
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carbon units responsible for de novo synthesis of purines and pyrimidines (100).
We hypothesized that since metformin has similar anti-cancer effects on colon
cancer cells that it has in breast and prostate cancer cells that there are novel
mechanisms relevant to colon cancer that can be determined with metabolomic
analysis. This study focuses on the effects cellular and molecular, as well as
metabolic changes seen with the use of metformin on four well-establish colon
cancer cell lines and a new, yet aggressive colon cancer cell line. Furthermore,
we suggest that metabolomic analysis of colon cancer cells treated with
metformin can determine if the drug has effects that can be seen with SIRM and
if not can identify where and how certain cancer cell lines and/or human tissues
are resistant.
Results
3.1 Cellular and molecular signaling
Metformin decreases colon cancer cell proliferation and increases pAMPK and p-ACC while decreasing p-S6
3.2 In vitro cellular and molecular signaling
Treatment with metformin results in decreased proliferation and in all cell
lines at 5mM for 24 hours, but only in cell lines HT29 and HCT116 was there an
effect prior to 72 hours or at a lower dose than 5 mM. Both of these cell lines are
less aggressive than S480, KM20, or PDX and the both of these cell lines had
virtually no expression of p-S6 with the 5mM dose. SW480 cell line did have a
notable decrease in expression of p-S6 and a moderate increase of p-AMPK and
p-ACC on Western blot (Figure 3.1A). Only at the 5mM dose of metformin after
72 hours of treatment did metformin significantly affect the proliferation of SW480
cells (Figure 3.1B).
The pattern of response seen in KM20 cells is very to the behavior that is
exhibited by SW480 cells. Both have a notable increase in p-S6 with the 5mM
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Figure 3.1A Western blot analysis identifies that metformin increases pACC and p-AMPK, and decreases p-S6 in SW480 cells.
Increasing doses of Metformin (1mM and 5mM) for a period of 24 hours
increases the phosphorylation of p-ACC and p-AMPK and decreases the amount
of p-S6.
Figure 3.1B Metformin decreases cell proliferation in SW480 cells.
Metformin only significantly decreases proliferation at doses of 5mM after 72
hours of treatment in SW480 cells (p=0.002).
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dose (Figure 3.2A). However, both of these metastatic cell lined do not
experience anti-proliferative effects with metformin treatment unless they have
been treated with 5mM for at least 72 hours (Figure 3.2B). The HT29 cell line
originated from a woman with grade I well-differentiated colon adenocarcinoma in
the 1970s. It does not have any very notable genetic mutations and only
expresses carcinoembryonic antigen (CEA). The notable difference over 24
hours between the control cell, 1mM, and 5mM is marked (Figure 3.3A). It is
also notable that metformin has an anti-proliferative effect on these cells a day
earlier than other three more aggressive colon cancer cell lines (5mM 48 hours
p=0.005, 5mM 72 hours p=0.002) (Figure 3.4B).
Interestingly, although metformin has a much more dramatic impact on
proliferation in HCT116 cells, the increase in p-AMPK and p-ACC and the
decrease in p-S6 in HT29 cells compared to the expression seen by Western
blotting with the HCT116 cell line suggests that metformin has more of an impact
on the pathways that regulate glycolysis, fatty acid synthesis metabolism, and a
decrease in protein synthesis (Figure 3.4A). The HCT116 cell line probably has
the most impressive response to the anti-proliferative properties of metformin
because it has a marked dose dependent response at 48 hours (5mM p=0.003),
but at 72 hours even the 1mM doses significantly decreases cancer cell
proliferation in HCT 116 cells (72 hours 1 mM p=0.007, 5mM p=0.001) (Figure
3.4B). Not surprisingly, the PDX cell line had virtually no response to treatment
with metformin at 24 hours (Figure 3.5A) and displayed decreased cell
proliferation only after 72 hours of in vitro treatment (Figure 3.5B).
PDX in from patients with colon cancer maintains histologic integrity
despite many generations. This is a very aggressive cell line that originated
this year after our lab performed implanted this aggressive locally advanced
stage IV adenocarcinoma into a SCID mouse (Figure 3.6).
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Figure 3.2A Western blot analysis identifies that metformin increases pACC and p-AMPK, and decreases p-S6 in KM20 cells.
Increasing doses of Metformin (1mM and 5mM) for a period of 24 hours
increases the phosphorylation of p-ACC and p-AMPK and decreases the amount
of p-S6. There is a significant decrease in the cells treated with the 5mM dose
(p=0.010).
Figure 3.2B Metformin decreases cell proliferation in KM20 cells.
Metformin only significantly decreases proliferation at doses of 5mM after 72
hours of treatment in KM20 cells.
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Figure 3.3A Western blot analysis identifies that metformin increases pACC and p-AMPK, and decreases p-S6 in HT29 cells.
Increasing doses of Metformin (1mM and 5mM) for a period of 24 hours markedly
increases the phosphorylation of p-ACC and p-AMPK and decreases the amount
of p-S6 suggesting that in this cell line is an increase in glycolysis, decrease in
fatty acid synthesis, and a decrease in protein synthesis and cell proliferation.
Figure 3.3B Metformin decreases cell proliferation in HT29 cells.
Metformin significantly decreases proliferation at the 5mM dose after 48 hours
(p=0.005) and even more so at 72 hours (p=0.002) in HT29 cells. This data
suggests that colon cancers with tumor characteristics similar to the HT29 cell
line may be more responsive to metformin as an anti-cancer agent.
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Figure 3.4A Western blot analysis identifies that metformin increases pACC and p-AMPK, and decreases p-S6 in HCT116 cells.
Increasing doses of Metformin (1mM and 5mM) for a period of 24 hours
increases the phosphorylation of p-ACC and p-AMPK and decreases the amount
of p-S6. This cell line is more responsive than the metastatic cell lines in the
study, but it is not as responsive as the HT29 cells.
Figure 3.4B Metformin decreases cell proliferation in HCT116 cells.
Metformin significantly decreases proliferation at the 5mM dose after 48 hours
(p=0.003) and even more so at 72 hours (p<0.001) in HCT 116 cells. Most
importantly, this cell line also demonstrates a significant decrease in cell
proliferation when treated for 72 hours with 1mM of the study drug (p=0.007).
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Figure 3.5A Western blot analysis identifies that metformin has less impact
on p-ACC and p-AMPK, and p-S6 when PDX is compared to other
commonly used colon cancer cell lines.
Increasing doses of Metformin (1mM and 5mM) for a period of 24 hours show
little impact on the phosphorylation of p- ACC and p-AMPK, nor does it seem to
decrease the amount of p-S6.
Figure 3.5B High doses of metformin decreases cell proliferation in PDX
cells after 72 hours.
Although little change is seen at 24 hours of treatment and there actually seems
to be an initial increase in metabolism at 24 hours in cells treated with metformin,
the drug does decrease proliferation at 48 hours (although not significantly,
p=0.444).
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Figure 3.6. Example of patient derived tissue implantation (A-D) and
resulting patient derived xenograft (PDX) (E-H).
A small pocket is created with an 11” blade scalpel (A). Next the subcutaneous
pocket is developed with a blunt 18”gauge needed and the matrigel/tumor slurry
is deposited into the subcutaneous pocket (B,C). The wound is closed with 5-0
absorbable suture. After one month of allowing the tumor to develop, a
subcutaneous PDX will form (E). The skin is incised and gently dissected away
from the tumor (F). The tumor is removed, cleansed, and sectioned (G). The
tumor is then implanted into another mouse (steps A-D) to create the next
generation of the PDX (H).
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Patients who undergo gastrointestinal cancer surgery at the University of
Kentucky are offered the option to participate in clinical research. Table 3.1 is a
deidentified record of patients whose tissues have evolved into xenografts
researchers can use to explore novel cancer therapies and molecular
mechanisms. For the most part these tumors maintain their histological integrity
after multiple generations through SCID mice, therefore these tissues are clinical
relevant and represent a translational science advance (Figure 3.7).
3.3 In vivo cellular and molecular signaling
Ten SCID mice were implanted with third generation tumor from patient 93
as was described in the previous methods section. Approximately three weeks
after their initial implantation all ten mice began to uniformly develop tumors.
There was no significant difference (p=0.39) when comparing the two
randomized groups (Figure 3.8) (Table 3.2).
The two groups started the trial at roughly the same weight, however the
treatment group was notably leaner than the control group after the first week
(Figure 3.9) (Table 3.3). The mice did gain weight over the course of the next
week. Although their tumor size was no different when compared to their
counterparts, it is hard to know if this weight gain was due to increased tumor
size or metabolic adaptation to metformin. Weight loss is a side effect of
metformin so the initial weight loss was not shocking. While these mice were
smaller than the control group on their respective days of sacrifice, this difference
was not statistically significant (p=0.051).
Metformin has little impact on pS6, p-AMPK, or p-ACC in SCID mice
carrying the aggressive PDX from the initial tumor of patient 93 (Figure 3.10).
However, observing the IHC staining reveals a decrease in Ki67 therefore
suggesting that metformin does indeed impact tumor proliferation in vivo (Figure
3.11). There is no significant difference between the metformin group and the
control group when evaluating the apoptotic marker cleaved caspase-3. These
findings suggest that an aggressive human tumor may not respond to short
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Table 3.1. Deidentified record of tumors progressing to successful patient
derived xenograft (PDX).
Patient

93

109

130

Age/ Gender

63/Male

79/Male

63/Male

Surgery

Resection of

Sigmoid

extended right

metastasis

colectomy/en bloc

colectomy/ileocolic anas.

bladder
Tumor size

.5cm (one

2.9x2.8x2.5cm

2.5x1.8x1.8cm

Poorly

Invasive poorly

invasive moderately

differentiated

differentiated

differentiated

AdenoCa-

adenocarcinoma

adenocarcinoma

abdominal wall
deposit)
Tumor grade
Tumor type

medullary
subtype
Stage

T3Nb1

T4N2

T3N*M1a(liver)

Number +LN

2 out of 23

4 out of 20

0 out of 14

Extramural

No

No

Yes

No

Yes

No

No

Yes

No

No

Yes

>3 HPF

<3

moderate

increased MSI,

loss of nuclear

loss of MLH1 and PMS2,

KRAS negative

expression of

+BRAFV600E

invasion
Intramural
invasion
Lymphvascul No
ar invasi
Perineural
invasion
Tumor inf.
Lymphs
Mutations

MLH1 and PMS2

59

Outcome to

No disease to

<1 year PFS

Died 6 days post op;

date

date (April 2015)

Notes:

Recurrent right

Palliative with

Sigmoid colectomy-CA

colon CA; 1st

Xeloda and

1976; Left colon polyp

surgery 2012

Bevacizumab

1991; Met to liver- treated

sepsis/cardiac failure

with Folfox; Avastin
neoadjuvantly
Abbreviations: lymph node (LN), CA (cancer), high power field (HPF),
microsatellite instability (MSI), progression free survival (PFS), anastomosis
(anas).
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Figure 3.7. Hemotoxylin and Eosin staining of patient derived xenografts
(PDX) through subsequent generations.
Three patients (patient 93, 109, and 130) provided tissues that have maintained
their histological integrity. This resource offers a tremendous opportunity to
pursue translational cancer questions with human derived tissues that provide a
more realistic structure in which to study tumor microenvironment.
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Figure 3.8. Severe combined immunodeficiency (SCID) tumor volume over
the study period.
There was no significant difference with respect to tumor size when comparing
the control group to the metformin group (p=0.39).
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Table 3.2. Severe combined immunodeficiency (SCID) mice metformin trial
tumor size.
This table corresponds to the raw data used to generate Figure 3.8.
Ear

Treat-

Day 1

Day 7

Day 14-16

tag

ment

L

W

H

L

W

H

L

W

H

no.

Group

610

Control

0.5

0.5

0.2

1.51

1.1

0.3

1.51

1.1

0.5

613

Control

0.4

0.2

0.3

2.21

1.2

0.5

2.21

1.2

1

616

Control

0.3

0.4

0.1

2.15

1.53

0.4

2.15

1.53

0.7

620

Control

0.5

0.3

0.2

1.25

1.91

0.2

1.25

1.91

0.4

627

Control

0.4

0.3

0.05

2.11

1.85

0.3

2.11

1.85

0.5

611

Met

0.5

0.4

0.1

2.02

1.61

0.5

2.02

1.61

1

612

Met

0.3

0.4

0.1

2.3

1.34

0.3

2.3

1.34

0.6

615

Met

0.4

0.3

0.05

1.92

1.38

0.2

1.92

1.38

0.5

618

Met

0.5

0.5

0.2

1.92

1.21

0.4

1.92

1.21

0.6

626

Met

0.3

0.5

0.2

1.89

1.48

0.3

1.89

1.48

0.7

Abbreviations: L, length (cm); W, width (cm), H, height (cm), Met, Metformin
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Figure 3.9. Severe combined immunodeficiency (SCID) weight over the
study period.
The treatment group initially lost weight which is likely due common side effects
from metformin, however this weight loss did not prove to be a significant factor
by the end of the murine trial (p=0.051).
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Table 3.3. Severe combined immunodeficiency (SCID) mice metformin trial
weights.
This table corresponds to the raw data used to generate Figure 3.9.
Ear tag

Treatment

Day 1

Day 7

Day 14-16

number

group

(gm)

(gm)

(gm)

610

Control

30.2

30.1

31.4

613

Control

33.1

33.2

33.5

616

Control

31.9

32

32.3

620

Control

28.8

29

29.6

627

Control

30.5

30.9

31.2

611

Metformin

30.4

30.1

31

612

Metformin

31

30.8

30.9

615

Metformin

32

30.5

31.1

618

Metformin

31

31

31.2

626

Metformin

27.8

27.7

28.3
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Figure 3.10. Western blotting analysis of PDX tumors from control and
metformin treated mice show minimal differences in p-ACC, p-AMPK, and
p-S6.
Ten severe combined immunodeficiency (SCID) mice received left
subcutaneous flank implanted with third generation tumor from a third generation
PDX. Based on cell signaling patterns there is a slight increase in p-ACC and pAMPK expression and a decrease in p-S6 expression in the treatment group
suggesting that metformin does cause some downstream changes in glycolysis,
lipid metabolism, and protein metabolism in mice harboring PDX.
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Figure 3.11. Immunohistochemistry (IHC) staining of patient derived
xenograft (PDX) tumors from control and metformin treated mice show a
decrease in Ki67 in the treatment group, but no significant difference in
cleaved caspase-3.
Ten severe combined immunodeficiency (SCID) mice received left
subcutaneous flank implanted with third generation tumor from PDX. Tumors
were allowed to grow to 0.5x0.5 cm and then were randomized into two
treatment groups. The control group (n=5) received a 30 uL IP injection of saline
each day for 14 days and the treatment group (n=5) received a 30uL (200mg/kg)
intraperitoneal injection Metformin for 14-16 days.
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course (i.e. 1 to 3 days) of in vitro treatment with a molecular inhibitor, but over a
course of time exposed to both the direct and indirect effects of the drug in vivo,
researchers may be able to elucidate more information regarding an
individualized tumor in a relatively controlled environment.
3.4 Ex vivo tissue labeling
Ex vivo tissue labeling offers a relatively simple technique to elegantly
observe human tissues and cancers in an environment that is at least applicable
to the human tumor microenvironment that previously accommodated the
respective neoplasm. During the same time we performed 13C6 labeling of
freshly resected tissues from patients we also incubated tissue for IHC analysis
to evaluate for sample quality. We determined that specimens maintain their
tissue structure and integrity despite 24 hours of being gently shaken in labeling
media (Figures 3.12). We also determined that larger tumors may be sectioned
and a PDX can be performed utilized as well. We were able to compare one
patient’s tissues both as a fresh primary sample and then later after one
generation through a SCID mouse (Figure 3.13). In the era of personalized
medicine, this strategy offers a safe, relatively easy, and cost-efficient way to
“trial” multiple different therapies on one patient without any worries for side
effects or subsequent therapy related morbidity or mortality to the patient.
3.5 In vitro metabolic data
After determining that different colon cancer cell lines had varying
metabolic responses to metformin based on their baseline phenotype using
various molecular markers such p-AMPK, p-ACC, p-S6, Ki67, and cleaved
caspase-3 and direct proliferation studies of cells, we then sought to probe
further into the metabolic profiles of all five cell lines to determine if the varied
responses to a single molecular inhibitor, metformin, could be elucidated by
mitochondrial stress tests and measurements of glycolytic energy responses.
Collectively the metabolic impact of metformin significantly decreases
mitochondrial respiration while increasing glycolysis. But this did not fully explain
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Figure 3.12. (Patient 109) Ex vivo labeled tissues are evaluated using
immunohistochemistry (IHC) staining to observe for markers of cell
proliferation (Ki67) and apoptosis (cleaved caspase 3).
Ex vivo labeled tissues are being used to determine the direct effects of tumor
microenvironment in a controlled environment. There was no difference in the
markers evaluated within these respective samples.
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Figure 3.13 (Patient 130) Another example of ex vivo labeled tissues are
evaluated using immunohistochemistry (IHC) staining to observe for
markers of cell proliferation (Ki67) and apoptosis (cleaved caspase 3).
Ex vivo labeled tissues are being used to determine the direct effects of tumor
microenvironment in a controlled environment. There was no difference in the
markers evaluated within these respective samples.
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why certain cell lines, namely SW480 and PDX, could also increase glycolysis
and decrease mitochondrial respiration in an effort to more efficiently metabolism
energy substrates, but have such little change to their overall metabolic
phenotype. This prompted us to use SIRM to evaluate SW480 and PDX cells
and their medial, in addition to murine in vivo labeled tissues and human ex vivo
labeled tissues to determine the specific impact metformin has on glycolysis
occurs by increasing 13C-6 Lactate and decreasing 13C-6 Alanine. However we
also found that in these two particular cell lines there appears to be a “recycled”
pathway that allows for continued metabolism despite a stressed environment
which normally forces cells into a more conservative and energy saving
phenotype.
3.6 Seahorse analysis of OCR and ECAR
Cellular OCR was used to measure basal respiration, non-mitochondrial
respiration, ATP-linked respiration, and proton leak and ECAR was used to
monitor glycolysis, glycolytic reserve, and glycolytic capacity.
Upon evaluating OCR in our five cell lines of interest we determined
certain patterns applied to each cell line. For example, we determined earlier that
the two cell lines that were not as phenotypically aggressive (i.e. HT29 and
HCT116) had more phosphorylation changes of factors associated with energy
balance (p-AMPK), fatty acid oxidation (p-ACC), and protein synthesis (p-S6), as
well as decreased proliferation measured by cell count. Also, we determined that
the three more aggressive and/or metastatic cell lines (SW480,KM20, and PDX)
were less responsive to metformin when evaluate with markers of cellular and
molecular metabolism.
However, upon evaluating the mitochondrial respiration, with the exception
of HCT116 and HT29 and non-mitochondrial respiration, each cell line has a
significant decreases in maximal respiration, non-mitochondrial respiration, ATPlinked respiration, and proton leak (Figures 3.14-3.18). Briefly, a decrease in
non-mitochondrial respiration suggests mitochondrial respiration is dysfunctional
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Figure 3.14. SW480 Oxygen consumption rate (OCR).
A. 24 hours of 1mM treatment with Metformin results in a significant decrease in
OCR. B. The overall phenotype of the cell changes from an energetic to a more
glycolytic state form of metabolism when observing both OCR and extracellular
acidification rate (ECAR). C. Both basal respiration and non-mitochondrial
respiration are significantly decreased with metformin treatment, suggesting
mitochondrial respiration has peaked and other energy pathways are being
utilized. D. ATP-linked respiration is significantly decreased with metformin
treatment, suggesting a decrease in the respiration used to drive mitochondrial
ATP synthesis. E. Maximal respiration is significantly decreased with metformin
treatment, suggesting substrate oxidation and respiratory chain activity increase
in an attempt to maintain mitochondrial membrane potential. F. Proton leak is
significantly decreased suggesting oxidation phosphorylation is incompletely
coupled.
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Figure 3.15. KM20 Oxygen consumption rate (OCR).
A. 24 hours of 1mM treatment with Metformin results in a significant decrease in
OCR. B. The overall phenotype of the cell changes to a more glycolytic strategy
of metabolism. The phenotypic change in this cell line is more marked compared
to SW480, HT29, HCT116, and UKPDX cells. C. Both basal respiration and nonmitochondrial respiration are significantly decreased with metformin treatment,
suggesting mitochondrial respiration has peaked and other energy pathways are
being utilized. D. ATP-linked respiration is significantly decreased with metformin
treatment, suggesting a decrease in the respiration used to drive mitochondrial
ATP synthesis. E. Maximal respiration is significantly decreased with metformin
treatment, suggesting substrate oxidation and respiratory chain activity increase
in an attempt to maintain mitochondrial membrane potential. F. Proton leak is
significantly decreased suggesting oxidation phosphorylation is incompletely
coupled.
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Figure 3.16. HT29 Oxygen consumption rate (OCR).
A. 24 hours of 1mM treatment with Metformin results in a significant decrease in
OCR. B. The overall phenotype of the cell changes to a more glycolytic form of
cellular metabolism, but this is not as marked as seen in other cell lines. C. Basal
respiration is significantly decreased with metformin treatment, but nonmitochondrial respiration is not. Overall this cell line responds more to metformin
treatment and this is because mitochondrial inhibition of complex I is increased in
this particular cell line, thus further sensitizing colon cancers with this phenotype
to metformin treatment. D. ATP-linked respiration is significantly decreased with
metformin treatment, suggesting a decrease in the respiration used to drive
mitochondrial ATP synthesis. E. Maximal respiration is significantly decreased
with metformin treatment, suggesting substrate oxidation and respiratory chain
activity increase in an attempt to maintain mitochondrial membrane potential. F.
Proton leak is significantly decreased suggesting oxidation phosphorylation is
incompletely coupled and mitochondrial respiration is significantly decreased,
likely through inhibition of complex I.
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Figure 3.17. HCT116 Oxygen consumption rate (OCR).
A. 24 hours of 1mM treatment with Metformin results in a significant decrease in
OCR. B. The overall phenotype of the cell changes to a more glycolytic form of
metabolism. C. Basal respiration is significantly decreased with metformin
treatment, but non- mitochondrial respiration is not. Overall this cell line
responds more to metformin treatment and this is because mitochondrial
inhibition of complex I is increased in this particular cell line, thus further
sensitizing colon cancers with this phenotype to metformin treatment. This
pattern is similar to HT29 cells, which also had a significant response to 24 hours
of treatment with 1mM Metformin. D. ATP-linked respiration is significantly
decreased with metformin treatment, suggesting a decrease in the respiration
used to drive mitochondrial ATP synthesis. E. Maximal respiration is significantly
decreased with metformin treatment, suggesting substrate oxidation and
respiratory chain activity increase in an attempt to maintain mitochondrial
membrane potential. F. Proton leak is significantly decreased suggesting
oxidation phosphorylation is incompletely coupled and mitochondrial respiration
is significantly decreased, likely through inhibition of complex I.
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Figure 3.18. PDX Oxygen consumption rate (OCR).
A. 24 hours of 1mM treatment with Metformin results in a significant decrease in
OCR. B. The overall phenotype of the cell changes to a more glycolytic form of
metabolism. C. Basal respiration is significantly decreased with metformin
treatment, but non- mitochondrial respiration is not. Overall this cell line
responds more to metformin treatment and this is because mitochondrial
inhibition of complex I is increased in this particular cell line, thus further
sensitizing colon cancers with this phenotype to metformin treatment. D. ATPlinked respiration is significantly decreased with metformin treatment, suggesting
a decrease in the respiration used to drive mitochondrial ATP synthesis. E.
Maximal respiration is significantly decreased with metformin treatment,
suggesting substrate oxidation and respiratory chain activity increase in an
attempt to maintain mitochondrial membrane potential. F. Proton leak is
significantly decreased suggesting oxidation phosphorylation is incompletely
coupled and mitochondrial respiration is significantly decreased.
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because of an overload or inhibition of complex I and complex III (109).
Therefore, HT29 and HCT116 (Figures 3.16 and 3.17), both of which are cell
lines that are quite responsive to metformin based on the fact that cellular and
molecular signaling is “maxed out” with regard to metformin’s inhibition of
respiratory complex I, a well-known mediator of metformin efficacy (58). The
three more aggressive cell lines have respective OCRs that are profoundly
affected by metformin, therefore they must be getting energy substrates from
another source. By observing the phenotypic changes in KM20 (Figure 3.15), it
seems that this cell line, which is metastatic and extremely chemo-resistant,
nearly exhausts its glycolytic pathways (Figure 3.20) by significantly increasing
glycolysis (p=0.040) and eventually limiting glycolytic reserve (p<0.001) in order
to deal with metformin’s metabolic assault. Unfortunately SW480 and PDX do not
follow this pattern, and in fact, although PDX does increase its glycolytic function,
it is the only cell line that does not have an significant increase in glycolysis
(p=0.304) (Figures 3.19-23). SW480 significantly increases its glycolysis levels,
but not as markedly as KM20. Furthermore, by taking a closer look at glycolytic
reserve in these three aggressive cell lines (Figures 3.20, 3.21, 3.23) a pattern
emerges that KM20 makes glycolysis its energy back-up plan and has a
significantly reduced glycolytic reserve as a trade-off. In contrast, SW480, which
also significantly increases its glycolytic levels, has a significant, yet more modest
decrease in glycolytic reserve. Surprisingly, PDX has a significant decrease in
glycolytic reserve without the significant increase in glycolysis (Figure 3.23).
Therefore, a more sensitive metabolic test is required to determine what the
back-up system these two aggressive cell lines (i.e. SW480 and PDX) use to
evade the inhibitory effects of metformin as an anti-cancer agent.
3.7 13C-NMR and 1H analysis of SW480 and PDX cells and media
Given that we hypothesized that certain more aggressive cell lines had an
alternate source of energy substrates to allow its evasion from metformin as a
targeted therapy we sought a more elegant way to answer this question. If there
are significant changes then SIRM labeling would allow us to see if and where in
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Figure 3.19. SW480 Extracellular acidification rate (ECAR).
A. Overall there are significant differences in ECAR in SW480 cells treated with
metformin versus those that are not for 24 hours, although these changes in
base levels and glycolytic capacity are not significantly different (B, D). There are
significant changes in both glycolysis (C) and glycolytic reserve (E), suggesting
that metformin does force the cells into a more glycolytic form of metabolism in
order to continue proliferation and metabolism of energy substrates while
decreasing reserve and later potentially exhausting this form of metabolism.
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Figure 3.20. KM20 Extracellular acidification rate (ECAR).
A. Overall there are significant differences in ECAR in KM20 cells treated with
metformin versus those that are not for 24 hours although the decreases in basal
levels and glycolytic capacity are not significantly different (B, D). There are
significant changes in both glycolysis (C) and glycolytic reserve (E) suggesting
that metformin induces an increase in glycolysis and forces cells into a more
glycolytic strategy of energy metabolism while also decreasing amount of
glycolytic reserve remaining to continue this source of metabolism.
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Figure 3.21. HT 29 Extracellular acidification rate (ECAR).
A. Overall there are significant differences in ECAR in HT29 cells treated with
metformin versus those that are not for 24 hours. Similar to other cell lines there
is little if no changes in both base levels and glycolytic capacity. There are
significant changes in both glycolysis (C) and glycolytic reserve (E) suggesting
that metformin does glycolysis and forces cells into a more glycolytic strategy of
energy metabolism while also decreasing amount of glycolytic reserve remaining
to continue this source of metabolism. Most notably, these changes are more
profound in this cell line which mirrors the cell signaling and proliferation data,
again suggesting that patients with tumor phenotypes similar to this cancer cell
line may exhibit a more positive response to metformin as an anti-cancer agent.
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Figure 3.22. HCT116 Extracellular acidification rate (ECAR).
A. Overall there are significant differences in ECAR in HCT116 cells treated with
metformin versus those that are not for 24 hours. Similar to other cell lines there
is little if no changes in both base levels and glycolytic capacity. There are
significant changes in both glycolysis (C) and glycolytic reserve (E) suggesting
that metformin does glycolysis and forces cells into a more glycolytic strategy of
energy metabolism while also decreasing amount of glycolytic reserve remaining
to continue this source of metabolism. Most notably, these changes are more
profound in this cell line which mirrors the cell signaling and proliferation data,
again suggesting that patients with tumor phenotypes similar to this cancer cell
line may exhibit a more positive response to metformin as an anti-cancer agent.
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Figure 3.23. PDX Extracellular acidification rate (ECAR).
A. Overall there are significant differences in ECAR in UKPDX cells treated with
metformin versus those that are not for 24 hours. Similar to other cell lines there
is little if no changes in both base levels and glycolytic capacity. Surprisingly,
glycolysis is increased in this aggressive and novel cell line, but there is not a
statistically significant difference between the treatment and control groups
(p=0.304). Glycolytic reserve is significantly decreased (p<0.001) (E) suggesting
in more aggressive colon adenocarcinomas metformin may cause cells to start
using an alternate energy source prior to completely exhausting their glycolytic
reserve.
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glycolysis these aggressive cell lines were able to evade molecular inhibitors that
normally induce a metabolic stress state by increasing glycolysis. The
interrogation of the metabolome to answer complex molecular questions focuses
on human disease by metabolite profiling for biomarker discovery, as well as
pharmacology and therapeutics. Recent advances in stable isotope tracer-based
metabolomic approaches enable unambiguous tracking of individual atoms
through compartmentalized metabolic networks directly in human subjects, which
made this resource an ideal tool to elucidate the complexities of the direct and
indirect actions of metformin, especially in its relationship with aggressive
molecularly evasive cancers.
The metabolomic analysis of the SW480 cells and PDX cells as well as
their respective media samples gave tremendous insight into our question and
hypothesis and confirmed that there is an alternate energy source that is being
utilized in addition to glycolysis during cellular metabolism when cells are treated
with metformin. Given the labeled stable isotopes identified during the 13C6glucose HSQC and 13C6-glucose, 1H analysis were namely 13C-lactate and small
peaks in 13C-alanine. Also, notably there are decreases in 13C-4-glutamine
suggesting that metformin may preferentially increase mitochondrial oxidation
therefore shunting glutamine into the system and forcing the cell to use this high
energy substrate as its best resource in a high stress system. The qualitative
data available through analysis of the media also suggested that metformin
causes cells to preferentially use alanine and secrete lactate as a waste product,
and that perhaps the alanine is being ”recycled” through another pathway to
ensure there is always a pyruvate pool available with ample energy substrates.
In Figure 3.24 NMR analysis with 13C6-Glc HSQC determined that SW480
cells treated with metformin versus those that were not treated with metformin
exhibit peaks in 13C-lactate and decreases in the peaks expressing evidence of
13

C- alanine metabolism. Also, notably there are decreases in 13C-4-glutamine,

13

C-4-glucose-total glutathione, and 13C-3-aspartate, as well as a slight increase

in 13C-G1-uridine diphosphate glucose. These findings indicate a decrease in
nucleotide synthesis in cells treated with Metformin. Figure 3.25 shows similar
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Figure 3.24 SW480 colon cancer cells 13C6-Glc HSQC.
NMR analysis with 13C6-Glc HSQC determined that SW480 cells treated with
metformin versus those that are not exhibit peaks in 13C-lactate and small peaks
in 13C- alanine. Also, notably there are decreases in 13C-4-Gln, 13C-4-GluGSH+GSSG, and 13C-3-Asp, as well as a slight increase in 13C-G1-UDPG.
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Figure 3.25. SW480 colon cancer cells 13C6-Glc, 1H.
NMR analysis with 13C6-Glc, 1H determined that SW480 cells treated with
metformin versus those that are not exhibit peaks in 13C-lactate and decrease in
13

C- alanine. Also, notably there are decreases in 13C-4-Gln, 13C-4-Glu-

GSH+GSSG, and 13C-3-Asp.
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peaks with a different 1H chemical shift (0.81-2.89 ppm) which also determined
that SW480 cells treated with metformin versus those that are not exhibit peaks
in 13C -lactate and small peaks in 13C - alanine, as well as the corresponding
changes in nucleotide synthesis. Figure 3.26 represents 1H shift between 5.146.56 ppm for SW480 colon cancer cells that are not labeled with 13C-glucose.
Analysis of unlabeled SW480 cells also revealed that the control groups had
peaks in the 12C -G1-Glycogen, 12C -G1-uridine diphosphate N acetylglucosamine, 12C -G1- uridine diphosphate N -acetylglucosamine, 12C
-1’-UXP (uracil nucleotide) suggesting they may use fructose 6-phosphate and
glutamine as an alternate energy sources. Figure 3.27 represents the 1H shift
analysis (0.81-2.89 ppm) of SW480 colon cancer cell medium associated with
cell treatment with 13C6-Glucose. Interestingly the media also had notable 13C-3Lactate peaks suggesting that the cells preferentially use glutamine and alanine
as their “primary” back-up energy sources and create a more acidic surrounding
environment by releasing more lactate into the surrounding media.
We observed similar results when we analyzed the metabolic changes
seen in PDX 93 cells treated with Metformin versus those treated with the control
media. Figure 3.28 represents the 13C6-Glucose HSQC analysis of PDX colon
cancer cells treated with metformin versus those that were not treated with
metformin. Here, were also noted that our PDX colon cancer cells also exhibit
primarily increased peaks in 13C-lactate and small peaks in 13C- alanine, again
suggesting that these cells get there additional energy source from additional
pyruvate pools. Figure 3.29 demonstrates that the 1H shift (0.81-2.89 ppm) for
PDX colon cancer cells also shows an increase in 13C-lactate. Figure 3.30 shows
that results of 1H shift (0.81-2.89 ppm) in unlabeled PDX colon cancer cells.
These results mirror those seen in the preexisting SW480 cell line and suggest
the control groups had peaks in the 12C -G1-Glycogen, 12C -G1-uridine
diphosphate N -acetylglucosamine, 12C -G1- uridine diphosphate N acetylglucosamine, 12C -1’-UXP (uracil nucleotide) suggesting they may use
fructose 6-phosphate and glutamine as an alternate energy sources. Figure
3.31 demonstrates that effects of metformin on the medium of PDX colon cancer
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cells with and without metformin. The 13C6-glucose analysis of the 1H shift (0.812.89 ppm), although not as pronounced due to the decreased amounts of protein,
that the PDX cells also demonstrate increases in 13C-lactate suggesting that
metformin causes these cells to use alternate energy pathways, although they
are not purely glycolytic.
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Figure 3.26. SW480 colon cancer cells unlabeled, 1H.
Unlabeled SW480 cells revealed the control groups had peaks in the 12C -G1Glycogen, 12C -G1-UDPGlcNAc, 12C -G1-UDPGalNAc, 12C -1’-UXP (uracil
nucleotide) suggesting they may use fructose 6-phosphate and glutamine as an
alternate energy sources.
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Figure 3.27. SW480 colon cancer cell medium 13C6-Glc, 1H.
Interestingly the media also had notable 13C-3-Lac peaks suggesting that the
cells preferentially use glutamine and alanine as their “primary” back-up energy
sources and create a more acidic surrounding environment by releasing more
lactate into the surrounding media.
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Figure 3.28. PDX colon cancer cells 13C6-Glc HSQC.
PDX colon cancer cells also exhibit primarily increased peaks in 13C-lactate and
small peaks in 13C- alanine, again suggesting that these cells get there additional
energy source from additional pyruvate pools.
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Figure 3.29. PDX colon cancer cells 13C6-Glc, 1H.
This sample also shows an increase in 13C-lactate and small peaks in 13Calanine, but the peaks are somewhat less clear with this example because there
is likely a low level of protein and possible issues with the sample causing the
data to be less precise.
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Figure 3.30. PDX cells colon cancer cells unlabeled, 1H.
Similarly to SW480 cells the unlabeled PDX cells showed increases in unlabeled
SW480 cells revealed increased uptake at 12C -G1-Glycogen, 12C -G1UDPGlcNAc, 12C -G1-UDPGalNAc, 12C -1’-UXP suggesting they may use
fructose 6-phosphate and glutamine as an alternate energy source and may be
a precursor to downstream lipid metabolism.
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Figure 3.31. PDX colon cancer cell medium 13C6-Glc, 1H.
Although not as pronounced due to the decreased amounts of protein, the PDX
cells also demonstrate increases in 13C-lactate suggesting that metformin
causes these cells to use alternate energy pathways, although they are not
purely glycolytic.
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CHAPTER FOUR: CLINICAL TRIAL DESIGN
4.1 Objectives
Primary Objectives
To estimate the percent increase of AMPK phosphorylation, by
immunohistochemistry, in patients receiving a minimum of 14-days of Metformin
given preoperatively, in stage I-IV colon cancer patients.
Secondary Objectives
1. To examine the difference in proliferative expression of Ki-67 using
immunohistochemistry comparing the two treatment populations.
2. To determine the expression of liver kinase B1 (LKB1), p-mTOR PhosphoS6K, and acetyl CoA using Western blotting in this population of subjects.
3. Post-hoc genetic analysis of surgical specimens to determine presence of Kras, hereditary nonpolyposis colon cancer (HNPCC), phosphoinositide- 3kinase gene (PI3KCA), and mismatch repair (MMR).
4. To delineate the effect of Metformin on glycolysis and downstream tumor
metabolism in human colon cancer tissues through the use of nuclear
magnetic resonance imaging (NMR) and mass spectrometry (MS)
metabolomics analysis.
4.2 Background
Study Disease(s): Colon Cancer
Colon cancer is the third leading cause of cancer mortality worldwide, has
become increasingly prevalent in Western populations, and is associated with
both obesity and Type II diabetes mellitus (DMII) (110, 111). Colon cancer is
increasingly prevalent in Appalachia, and our cancer center serves a large
number of colon cancer victims from this area (112). Metformin is an oral
antidiabetic drug in the biguanide class and is FDA approved as the first line drug
of choice for the treatment of DMII, but has also been shown to have potential
anti-cancer effects (11, 113).Our central hypothesis is that the predominant role

94

of Metformin in colon cancer cells is to activate AMPK which has downstream
impacts on decreasing protein metabolism through the its effect Akt/mTOR
pathway, and decreasing fatty acid metabolism through decreasing ACC and its
targeted impact on fatty acid metabolism. Moreover, we speculate that
Metformin’s impact on these molecular growth factors will inhibit colon cancer cell
growth, proliferation, and tumor metabolism during the time interval after
diagnosis and prior to surgery, and may even offer a therapeutic option for
patients whom cannot tolerate aggressive traditional chemotherapy agents.
Study Drug: Metformin
Metformin is an oral antidiabetic drug in the biguanide class and is FDA
approved as the first line drug of choice for the treatment of DMII, but has also
been shown to have potential anti-cancer effects (11, 112). The primary antitumor molecular target of Metformin is AMP-activated protein kinase (AMPK),
which is a serine/threonine protein kinase (39). AMPK plays a crucial role in
monitoring systemic and cellular energy status and which protects crucial cellular
functions under energy-restricted conditions such as metabolic stress, i.e. tumor
development (45). Specific downstream metabolic mechanisms proposed to be
affected by Metformin’s action on AMPK in colon cancers are i)protein
metabolism and translation by the mammalian target of rapamycin (mTOR)
pathway and ii) acetyl co-enzyme A (ACC) pathway in lipid metabolism (18, 114,
115).
In addition to its function as a gluconeogenesis suppressor, Metformin has
recently been shown to possess strong anti-cancer properties. It has been shown
to reduce proliferation, induce apoptosis, cause cell cycle arrest, and improve
response to breast tumor xenografts in pre-clinical studies (18, 51, 99, 116-118).
Pre-clinical studies of the impact of Metformin on lung, prostate, colon, and
pancreatic cancer have been explored (20, 22, 24, 69). Metformin is a safe
therapeutic agent that has been previously used in many cancer clinical trials
studying breast cancer (19, 81, 82). For pre-clinical treatment studies similar to
the study we propose, safe doses range from 500mg two times per day up to
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1,700 mg per day (19, 82, 119). Recent pharmacokinetic data shows that
effective metformin induced inhibition of hepatic gluconeogenesis can be
achieved with bi-daily dosing of metformin to achieve 74-100 µM peak average
values of serum concentrations (31).
Metformin’s most common side effects are gastrointestinal, and these
symptoms are often resolve spontaneously and can often be avoided by gradual
escalation of dosage. We do not plan to escalate the dose of metformin in this
study, but similarly to previously performed studies in breast cancer and other
ongoing trials exploring colon cancer, we intend to give two to three week trials
of clinically accepted levels of this agent. Metformin treatment has not been
associated with hypoglycemia unless used in conjunction with other glucoselowering medicines (sulfonylureas or insulin). In U.S. clinical trials, about 4% of
participants were unable to continue metformin due to adverse effects. Serious
adverse events are infrequent and generally limited to lactic acidosis, which
occurs only in persons with renal or hepatic insufficiency or other
contraindications (120).
Contraindications to this drug include CHF, metabolic acidosis with or
without coma, DKA, renal disease (serum creatinine >1.5 mg/dL in males or
>1.4mg/dL in females), abnormal creatinine clearance resulting from shock,
septicemia, or myocardial infarction, radiologic contrast study for 48 hr after, and
current lactation (9). Metformin has a bioavailability of 50-60% and the peak
plasma time of the regular release form is 2-3 hours. It is eliminated by the
kidneys (90% by tubular secretion) at 450-540 ml/min with a t1/2 of 4-9 hours
(121).
Rationale
Colon cancer is a devastating disease that is increasing in incidence
regionally, nationally, and worldwide. Colon cancer is strongly associated with
obesity, now considered an epidemic in the United States. Our surrounding
Appalachian population has the highest rates of both obesity and colon cancer in
the country, and could benefit significantly from our proposed pilot study. Our
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proposed project using Metformin as a safe, low cost, targeted therapy offers an
agent which can affect the correlated conditions of colon cancer and obesity.
Current recommendations for the treatment of colon cancer include surgery and
chemotherapy. Metformin offers an alternative that will allow decrease doses,
and therefore toxicity, of aggressive traditional chemotherapy. We also speculate
using this drug during the pre-surgical and immediate post-surgical interval when
no other therapeutic intervention such as chemotherapy can safely be offered
could potentially lead to decreased micro-metastatic disease which results in
later recurrences. Furthermore, patients who cannot tolerate aggressive
chemotherapy due to age or other medical conditions could significantly benefit
from this safe and less toxic alternative.
Epidemiologic data in human colon cancers suggests patients taking
Metformin for the treatment of diabetes have better outcomes than their nondiabetic counterparts, which seems counterintuitive as these patients often have
other comorbidities such as obesity which contribute to less optimal outcomes
(67, 121). Both in vitro and in vivo animal data in colon cancer also suggest
Metformin does have an anti-tumor effect, but the direct metabolic implications of
the drug have yet to be determined (122, 123). Previous studies have shown the
anti-tumor effects of Metformin in breast, prostate, gastric, and pancreatic
cancers (83, 124-126). However, a randomized trial studying the specific
metabolic effects of Metformin in human colon cancer has yet to be performed.
We therefore propose to explore a novel, innovative approach studying the
metabolic effects of Metformin in human colon cancer tissues using a
prospective, double-blinded, randomized control pilot study at the University of
Kentucky Markey Cancer Center. We intend to determine the metabolic impact of
Metformin treatment in patients with colon cancer by examining the role of
Metformin on protein metabolism and tumor cell proliferation in colon cancer
tissues, as well as delineating the effect of Metformin on fatty acid metabolism in
human colon cancer tissues.

97

Correlative Studies Background
AMPK analysis by IHC staining
We plan to analyze both the pre and post treatment specimens to
determine phosphorylation changes of AMPK in the Metformin treated
specimens. IHC staining is an established and well characterized technique to
identify and analyze AMPK in both pre-clinical and clinical studies (71, 127, 128).
AMPK is an enzyme that plays a role in cellular energy homeostasis. It is also
acts as an effector of metformin action on glucose uptake in cellular processes
(129). Since Metformin targets AMPK we intend to use it as a primary biomarker
in our study. We anticipate that Metformin treated tissues will show increased
phosphorylation changes in AMPK when compared to specimens not treated
with Metformin. We plan to prepare and stain these tissues in our laboratory at
the Markey Cancer Center and have the resources and equipment to carry out
all procedures. We plan to quantify and compare differences in AMPK
phosphorylation with Aperioscope imaging and quantification.
Ki67 analysis by IHC staining
We plan to analyze both the pre and post treatment specimens to
determine the proliferative changes present by comparing and quantifying the
positive staining of Ki67 in the tissues. Ki67 is a nuclear protein that is associated
with and may be necessary for cellular proliferation, and it is also associated with
ribosomal RNA protein transcription (130, 131). There are multiple pre-clinical
and clinical studies supporting the evaluation of Ki67 as a proliferative marker in
tumor biology studies and that it can be accurately quantified and used as a
reliable marker (131). We anticipate that tumor specimens which have not been
exposed to the study drug will have an increased observance of the staining of
Ki67, thus indicating an increase of proliferation in tissues not exposed to
Metformin. We plan to stain all tissues for this biomarker by the same protocol to
maintain consistency and we plan to quantify and compare differences in Ki67
staining with Aperioscope imaging and quantification.
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LKB1 analysis by Western blotting
LKB1 is a primary upstream kinase of AMPK and exerts its growth
suppressing effects by activating a group of ~14 other kinases, comprising AMPK
and AMPK-related kinases (48). Activation of AMPK by LKB1 suppresses growth
and proliferation when energy and nutrient levels are scarce. Activation of AMPKrelated kinases by LKB1 plays vital roles maintaining cell polarity thereby
inhibiting inappropriate expansion of tumor cells (34). LKB1 leads to
disorganization of cell polarity and facilitates tumor growth under energetically
unfavorable conditions (132). We plan to analyze both the pre and post treatment
specimens to determine the presence of LKB1. We anticipate an increase in
LKB1 in the tissues not exposed to Metformin as this kinase which is upstream of
the anticipated target biomarker as it is allows tumor growth in settings of cellular
stress. Western blotting analysis will allow us to study qualitative data of protein
expression related to LKB1.
p-mTOR and phospho-S6K analysis by Western blotting
mTOR and phospho-S6K are both effectors of cell growth and proliferation
via the regulation of protein synthesis in tumor cell growth and metabolism we
intend to analyze with Western blotting. mTOR is a phylogenetically conserved
serine/threonine kinase which is phosphorylated and activated by Akt, but can
also auto phosphorylate when experiencing metabolic stress (133). mTOR
regulates protein synthesis through the phosphorylation and inactivation of the
repressor of mRNA translation, eukaryotic initiation factor 4E-binding protein (4EBP1), and through the phosphorylation and activation of S6 kinase (S6K1) (53).
Pre-clinical studies have shown that metformin potentiates the effects of
paclitaxel in endometrial cancer cells through inhibition of cell proliferation and
modulation of the mTOR pathway and clinical studies in human tumor xenografts
show that Metformin treatment results in a downregulation of mTOR and
downstream effectors such as pS6K (42, 134). We intend to use Western blotting
analysis to study qualitative data of protein expression related to the mTOR and
pS6K inhibition we expect to observe in Metformin treated tissue specimens.
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acetyl CoA analysis by Western blotting
Acetyl-CoA is produced during the second step of aerobic cellular
respiration, pyruvate decarboxylation, which occurs in the matrix of the
mitochondria and its main function is to convey the carbon atoms within the
acetyl group to the citric acid cycle to be oxidized for energy production. This
metabolic molecule is extremely important in the understanding of cellular
metabolism and for this reason we would like to include it in our qualitative
Western blotting analysis studies. Preclinical data shows that fatty acid oxidation
is increased in the presence of Metformin and downstream effectors involved in
fatty acid metabolism such as acetyl CoA and fatty acid synthase (FASN) are
increased in models of cellular stress (23, 106, 135). We anticipate that the
Metformin treated tissues will show an increase in the protein expression of
acetyl CoA using Western blotting analysis.
Genetic studies of surgical specimens
Genetic analysis of all tumor specimens is important as we need to
understand the implications of any genetic differences we find in comparing the
pre and post treatment specimens. We intend to observe mutations for K-ras,
PI3KCA, HNPCC, and MMR, all of which are important genetic mutations in
colon cancer known to effect tumor biology (136-139). It is currently unknown if
or how Metformin treatment changes expression of any of these genetic profiles.
Unfortunately adequate tumor biopsy tissue will not be available in quantity or in
a timely manner in order to stratify patient to a respective treatment arm based
on genetic information, however a post-hoc analysis to determine if there is a
relationship between Metformin and any of these mutations will present novel
and interesting data.
Metabolomic analysis of specimens with NMR and MS
Metabolomic analysis is a new and exciting high throughput analysis
which will allow for rapid progress that will significantly advance the fields of
colon cancer physiology, endocrinology, and metabolism. Ultimately, our findings
will provide insight into the specific mechanisms by which Metformin acts on
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human colon cancer tissues could provide other insights into other novel
avenues of research for drug development in the treatment and control of this
devastating disease. This technology has been utilized by other groups to study
the pharmacokinetics of Metformin and suggest its effect in in vitro studies, but
has yet to be used to study Metformin and/or colon cancer in human tissue
studies (100, 106, 140). Fan et al. has shown that human tissue studies in lung
cancers can be performed using both NMR and MS (92, 94, 97). We anticipate
that tissues treated with Metformin will show decrease levels of glycolysis and
downstream effects of tumor metabolism, but these secondary outcomes will
involve drug and pathway discovery in Metformin and its relationship to colon
cancer.
4.3 Patient Selection
Eligibility Criteria
•

Patients must have histologically or cytologically confirmed colon cancer
stage I-IV.

•

Patients must have surgically resectable disease

•

Age ≥18 years and < 90 years of age. Because no dosing or adverse event
data are currently available on the use of metformin in patients <18 years of
age, children are excluded from this study, but will be eligible for future
pediatric trials.

•

ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).

•

Life expectancy of greater than 3 months.

•

Patients must have normal hepatic and renal function as defined below:

•

AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal

•

creatinine < 1.5 mg/dL

•

The effects of metformin on the developing human fetus are unknown. For
this reason and because biguanide agents are known to be teratogenic
(Category B), women of child-bearing potential and men must agree to use
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adequate contraception (hormonal or barrier method of birth control;
abstinence) prior to study entry and for the duration of study participation.
Should a woman become pregnant or suspect she is pregnant while she or
her partner is participating in this study, she should inform her treating
physician immediately. Men treated or enrolled on this protocol must also
agree to use adequate contraception prior to the study, for the duration of
study participation, and 4 months after completion of metformin
administration.
•

Ability to understand and the willingness to sign a written informed consent
document.

Exclusion Criteria
•

Patients who are not able to undergo surgical resection of their colorectal
cancer

•

Stage 0 (carcinoma in situ) and suspected but not biopsy proven colon cancer

•

Surgical intervention at another institution for treatment of colorectal cancer
prior to being treated at University of Kentucky

•

Subjects with a history of previous malignancy treated with chemotherapy or
radiation within the last 6 months.

•

Current pregnancy or breast feeding. If patient becomes pregnant during their
time in the study they will be removed from the study.

•

Pre-operative testing that includes any of the following:
o Creatinine level (renal function test)- > 1.5 mg/dL
o AST/ALT > 2.5 ULN
o Glucose testing that reveals persistent (> 3 laboratory measurements)
hypoglycemia without patient being in fasting state.

•

Patients with known brain metastases should be excluded from this clinical
trial because of their poor prognosis and because they often develop
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progressive neurologic dysfunction that would confound the evaluation of
neurologic and other adverse events.
History of allergic reactions attributed to compounds of similar chemical or
biologic composition to metformin.
Uncontrolled intercurrent illness including, but not limited to, ongoing or
active infection, symptomatic congestive heart failure, unstable angina pectoris,
cardiac arrhythmia, or psychiatric illness/social situations that would limit
compliance with study requirements.
Pregnant women are excluded from this study because metformin is an
agent with the potential for teratogenic or abortifacient effects (Category B).
Because there is an unknown but potential risk for adverse events in nursing
infants secondary to treatment of the mother with metformin, breastfeeding
should be discontinued if the mother is treated with metformin.
HIV-positive patients on combination antiretroviral therapy are ineligible
because of the potential for pharmacokinetic interactions with metformin.
Inclusion of Women and Minorities
•

Both men and women of all races and ethnic groups are eligible for this
trial.

•

We shall enroll 50% women in this study as previous census and patient
population data show that this is an appropriate representation of the
state, region, and disease demographic.

•

At least 10% of the sample we include we will recruit will comprise minority
participants. We also plan to enroll at least 40% of our population from
native Appalachians.
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4.4 Registration Procedures
Protocol Review and Monitoring Committee and Institutional Review Board
Review
Before implementing this study, the protocol, the proposed informed
consent form and other information to subjects, must be reviewed by the Markey
Cancer Center’s Protocol Review and Monitoring Committee and the University
of Kentucky Institutional Review Board (IRB). A signed and dated statement that
the protocol and informed consent have been approved by the IRB must be
maintained in the Markey Cancer Center Clinical Research Office (MCC CRO)
regulatory binder. Any amendments to the protocol, other than administrative
ones, must be approved by the study sponsor and the UK IRB.
Enrollment Guidelines
Eligible patients will be identified by the principal investigator and coinvestigators of this study. Potentially eligible patients will be screened in the
University of Kentucky Markey Cancer Center clinics by the investigators, study
personnel, and the Principal Investigator (PI). Upon obtaining proper consent,
patients will be enrolled into the study.
Informed Consent
The goal of the informed consent process is to provide people with
sufficient information so they can make informed choices about whether to begin
or continue participation in clinical research. The process involves a dynamic
and continuing exchange of information between the research team and the
participant throughout the research experience. It includes discussion of the
study’s purpose, research procedures, risks and potential benefits, and the
voluntary nature of participation.
The informed consent document provides a summary of the clinical study
and the individual’s rights as a research participant. The document acts as a
starting point for the necessary exchange of information between the investigator
and potential research participant. Also, research participants and their families
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may use the consent document as an information resource and reference
throughout participation in the trial. The informed consent document is often
considered the foundation of the informed consent process; it does not, however,
represent the entirety of the process. Nor is the informed consent document a
risk-management tool for the investigator and/or institution.
The investigator must explain to each subject (or legally authorized
representative) the nature of the study, its purpose, the procedures involved, the
expected duration, the potential risks and benefits involved and any discomfort it
may entail. Each subject must be informed that participation in the study is
voluntary and that he/she may withdraw from the study at any time and that
withdrawal of consent will not affect his/her subsequent medical treatment or
relationship with the treating physician.
This informed consent should be given by means of a standard written
statement, written in non-technical language. The subject should read and
consider the statement before signing and dating it, and should be given a copy
of the signed document. If the subject cannot read or sign the documents, oral
presentation may be made or signature given by the subject’s legally appointed
representative, if witnessed by a person not involved in the study, mentioning
that the patient could not read or sign the documents. No patient can enter the
study before his/her informed consent has been obtained. The informed consent
form is considered to be part of the protocol, and must be submitted by the
investigator with the protocol at the time of IRB review.
Compliance with Laws and Regulations
The study will be conducted in accordance with U.S. Food and Drug
Administration (FDA) and International Conference on Harmonization (ICH)
Guidelines for Good Clinical Practice (GCP), the Declaration of Helsinki, any
applicable local health authority, and IRB requirements. The PI or designee will
be responsible for obtaining continuing and not less than annual IRB re-approval
throughout the duration of the study. Copies of the Investigator’s annual report to
the IRB and copies of the IRB continuance of approval must maintained by the
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MCC CRO. The PI or designee is also responsible for notifying the Data and
Safety Monitoring Committee of the MCC and the UK IRB of any significant
adverse events that are serious and/or unexpected, as per SOP’s of those
entities.
4.5 Treatment Plan
Enrollment and Screening Process
Prior to any study-required tests, subjects must first provide written
informed consent to participate in this study. All lab tests and radiographic
studies should be completed within 1 week prior to registration/initiation of
treatment. These studies will include, but are not limited to the following:
Complete history, physical examination, and evaluation of Zubrod Performance
Status. Pathological biopsy or cytologically proven colon cancer. CT of the
abdomen and pelvis with contrast or PET/CT Bone scan, only if the patient has
bone pain and/or elevated alkaline phosphatase. CBC; serum chemistry tests to
include alkaline phosphatase, glucose, creatinine, electrolytes, AST (SGOT), and
total bilirubin. All radiographic studies should be completed within 1 week prior to
registration/initiation of treatment.
Agent Administration
Treatment will be administered on an outpatient basis. Reported adverse
events and potential risks are described in Section 7. The patient will discontinue
the study if they experience adverse events during the 14-21 days of treatment
with the research drug. No investigational or commercial agents or therapies
other than those described below may be administered with the intent to treat the
patient’s malignancy. The patients will receive a reminder of their choice (i.e. text
messaging, email, phone call) from the research coordinator. We will also
request that the patient keep either an electronic or hard copy medication diary
to be given to research staff on the day of their scheduled operation. Plasma
obtained in the pre-operative holding area prior to surgery will be analyzed for
presence of Metformin in the patient’s circulatory system. Any patient having a
plasma sample without evidence of the study drug will be excluded from the
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study.
Metformin
Metformin will be supplied by the IDS pharmacy and will be given at a
dose of 850 mg BID for a minimum of 14 days and a maximum of 21 days prior
to surgery. Patients will not receive any prophylactic or supportive care regimens
during the use of this study drug. We will ensure all patients have not had
imaging with contrast studies within one week of starting study drug as this could
significantly impair renal function.
General Concomitant Medication and Supportive Care Guidelines
Metformin is metabolized via hepatic and intestinal CYP3A1/2 and is
renally excreted. Therefore, we anticipate there will be little interaction with
medications that are metabolized by the cytochrome P450 system, but we will
take care to protect patients from drugs with increased renal elimination, most
notably patients undergoing radiographic imaging with renally cleared contrast
dyes. Because there is a potential for interaction of metformin with other
concomitantly administered drugs eliminated through renal secretion, the case
report form must capture the concurrent use of all other drugs, over-the-counter
medications, or alternative therapies. The Principal Investigator should be
alerted if the patient is taking any agent known to affect or with the potential to
affect renal function.
Duration of Therapy
In the absence of treatment delays due to adverse event(s), treatment will
consist of a single 14-21 day period of oral metformin ingestion, followed by
surgical resection of the subject’s colon cancer per institutional standards, or until
one of the following criteria applies:
•

Disease progression

•

Intercurrent illness that prevents further administration of treatment,

•

Unacceptable adverse event(s),
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•

Patient decides to withdraw from the study, or

•

General or specific changes in the patient’s condition render the patient
unacceptable for further treatment in the judgment of the investigator.

Duration of Follow Up
Patients will be followed for 4 weeks after removal from study or until
death, whichever occurs first. Patients removed from study for unacceptable
adverse event(s) will be followed until resolution or stabilization of the adverse
event.
Criteria for Removal from Study
Patients will be removed from study when any of the criteria listed in
Section 5.5 applies. The reason for study removal and the date the patient was
removed must be documented in the Case Report Form.
4.6 Dosing Delays/Dose Modifications
Below are dose modification tables for the following adverse events:
nausea, vomiting, diarrhea, hypoglycemia, renal dysfunction, and hepatic
dysfunction.
Nausea or

Management/Next Dose for Metformin

Vomiting
≤ Grade 1

No change in dose

Grade 2

Hold until ≤ Grade 1. Resume at same dose level.

Grade 3

Off protocol therapy

Grade 4

Off protocol therapy

*Patients requiring a delay of >2 weeks should go off protocol therapy.
**Patients requiring > two dose reductions should go off protocol therapy.
Recommended management: antiemetics.
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Diarrhea

Management/Next Dose for Metformin

≤ Grade 1

No change in dose

Grade 2

Hold until ≤ Grade 1. Resume at same dose level.

Grade 3

Off protocol therapy

Grade 4

Off protocol therapy

*Patients requiring a delay of >2 weeks should go off protocol therapy.
**Patients requiring > two dose reductions should go off protocol therapy.
Recommended management: Loperamide antidiarrheal therapy
Dosage schedule: 4 mg at first onset, followed by 2 mg with each loose motion
until diarrhea-free for 12 hours (maximum dosage: 16 mg/24 hours)

Diarrhea

Management/Next Dose for Metformin

Adjunct anti-diarrheal therapy is permitted and should be recorded when used.

Renal

Management/Next Dose for Metformin

dysfunction
≤ Grade 1

No change in dose

Grade 2

Hold until ≤ Grade 1. Resume at same dose level.

Grade 3

Off protocol therapy.

Grade 4

Off protocol therapy

*Patients requiring a delay of >2 weeks should go off protocol therapy.
**Patients requiring > two dose reductions should go off protocol therapy.
Recommended management: Per NCCN guidelines
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Hepatic

Management/Next Dose for Metformin

dysfunction
≤ Grade 1

No change in dose

Grade 2

Hold until ≤ Grade 1. Resume at same dose level.

Grade 3

Hold* until < Grade 2. Resume at one dose level lower, if
indicated.**

Grade 4

Off protocol therapy

*Patients requiring a delay of >2 weeks should go off protocol therapy.

Hepatic

Management/Next Dose for Metformin

dysfunction
**Patients requiring > two dose reductions should go off protocol therapy.
Insert any recommended management guidelines, if appropriate.

Hypoglycemia

Management/Next Dose for Metformin

≤ Grade 1

No change in dose

Grade 2

Hold until ≤ Grade 1. Resume at same dose level.

Grade 3

Off protocol therapy.

Grade 4

Off protocol therapy

*Patients requiring a delay of >2 weeks should go off protocol therapy.
**Patients requiring > two dose reductions should go off protocol therapy.
Recommended management: antiemetics.
Insert any recommended management guidelines, if appropriate.
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4.7 Adverse Events: List and Reporting Requirements
Adverse event (AE) monitoring and reporting is a routine part of every
clinical trial.
Expected Toxicities
Adverse Events List
Adverse Event List(s) for Metformin
More common
•

Abdominal or stomach discomfort

•

cough or hoarseness

•

decreased appetite

•

diarrhea

•

fast or shallow breathing

•

fever or chills

•

general feeling of discomfort

•

lower back or side pain

•

muscle pain or cramping

•

painful or difficult urination

•

sleepiness
Less common

•

Anxiety

•

blurred vision

•

chest discomfort

•

cold sweats

•

coma

•

confusion

•

cool, pale skin

•

depression

•

difficult or labored breathing

•

dizziness
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•

fast, irregular, pounding, or racing heartbeat or pulse

•

feeling of warmth

•

headache

•

increased hunger

•

increased sweating

•

nausea

•

nervousness

•

nightmares

•

redness of the face, neck, arms, and occasionally, upper chest

•

seizures

•

shakiness

•

shortness of breath

•

slurred speech

•

tightness in the chest

•

unusual tiredness or weakness

•

wheezing
Rare

•

Behavior change similar to being drunk

•

difficulty with concentrating

•

drowsiness

•

lack or loss of strength

•

restless sleep

•

unusual sleepiness
Serious side effects include the following:

•

Renal failure most common in patients with impaired CrCl

•

Lactic acidosis most common in patients with diabetic ketoacidosis or
pre- existing metabolic derangement

Adverse Event List(s) for Other Agent(s) Oral Glucose Tablet?
•
•

Hyperglycemia
Excitability
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Adverse Event Characteristics
•

CTCAE term (AE description) and grade: The descriptions and grading
scales found in the revised NCI Common Terminology Criteria for Adverse
Events (CTCAE) version 4.0 will be utilized for AE reporting. All appropriate
treatment areas should have access to a copy of the CTCAE version 4.0. A
copy of the CTCAE version 4.0 can be downloaded from the CTEP web site:
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.ht.

•

For expedited reporting purposes only:
o aEs for the agent(s) that are listed above should be reported only if the
adverse event varies in nature, intensity or frequency from the expected
toxicity information which is provided.
o Other Aes for the protocol that do not require expedited reporting are
outlined in the next section (Expedited Adverse Event Reporting) under
the sub-heading of Protocol-Specific Expedited Adverse Event Reporting
Exclusions.
§

•

Attribution of the AE:
-

Definite – The AE is clearly related to the study treatment.

-

Probable – The AE is likely related to the study treatment.

-

Possible – The AE may be related to the study treatment.

-

Unlikely – The AE is doubtfully related to the study treatment.

-

Unrelated – The AE is clearly NOT related to the study treatment.

Expedited Adverse Event Reporting

For MCC Investigator-Initiated Trials (IITs), investigators must report to
the Overall PI any serious adverse event (SAE) that occurs after the initial dose
of study treatment, during treatment, or within 30 days of the last dose of
treatment on the local institutional SAE form. This applies to the following
categories:
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•

Grade 3 (severe) Medical Events – Only events that are Unexpected and
Possibly, Probably or Definitely Related / Associated with the Intervention.

•

ALL Grade 4 (life threatening or disabling) Medical Events – Unless
expected AND specifically listed in protocol as not requiring reporting.

•

ALL Grade 5 (fatal) Events regardless of study phase or attribution
Note: If subject is in Long Term Follow Up, death is reported at continuing

review.
Note: Abnormal laboratory values are not considered medical events,
unless determined to be causative of SAE by the investigator or grade 5.
The following table (Table 4.1) outlines the required forms and reporting
structure for clinical trials. Table 4.2 outlines MCC reportable complications.
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Table 4.1 Required forms and reporting structure for clinical trials.
Study

Expedited

Expedited

Non-

type

reporting to

reporting

expedited

MCC

to External

AE

Form

IRB

Agency
IIT where

Grade 3 –

FDA:

OnCore

Mandatory

Yes if it

MCC

Unexpected

Suspected

and

Medwatch

meets the

Investi-

AE PLUS

AE that is

DSMC

3500a for

IRB

gator

Possibly,

serious and

reporting

Serious

reporting

holds the

Probably or

Unanticipat

only

and

require-

IDE or

Definitely

ed (not

unanticipat ments:

IND

Related

listed in IDB

ed

Unantici-

ALL Grade 4

or consent)

OnCore

pated

Unless

for all Aes, Problem

expected

including

and/or

AND listed in

SAEs

Serious AE

protocol as

(use IRB AE

not requiring

reporting

reporting.

form for all

ALL Grade 5

correspond-

(fatal)

dence with

Events

IRB)

IIT by

Grade 3 –

FDA:

OnCore

Voluntary

MCC

Unexpected

Suspected

and

Medwatch

Investi-

AE PLUS

AE that is

DSMC

3500 for

gator of

Possibly,

serious and

reporting

Serious

comer-

Probably or

Unantici-

only

and

cially

Definitely

pated (not

unantici-

available

Related

listed in IDB

pated

agent

ALL Grade 4

or consent)

OnCore
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(non-IND

Unless

for all Aes,

and non-

expected

including

IDE)

AND listed

SAEs

in protocol
as not
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Table 4.2. MCC reportable complications.
Gr. 2 & 3

Gr. 2 & 3

Gr. 5 AE

AE

AE

Gr. 4 AE

Gr. 4 AE

Expected or

Attribution Expected

Unexpected

Expected

Unexpected

Unexpected

Unrelated

Not

Not

5 calendar

5 calendar

Unlikely

required

required

days#

days

Probable

Not

5 calendar

5 calendar

5 calendar

Definite

required

days

days#

days

24 hours*

Possible
24 hours*

# If listed in protocol as expected and not requiring expedited reporting, event
does not need to be reported.
* For participants enrolled and actively participating in the study or for Aes
occurring
Protocol-Specific Expedited Adverse Event Reporting Exclusions for
this protocol only, the Aes/grades listed below do not require expedited reporting
to the Overall PI or the MCC DSMC, however, they still must be reported
through the routine reporting mechanism (i.e. case report form). IRB reporting is
as outlined in IRB SOP: http://www.research.uky.edu/ori/SOPs_Policies/C20350- .
CTCAE

Adverse

SOC

Event

Grade

Hospitalization
/ Prolongation of
Hospitalization
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Attribution

Comments

Expedited Reporting to External Agencies
The Overall PI will comply with the policies of all external funding agencies
and the UK IRB regarding expedited reporting, as per the UK IRB’s SOP:
http://www.research.uky.edu/ori/SOPs_Policies/C4-0150- .
Expedited Reporting to the FDA
The Overall PI, as study sponsor, will be responsible for all
communications with the FDA. The Overall PI will report to the FDA, regardless
of the site of occurrence, any serious adverse event that meets the FDA’s criteria
for expedited reporting following the reporting requirements and timelines set by
the FDA.
Expedited Reporting to Hospital Risk Management
Participating investigators will report to the UK Office of Risk Management
any participant safety reports or sentinel events that require reporting according
to institutional policy.
Routine Adverse Event Reporting
All Adverse Events must be reported in routine study data submissions to
the Overall PI on the OnCore case report forms. Aes reported through expedited
processes (e.g., reported to the IRB, FDA, etc.) must also be reported in routine
study data submissions
4.8 Pharmaceutical Information
Metformin Product description:
Metformin will be dosed in single 850 mg tablets and dispersed to the
patients in a blinded fashion by the clinical research technician. The study drug
will be purchased through the UK-Chandler Pharmacy in Lexington, KY and will
all be pharmaceutical grade medication acceptable for human use.
Solution preparation
The study medication will be prepared in a standard fashion by the UK
Chandler Pharmacy. Please see package insert for details.
118

Route of administration:
Patients will take Metformin 850 mg PO two times per day, Q 12 hours.
We suggest taking medication in an upright position to prevent aspiration and
staying well hydrated while taking the study drug. Patients taking Glucose 10 mg
PO two times per day, Q 12 hours will also be encouraged to maintain an upright
position to prevent aspiration and staying well hydrated while taking the study
drug.
Metformin should be taken with meals to reduce gastrointestinal side
effects. Glucophage can cause lactic acidosis leading to hypoxic states and
impairment of renal function. Metformin should not be administered in pregnant
women and breast feeding mothers unless clearly indicated. Metformin tablet
should be taken as whole without chewing or crushing. Glucophage is not
recommended in patients with active hepatic disease. It is advised to avoid
alcohol intake while on Metformin treatment as alcohol potentiates lactic acidosis.
Agent Ordering:
We will obtain all study drug materials through the UK-Chandler
Pharmacy. All study drugs will be de-identified and labeled in such a fashion that
only the clinical research nurse and the pharmacist will be aware of which study
drug the patient is given. Patient will be given amount of study drug necessary for
treatment up until the night before their surgery. Their medication container will
contain their name, study number, and contact information for the clinical
research nurse.
4.9 Biomarker, Correlative, and Special Studies
Pre-treatment samples will be collected at the colonoscopy suite and
surgical specimens will be retrieved with the pathologist in the pathology suite.
The patient samples will be retrieved immediately and cryopreserved with liquid
nitrogen after diagnostic biopsy during the colonoscopy procedure and the
surgical procedures, respectively. Another portion of the tissues will be collected
in cold 10% formalin and prepared for IHC staining. Our lab as well as our
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collaborator’s lab (Fan) have an extensive background in tissue collection,
cryopreservation, processing, and storage
Biomarker Studies
AMPK analysis by IHC staining
We plan to analyze both the pre and post treatment specimens to
determine phosphorylation changes of AMPK in the Metformin treated
specimens. IHC staining is an established and well characterized technique to
identify and analyze AMPK in both pre-clinical and clinical studies (71, 127, 128).
AMPK is an enzyme that plays a role in cellular energy homeostasis. It is also
acts as an effector of metformin action on glucose uptake in cellular processes
(129). Since Metformin targets AMPK we intend to use it as a primary biomarker
in our study. We anticipate that Metformin treated tissues will show increased
phosphorylation changes in AMPK when compared to specimens not treated
with Metformin. We plan to prepare and stain these tissues in our laboratory at
the Markey Cancer Center and have the resources and equipment to carry out
all procedures (Harris, Gao). We plan to quantify and compare differences in
AMPK phosphorylation with Aperioscope imaging and quantification.
Ki67 analysis by IHC staining
We plan to analyze both the pre and post treatment specimens to
determine the proliferative changes present by comparing and quantifying the
positive staining of Ki67 in the tissues. Ki67 is a nuclear protein that is
associated with and may be necessary for cellular proliferation, and it is also
associated with ribosomal RNA protein transcription (130, 131). There are
multiple pre-clinical and clinical studies supporting the evaluation of Ki67 as a
proliferative marker in tumor biology studies and that it can be accurately
quantified and used as a reliable marker (131, 141). We anticipate that tumor
specimens which have not been exposed to the study drug will have an
increased observance of the staining of Ki67, thus indicating an increase of
proliferation in tissues not exposed to Metformin. We plan to stain all tissues for
this biomarker by the same protocol to maintain consistency and we plan to
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quantify and compare differences in Ki67 staining with Aperioscope imaging and
quantification.
LKB1 analysis by Western blotting
LKB1 is a primary upstream kinase of AMPK and exerts its growth
suppressing effects by activating a group of ~14 other kinases, comprising
AMPK and AMPK- related kinases (48). Activation of AMPK by LKB1
suppresses growth and proliferation when energy and nutrient levels are scarce.
Activation of AMPK- related kinases by LKB1 plays vital roles maintaining cell
polarity thereby inhibiting inappropriate expansion of tumor cells (34). LKB1
leads to disorganization of cell polarity and facilitates tumor growth under
energetically unfavorable conditions (132). We plan to analyze both the pre and
post treatment specimens to determine the presence of LKB1. We anticipate an
increase in LKB1 in the tissues not exposed to Metformin as this kinase which is
upstream of the anticipated target biomarker as it is allows tumor growth in
settings of cellular stress. Western blotting analysis will allow us to study
qualitative data of protein expression related to LKB1.
p-mTOR and phospho-S6K analysis by Western blotting
mTOR and phospho-S6K are both effectors of cell growth and proliferation
via the regulation of protein synthesis in tumor cell growth and metabolism we
intend to analyze with Western blotting. mTOR is a phylogenetically conserved
serine/threonine kinase which is phosphorylated and activated by Akt, but can
also auto phosphorylate when experiencing metabolic stress (133).
Pre-clinical studies have shown that metformin potentiates the effects of
paclitaxel in endometrial cancer cells through inhibition of cell proliferation and
modulation of the mTOR pathway and clinical studies in human tumor xenografts
show that Metformin treatment results in a downregulation of mTOR and
downstream effectors such as pS6K (42, 134). We intend to use Western blotting
analysis to study qualitative data of protein expression related to the mTOR and
pS6K inhibition we expect to observe in Metformin treated tissue specimens.
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ACC analysis by W estern blotting
is produced during the second step of aerobic cellular respiration,
pyruvate decarboxylation, which occurs in the matrix of the mitochondria and its
main function is to convey the carbon atoms within the acetyl group to the citric
acid cycle to be oxidized for energy production. This metabolic molecule is
extremely important in the understanding of cellular metabolism and for this
reason we would like to include it in our qualitative Western blotting analysis
studies. Preclinical data shows that fatty acid oxidation is increased in the
presence of Metformin and downstream effectors involved in fatty acid
metabolism such as ACC and fatty acid synthase (FASN) are increased in
models of cellular stress (23, 106, 135). We anticipate that the Metformin treated
tissues will show an increase in the protein expression of acetyl CoA using
Western blotting analysis.
Genetic studies of surgical specimens
Genetic analysis of all tumor specimens is important as we need to
understand the implications of any genetic differences we find in comparing the
pre and post treatment specimens. We intend to observe mutations for K-ras,
PI3KCA, HNPCC, and MMR, all of which are important genetic mutations in
colon cancer known to effect tumor biology (136-139). It is currently unknown if
or how Metformin treatment changes expression of any of these genetic profiles.
Unfortunately adequate tumor biopsy tissue will not be available in quantity or in
a timely manner in order to stratify patient to a respective treatment arm based
on genetic information, however a post-hoc analysis to determine if there is a
relationship between Metformin and any of these mutations will present novel
and interesting data.
Metabolomic analysis of specimens with NMR and MS
Metabolomic analysis is a new and exciting high throughput analysis
which will allow for rapid progress that will significantly advance the fields of
colon cancer physiology, endocrinology, and metabolism. Ultimately, our findings
will provide insight into the specific mechanisms by which Metformin acts on
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human colon cancer tissues could provide other insights into other novel
avenues of research for drug development in the treatment and control of this
devastating disease. This technology has been utilized by other groups to study
the pharmacokinetics of Metformin and suggest its effect in in vitro studies, but
has yet to be used to study Metformin and/or colon cancer in human tissue
studies (100, 106, 140). Fan et al. has shown that human tissue studies in lung
cancers can be performed using both NMR and MS (92, 94, 97). We anticipate
that tissues treated with Metformin will show decrease levels of glycolysis and
downstream effects of tumor metabolism, but these secondary outcomes will
involve drug and pathway discovery in Metformin and its relationship to colon
cancer.
4.10 Study Calendar
Schedules shown in the Study Calendar (Table 4.3) below are provided as
an example and should be modified as appropriate.
Baseline evaluations are to be conducted within 1 week prior to start of
protocol therapy. Scans and x-rays must be done <4 weeks prior to the start of
therapy. In the event that the patient’s condition is deteriorating, laboratory
evaluations should be repeated within 48 hours prior to initiation of the next
cycle of therapy.
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Table 4.3. Study calendar.
Pre-

Wk.

Wk.

Wk.

Off

Study

1

2

3

Study

A

A

A

Metformin vs Placebo

(if
indicated)
Informed consent

X

Demographics

X

Medical history

X

Concurrent meds

X

Physical exam

X

X

X

Vital signs

X

X

X

Height

X

Weight

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Performance status
CBC w/diff, plts
Serum chemistry

a

EKG (as indicated)

X

Adverse event

X

evaluation
Tumor measurements

X

X

Radiologic evaluation

X

X

B-HCG

X

b

Other tests, as
appropriate
Other correlative
studies
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4.11 Measurement of Effect
This is a pilot study of metformin in the preoperative setting and as such,
is not intended to have a significant cancer therapy effect.
4.12 Data Reporting / Regulatory Requirements
Adverse event lists, guidelines, and instructions for AE reporting can be
found in Section 7.0 (Adverse Events: List and Reporting Requirements).
Data Reporting
This study will require data submission and reporting via the OnCore
Database, which is the official database of the Markey Cancer Center Clinical
Research and Data Management Shared Resource Facility (CRO). Instructions
for submitting data is listed in Study-Specific Data Management Plans created by
CRO staff.
Responsibility for Data Submission
Study staff are responsible for submitting study data and/or data forms to
OnCore as per the Markey Cancer Center CRO SOP’s. This trial will be
monitored by the MCC Data and Safety Monitoring Committee (DSMC) on a
schedule determined by the Protocol Review and Monitoring Committee at the
initial PRMC review. THE CRO staff is responsible for compiling and submitting
data for all participants and for providing the data to the Principal Investigator for
review.
4.13 Statistical Considerations
Study Design/Endpoints
Draft Sample Size Calculation:
Study Design and Sample Size. A (two armed) one-arm trial will be
employed wherein upregulation of AMPK will be compared from pre to posttreatment tissues within the same patient. AMPK will be measured using
standard technique of immunohistochemistry (IHC) tissue staining which is
routinely performed in our lab (Harris, Gao). Changes in quantitatively measured
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AMPK IHC score from pre to post-treatment samples will be evaluated. Using
published data on histoscore of AMPK alpha 2 levels), we will assume that the
mean increase from pre to post-treatment sample will be equal to 75 (SD of the
difference = 125), resulting in a moderate effect size equal to 0.60 (128). A
sample of 26 patients will provide 80% power to detect this effect size based on a
two-sided, nonparametric Wilcoxon signed ranks test with 5% significance level.
In order to account for at most a 10% possibility of unpaired pre and post sample
in a patient, we will enroll a total of 30 patients into the trial.
A secondary, exploratory goal of the study is to compare high-throughput
metabolomics parameters between pre and post treated samples. We assume at
least 3% of metabolites are truly differentially expressed with a 2-fold difference
between pre versus post treatment samples. The standard deviation of
metabolite expression is assumed to be 25% of the mean value based on our
experience. Based on Monte Carlo simulations, a sample of 10 patients (with
matching pre and post specimens) will provide over 80% power to detect
metabolite changes at 5% FDR based on a paired t-test.
Statistical Analysis. Data analysis for quantitative levels of AMPK, Ki-67
and other biomarkers will involve descriptive summaries and graphical
presentations of pre, post-treatment and changes from pre to post evaluations.
Comparisons of changes in biomarker levels will be performed using nonparametric Wilcoxon signed ranks test (or paired t-test, if appropriate).
Correlations between biomarkers will be assessed using measures of correlation
coefficient such as Spearman’s correlation.
Bioinformatics methods including computational processing and statistical
analysis for differential analysis will be employed for the metabolomics studies.
Specifically, before downstream statistical data analysis can begin system
biochemistry and bioinformatics methods will be employed in collaboration with
Dr. Fan and her team. Statistical analysis for the processed metabolite
endpoints will involve pairwise comparisons for each endpoint based on paired ttests as well as general linear and linear mixed models to evaluate kinetics over
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stratification factors.
Interim Analyses
Interim analysis will be performed after 15 patients have been accrued and
relevant data is reviewed. We will ensure there is a difference in our primary
endpoint, phosphorylation, and also determine that all tissues specimens are
being processed and stored appropriately for NMR and MS analysis.
Data Management. The study statistician and staff from the Biostatistics
and Bioinformatics Shared Resource Facility (B2SRF) of the Markey Cancer
Center will work closely with the study PI and the CRO at Markey in the
development of eCRFs for the study. A draft data collection form has been
devised as part of the protocol submission. In addition to the standard eCRF
forms available in Oncore, this draft data collection form will serve as a guide for
development of additional protocol- specific eCRFs in Oncore. Specifically, the
statisticians will attend several meetings including the Protocol Initiation Meeting
(PIM) to address all statistical considerations for this protocol including data
collection forms and database for quantitative assessments of AMPK, Ki-67 and
other biomarkers. The OnCore clinical trial management system, managed by
Markey’s CRO, will be the primary database repository of clinical data from all
patients enrolled into this trial. Data will be accessed by the study statistician on
a regularly-scheduled basis to perform statistical programming for conduct of
data quality control, data management, generation of interim reports and
statistical analysis. The B2SRF has developed an automated mechanism for
generating the interim reports of accrual and safety data. In collaboration with
the study team, procedures will be developed for timelines for data quality
control, resolution of data queries, and final data analysis. Finally, access of the
high-throughput metabolomics data and linkage with the clinical data will be
arranged between the study PI, statistician and Dr. Fan’s study team.
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CHAPTER FIVE: DISCUSSION
5.1 Overview of determined mechanisms of action
The oral anti-diabetic drug metformin is beneficial for at least a subset of
cancer patients, but there continues to be a staunch debate about whether
metformin can directly affect tumor metabolism or if it can actually reduce the risk
of cancer at all (142). The majority of existing data regarding the effect of
metformin on tumorigenesis has focused on breast and prostate cancer. As the
literature is currently lacking data specific to the metabolomic effects of
metformin on combined in vitro, in vivo , and ex vivo data in colon cancers this
prompted us to systematically determine this agent’s specific effects on tumor
cells and tissues in these settings. We carefully designed our experiments to first
evaluate in vitro cellular and molecular mechanisms in multiple and varied colon
cancer cell lines to determine which phenotypes best respond to metformin. We
determined that responsive colon cancer cell lines involve the canonical and
known mechanisms of action involving metformin such as increased
phosphorylation of AMPK and ACC and downregulation of pS6 indirectly through
the PI3K/mTOR pathway. However, we determined that “resistant” cancer cell
lines don’t follow this pattern and participate in adaptive metabolic behaviors to
evade effects of metformin. Our next step was to follow these experiments with
studies to determine the metabolic alterations metformin triggers in certain
cancer cell lines through mitochondrial complex I inhibition. This gave us further
insight into how more aggressive cancer cell lines such as SW480, KM20, and
our newly synthesized PDX evade targeted molecular therapies. Using SIRM
metabolomics and NMR analysis we determined that in cancer cell lines that
evade metformin as a targeted agent tend to preferentially utilize alanine as an
seemingly renewable energy substrate. Determining how and where alanine is
“renewed” is a potential next step with our current hypotheses including that it
may be recycled through additional pyruvate pools or that a high rate of recycling
via the pentose cycle suggests that a significant fraction of cellular NADPH is
generated by the pentose cycle as opposed to generation by the malate-pyruvate
shuttle and this is the actually “additional” energy substrate (143).
128

5.2 The potential impact of metabolomics on preclinical and clinical data
Our next step in determining the specific mechanisms of metformin in
colon cancer was to collect human colon cancer tissues in order to develop truly
translational in vivo and ex vivo models to specifically evaluate aggressive
tumors and use metabolomic analyses to determine how we can potentially
target them. These models maintain their structural and oncogenic integrity
through multiple generations and are reproducible. This provides a realistic
canvas to test new molecular inhibitors and anti-oncogenics on human tissues
without any risk to the patient. Using human tissues in conjunction with SIRM
offers the best opportunity to create novel research models of human colon
cancer that are clinically applicable (92, 144).
Improving our current work with in vitro and in vivo models is paramount to
producing research that is clinically valid and relevant. Many current animal
models used to study colon cancer use quite a variety of species, as well as
methods of oncogenic vector introduction, and even variable doses of drugs with
and without combinations of other therapies that may or may not be effective
(145). As translational researchers we must aim to make tedious and expensive
animal work as clinically relevant as possible (73, 146). However,
xenotransplantation of human tissue into animals requires ethical training and
consideration and clinical and translational scientists must agree to take on the
tremendous responsibility of doing no harm on the bench or at the bedside (147,
148). Long-standing cancer cell lines are still common sources of scientific data
when evaluating colon cancer, and although high throughput metabolomics can
be used for these types of studies, the great power of metabolomic analysis is
that real, human cancer tissues can literally collected at the bedside, the
surgeon’s bedside, and processed and stable isotope labeled within minutes.
Hours to days later scientists, physicians, and surgeons can begin to gather
valuable data that can potentially lead to better tailored therapies for patients in
the form of molecular inhibitors and anti- oncogenic immunomodulators. For
example Jahnke et al. developed a label-free monitoring system to directly
analyze the chemosensitivity of undissociated tumor tissue. Using a preparation
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of tumor micro-fragments (TMF) established from melanoma biopsies, we
characterized the tissue organization and biomarker expression by
immunocytochemistry. Robust generation of TMF was established successfully
and demonstrated on a broad range of primary melanoma tumors and tumor
metastases. Using isolated TMF, sensitivity to six clinically relevant
chemotherapeutic drugs (dacarbazine, doxorubicin, paclitaxel, cisplatin,
gemcitabine, and treosulfan) was determined by impedance spectroscopy in
combination with a unique microcavity array technology we developed. In
parallel, comparative analyses were performed on monolayer tumor cell cultures.
Lastly, we determined the efficacy of chemotherapeutic agents on TMF by
impedance spectroscopy to obtain individual chemosensitivity patterns (149).
5.3 Clinical and Translational Scientists, Cash, and Clinical Trials
Some of the major impediments to these valuable studies are funding,
lack of collaboration between scientists and direct health care providers, and
difficulty design valid clinical trials that will successfully meet accrual while also
assessing relevant primary endpoints (150, 151). Unfortunately, The US is
experiencing a severe shortage of underrepresented biomedical researchers
(152). Even more discouraging, Hu et al. determined Inflation-adjusted NIH
funding for surgical research decreased 19% from $270M in 2003 to $219M in
2013, with a shift from R-awards to U-awards. Proportional funding to outcomes
research almost tripled, while translational research diminished. Nonsurgical
departments have increased NIH application volume over the last 10 years;
however, surgery's application volume has been stagnant. To preserve surgery's
role in innovative research, new efforts are needed to incentivize an increase in
application volume (153). Programs like the Center for Clinical and Translational
Studies and the current T32 grant at the University of Kentucky offer an excellent
opportunity for residents who intend to pursue a career in academia and need
the training and guidance to be part of developing projects and trials that will be
beneficial to patients and cost-effective for funding organizations.
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5.4 Conclusions and Further Directions
In conclusion, we embarked on a project to determine the true mechanism
of action of metformin on colon cancer cells. We determined that metformin
decreases cell proliferation and protein synthesis through the mTOR pathway,
and increases metabolic stress points by the activation of p-AMPK and p-ACC in
certain less aggressive cell lines such as HT29 and HCT116. However,
determining the specific mechanisms of more aggressive and elusive cell lines
like SW480, KM20, and PDX required more investigative work through metabolic
analysis with measurements of OCR and ECAR to determine if and where they
may be mitochondrial complex stress points that could be targeted. We
determined that very aggressive cell lines will seek other energy sources to
continue to grow and live. We used SIRM and 13C-NMR to determine that certain
aggressive colon cancer cell lines evade the glycolytic inducing stress of
metformin by seek renewable energy sources available via the Kreb’s cycle and
potential the pentose phosphate pathway. Also, we determined that metformin
does anti-proliferative effects on human tissues carried in a PDX treated with and
without metformin for a two week period. Finally we have performed initial ex vivo
13

C-glucose labeling of human tissues and with and without metformin and intend

to perform the necessary analysis to determine if the effect in human tissues
mirrors our findings in two aggressive colon cancer cell lines, one that was
developed during my training and offers a solid clinical and translational model of
developing in vitro, in vivo, and ex vivo studies with a single human tissue.
Finally, I hope that additional future directions lead to a continued career
as an academic surgeon with active basic science and clinical and translational
projects throughout my career.

131

APPENDIX A. Institutional Review Board Approval for Gastrointestinal
Tissue Collection Protocol
Background
Gastrointestinal malignancies in the United States are increasing in
incidence, and Kentucky leads the nation in number of colorectal cancer and
pancreatic cancer deaths in both men and women in data from 2004-2008
according to the American Cancer Society. The Center for Disease Control
evaluated cancer rates in Appalachia and determined that the incidence of
gastrointestinal malignancies for this population is even higher than other parts of
the United States. In order to better understand tumor growth and metastasis of
these diseases, we must evaluate tumor metabolism and microenvironments
responsible for the aggressive nature of these processes. Biospecimens and
data collected from cancer patients and people without cancer are paramount to
understanding the metabolic function of these tumors and developing modalities
that can impede or halt their growth. We will use de-identified biospecimens
collected from leftover resected patient tissues for non-human research purposes
to study molecular pathways and signaling related to cancer growth. We also
intend to obtain serum and plasma from these patients prior to the initiation of
their surgical procedure. This protocol describes the methods used to protect
human subjects for Markey Cancer Center (MCC) sponsored/sanctioned
research studies that use biospecimens and data collected from such people. It
details the standard operating procedure we intend to use to consent patients for
biospecimen collection and collection of these specimens by our honest brokers.
Fresh tissue including normal and primary tumor is prospectively collected
in patients already undergoing surgical resection for gastrointestinal malignancy
and inflammatory bowel diseases. Frozen previously banked specimens are also
available. We also intend to collect one total milliliter of serum and plasma in the
pre-operative holding area from the patient prior to surgery. A technician in the
Markey Cancer Center Biospecimen and Tissue Procurement Shared Resource
Facility (MCC BSTP SRF) will act as an honest broker and will provide
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specimens completely de-identified of PHI to Dr. Evers’ lab personnel for nonhuman research purposes. The tissues, serum, and plasma samples collected
will be analyzed by Markey Cancer Center laboratory staff by methods to analyze
tumor metabolism and cellular and molecular signaling. While this research will
not affect the care of the patients providing the samples, their tissues will be used
to better understand mechanisms that contribute to tumor signaling, growth, and
metastasis. We intend to develop methods to slow, or potentially inhibit these
pathways. Better understanding of these pathways and strategies to diminish
them can result in development of treatment options for future patients suffering
with malignancies of the gastrointestinal tract.
Objectives
To obtain bio specimens from an honest broker to perform non-human
research using tissues from surgical specimen while protecting the rights of the
individuals from whom the specimens and information was obtained. Non-human
research experiments will include protein and biomarker analysis using Western
blotting, cell culture, molecular signaling pathway analysis and metabolic
analyses using ELISA (enzyme-linked immunosorbent assay), study of genetic
polymorphisms using PCR (polymerase chain reaction), and genetic and
epigenetic testing using DNA microarrays. Only the biospecimens mentioned in
this protocol will be used for non-human research, and their retrieval will have no
impact on patient treatment or plan of care.
Biospecimens
Tissue including primary tumor and/or nonneoplastic tissue that
automatically comes with the surgical specimen (e.g. mesenteric fat) is
prospectively collected in patients already undergoing resection for
gastrointestinal disease. After the specimen is acquired it will be evaluated by the
pathology department to determine what tissue is necessary and unnecessary for
clinical workup and pathologic staging of the tumor. Fresh (unprocessed) tissue
designated as unnecessary for clinical care will therefore be available for
research, as it represents material in excess of what is needed for clinical care
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and, thus, would otherwise be disposed. Tissues will be stored in solution of
phosphate buffered solution and 20mg/ml fetal bovine serum and deidentified by
Brent Hallahan, both of whom are honest brokers in the MCC BSTP SRF. This
sort of approach to fresh tissue processing by the BSTP has already been
approved by the IRB (protocol 04-0454). The specimens will then be collected by
Evers lab associates.
Regarding the use of already-existing archival formalin-fixed paraffin
embedded material (FFPE) housed in the department of pathology, FFPE tissue
blocks will be obtained from archival clinical material stored in the pathology
department. These are cases that have already been processed, evaluated, and
signed out by an attending pathologist. In most instances, after tissue sections
are cut from such blocks, the remaining FFPE tissue is no longer needed for
patient care. Judging when a given FFPE tissue block is no longer needed will be
the responsibility of Dr. Horbinski, the MCC BSTP SRF Director and a boardcertified anatomic pathologist. Dana Napier, a histotechnician in the MCC BSTP
SRF, will act as an honest broker and will provide FFPE specimens completely
de-identified of PHI to Markey Cancer Center lab personnel for non-human
research purposes.
Patients who also consent to providing serum and plasma biospecimens
under the IRB protocol # 04-0454 will have a blood sample drawn from a
previously placed intravenous catheter at the same time as specimen retrieval
specified in IRB protocol #04-0454. These specimens will not be obtained by
separate venipuncture, fingerstick, heelstick, or earstick. One milliliter of blood
will be aliquoted from the sample drawn for the IRB protocol # 04-0454 for our
purposes and poses minimal risk and discomfort to the patient. After retrieval the
sample will be placed on ice and the honest broker will de-identify the sample
prior to contacting Markey Cancer Center laboratory personnel for biospecimen
retrieval. The de-identified specimen will be given a study code or number and
the laboratory personnel will have no access to patient health information.
Regarding patients who have already consented to tissue collection using
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IRB protocol # 04-0454 we are requesting the ability to retrospectively obtain
plasma and serum samples that are archived in the MCC BSTP SRF. Dana
Napier a histotechnician in the MCC BSTP SRF, will act as an honest broker and
will provide these specimens completely de-identified of PHI to Markey Cancer
Center lab personnel for non-human research purposes.
Data
Honest brokers will be responsible for entering, tracking, and maintaining
the identity of the samples through electronic database tables. For research
purposes, the honest brokers will assign a unique de-identified study code to
each sample. The following data will be collected by the MCC BSTP SRF:
Patient demographics, specimen characteristics, specimen tracking information,
cancer pathology where applicable, cancer registry information (diagnosis,
staging, treatment, survival, historical cancer diagnoses, etc.), patient survey
information, biospecimen analytic results, environmental specimen analytic
results, etc. The information will be stored in database tables that reside on
access-restricted servers managed by the MCC Informatics Shared Resource
Facility (ISRF). Some, but not all database tables may contain PHI. Database
tables will utilize one or more unique identifiers (such as medical record number)
with the associated unique de-identified study code to associate records across
database tables. Database tables may be managed by one or more software
applications such as caTISSUE and custom applications developed by the ISRF.
All computer systems and applications will require authentication through unique
logins and passwords. Computer systems, network, and applications will be
maintained with due diligence to modern security standards. Servers will reside
behind appropriately configured firewalls managed by UK Communications and
monitored by ISRF personnel. Access to patient information will be restricted to
the honest brokers and clinical research personnel who come into contact with
patients prior to their operation for consenting purposes. Only de-identified,
coded or aggregate information will be given to investigators/study personnel by
the honest brokers, and honest brokers will provide laboratory staff with de-
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identified tissue, plasma, or serum specimen. As stated above, the honest
brokers will maintain the identity of the samples through unique identifiers such
as medical record numbers and each sample will be assigned a unique deidentified study code. Study personnel will only obtain samples with the specific,
de-identified study code.
Study population
Biospecimens and data from adult patients of UK Healthcare and MCC
affiliates will be collected. Patients undergoing surgical resection for
gastrointestinal malignancy or inflammatory bowel disease in which the treatment
procedure includes resection of all or portions of visceral fat or mesentery will
meet inclusion criteria for the study. Any archival FFPE tissue from a cancer
patient obtained before 2008 is automatically included, as it is likely that the
individual from whom the tissue was removed is no longer available to give
specific consent. As this represents a repository for future research, its size is not
limited.
Subject recruitment methods and privacy
BSTP employees identify potential donors by monitoring the UK
Healthcare data base for patients undergoing surgery for gastrointestinal
diseases, and who are/will be treated at UK Healthcare or an affiliate health care
provider. They will be asked to participate and will be asked to sign the general
banking protocol consent form (already IRB approved, IRB# 04-0454) For the
use of specimens for existing studies, the possible uses are covered in the
general banking consent form. This consent includes a discussion of the possible
uses and risks for their specimens that adequately inform the subject for the
limited types of existing and future studies of banked specimens that are eligible
to receive specimens. Privacy will be maintained by not providing the specimen
to investigators with any unique patient identifiers.
Informed consent process
Patients will be consented by BSTP-SRF and clinical research personnel
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using the general banking combined consent and authorization form from the
Markey Cancer Center General Specimen Banking Protocol (IRB# 04-0454). A
waiver of informed consent has been requested for the existing FFPE block data
base, serum, and plasma specimens and is requested in this application for the
use of clinical/epidemiologic data.
Research Procedures
This protocol involves obtaining biospecimens that will be used for nonhuman research only. Non-human research experiments will include protein and
biomarker analysis using Western blotting, cell culture, molecular signaling
pathway analysis and metabolic analyses using ELISA (enzyme-linked
immunosorbent assay), study of genetic polymorphisms using PCR (polymerase
chain reaction), and genetic and epigenetic testing using DNA microarrays.
Molecular pathway inhibitors and modulators of genetic and epigenetic
expression will be developed in efforts to learn how to slow down and/or inhibit
the processes that contribute to tumor metabolism and growth. Only leftover
tissues will be used for non-human research, and will have no impact on patient
treatment or plan of care.
Resources
This protocol will utilize physical resources and established operations
within the department of pathology and the BSTP. The department of pathology’s
surgical pathology laboratory will be used to obtain fresh (unprocessed)
specimens from clinical specimens that are not needed for clinical care. Plasma
and serum samples will be collected at the same time as plasma and serum
samples are collected for patients consenting to biospecimen donation using IRB
protocol # 04-0454. Archival FFPE material as well as archived serum and
plasma samples will be obtained from material stored in the pathology
department.
Storage of the biospecimens will follow established procedures. The
material obtained from fresh specimens is available for immediate use or can be
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frozen and stored in the MCC BSTP laboratory for future use. The archival
clinically derived FFPE material is stored in the department of pathology.
Once de-identified tissues are received from the honest broker,
researchers associated with the Evers lab will perform experiments as mentioned
above. Data will be stored within the MCC ISRF. Database tables may be
managed by one or more software applications such as caTISSUE and custom
applications developed by the ISRF. Access to patient information will be
restricted to authorized study, clinical research personnel, MCC biospecimen
core personnel, and ISRF personnel. All computer systems and applications will
require authentication through unique logins and passwords. Computer systems,
network, and applications will be maintained with due diligence to modern
security standards. Servers will reside behind appropriately configured firewalls
managed by UK Communications and monitored by ISRF personnel. Only coded
or aggregate information will be given to investigators. Information will not be
provided using personal identifiers.
Personnel
All key personnel and the individuals acting as honest brokers will have
training in human subject protection. Basic science research personnel
associated with Dr. Evers’ lab will only have contact to the honest broker in order
to obtain the de-identified tissue.
Potential risks
Privacy and confidentiality see data section and request for wavier of
informed consent.
Safety precautions
Use of a unique identifier so that the donor of the specimen/data remains
anonymous to the user of the specimen. Use of hospital or General consent to
confirm intent. Tissue will be retrieved from resected specimens who are involved
in the anticipated surgical specimen with regards to appropriate oncological
margins.
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Benefit vs risk
No direct benefit. Indirect benefit to everyone including subject if
information that leads to more effective ways to prevent, treat or cure cancer are
found. No physical risks as specimen/data are collected as part of routine patient
care. There is a minimal risk of breach or privacy/confidentiality as noted above.
Available alternatives
None.
Research materials
Existing and to be collected material in conjunction with routine patient
care.
Privacy and confidentiality
As noted above all material stored and distributed to investigators using
unique (non-patient) identifiers and an “honest broker” system that isolates the
identity of the source of the material being used for research from the researcher.
All data stored in limited access and password protected manner.
Payment
None
Cost to subject
None
Data and Safety monitoring
By Markey scientific advisory committee. The ultimate responsibility for
oversight of data and specimen handling is the Director of Markey Cancer Center
who is listed as the PI of this application.
Subject Complaints
Subjects may address questions or complaints to Craig Horbinski, MD,
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PhD, The Markey Cancer Center director of research, UK Healthcare customer
service, the UK Hospital ethics committee or the IRB.
Research involving non-English speaking subjects
HIV/AIDS
Not available.
PI- sponsored FDA regulated research
Not available.
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APPENDIX B: Institutional Animal Care and Use Committee Approval for
Patient Derived Xenografts for the Implantation of Human Tissues
USDA Pain Category: D
Preoperative Evaluation: Animals and occupied animal cages should be
placed on a preheated circulating water heating pads set to 90-100F to prevent
hypothermia which can result in slowed metabolism, prolonged induction, and
extended postsurgical recovery times.
Preoperative xenografts preparation: All patient tissues will be handled
with sterile, autoclaved instruments and be processed under a sterile hood.
Patient tissues will be cleansed with Phosphate buffered solution (Sigma) and
2% penicillin/streptomycin (Sigma) and fungizone (LifeSciences). Once cleansed
the tissues will be cut into 5mm pieces and mixed with 100 uL of sterile Matrigel
(BDBiosciences). This tissue/Matrigel mixture will be placed in sterile 1.5mL
microcentrifuge tubes and placed in an opaque container with ice for transport to
the animal facility.
Type of surgery to be performed: Surgical Implantation: Patient derived
xenografts, colon, pancreatic
Is this a Recovery or Non-recovery Type of Surgery: Recovery
Duration of anesthesia/surgery: 15-30 min
Describe pre-op health assessment: Animals will be visually examined
to ensure they are healthy and normally active. Individual animal body weights
will be determined and noted on the pink DLAR Surgery Cards.
Describe use of pre-anesthetic medications: Buprenorphine 0.05-0.1
mg/kg SC (only when using Isoflurane anesthesia).
Operative Anesthesia: Isoflurane (1-4% in O2, inhaled-nosecone)
How will anesthetic depth be measured? Adequate depth of anesthesia
will be assessed by presence of regular steady respirations and absence of a
withdrawal reflex (toe or tail pinch) or corneal reflexes.
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Surgical table, incision site and surgeon preparation: Surgical table,
incision site and surgeon preparation. Standard procedures for rodent survival
surgery will be followed as described in the IACUC Policies, Procedures and
Guidelines on Rodent Surgery. Procedures will be performed in a designated
area of the laboratory specifically prepared in advance for that purpose.
Following induction of anesthesia an artificial tear or ophthalmic ointment is
applied to both eyes. The skin will then be shaved and scrubbed thoroughly with
Povidone iodine or Chlorhexidine solution. The animal’s body temperature will
be maintained with heating pads or lamps, as necessary. The surgeon will wear
a mask and sterile gloves. Instruments will be steam autoclaved prior to use and
sterilized with a glass bead sterilizer between animals. Assurance is made that
the temperature of instruments from the hot bead sterilizer are normalized
before use. The pump will be prepared aseptically.
Support equipment: Isoflurane vaporizer with gas scavenging (if using
isoflurane), recirculating water heating pad(s), and glass bead sterilizer.
Describe surgical procedure Prior to surgery mice will be assessed for
normal activity, inquisitiveness, condition of hair coat, eating, drinking,
defecation, urination, appearance of eyes, breathing rate, gait and bodyweight. If
any abnormal condition is observed, the animal will not be used and the PI or one
of the co-investigators will consult with a DLAR veterinarian.
Adequate anesthesia will be assessed by checking eye blinking, response
to toe pinch, palpebral reflex muscle relaxation, lack of response to incision,
respiratory rate and depth.
If animals respond to any of these, they are not adequately anesthesized
and anesthesia will continue until these signs are absent. Additional isoflurane
will be administered through inhalation for isoflurane (via cone placed over the
animal’s nose and connected via a hose to isoflurane vaporizer) as necessary.
At all times, sterile techniques will be followed. Instruments will be initially
steam sterilized. Between animals, instruments will be rinsed with sterile saline
and heat sterilized (glass bead sterilizer). Two sets of instruments will be used
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alternately in the event that surgery is being performed on >4 animals per day.
Persons performing the surgery will scrub their hands with bactericidal
scrub and wear a clean lab coat, sterile surgical gloves, and a surgical mask.
The surgical table will be disinfected and covered with sterile drapes.
The surgical site(s) (abdominal fossa located caudal to the margin of the
ribcage and ventral to the transverse spinous processes of the lumbar vertebra)
will be shaved in case of SCID mice. The surgical sites will be cleaned with a
Betadine swab stick from the center of the incision to the periphery. This process
will be repeated with 70% alcohol prep pads. Scrubbing will be alternated
between the Betadine and alcohol and repeated at least three times, ending with
the Betadine. The surgical sites will be draped with sterile drapes.
Once the surgical sites have been prepared, disinfected and covered with
a sterile drape, small flank incision just inferior to the scapula will be made using
an 11” blade scalpel. The subcutaneous tissues will be bluntly dissected using a
hemostat. The PDX/matrigel mixture prepared under sterile conditions in the lab
with by introduced into the subcutaneous pocket using sterile large opening
micropipette tips to deposit the PDX. Once the PDX has been deposited the
incision will be closed with a subcuticular 5-0 Vicryl (Ethicon) suture, or wound
clips. The wound will be cleaned with alcohol wipe. Drapes will be removed and
the animal will be allowed to recover from anesthesia.
Reference article for the caecal injection of CRC cells:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2557075/
Post-surgery/anesthetic recovery monitoring plan: Postoperatively,
animals will be placed on warm heating pads and monitored for signs of
recovery, including signs of pain or discomfort (lethargy, hunched position). The
animals’ progress will be monitored daily by members of the Mark Evers lab.
Post- operative animals, will be given buprenorphine (opioid) analgesia 0.1mg/kg
by IP every 12 hours for 48 hours.
As part of our standard post-operative care, mice will be monitored for
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normal grooming behavior, clean coat, clear eyes and normal locomotion and
inquisitiveness. The incisions will be checked for swelling and redness. If the
animals do not appear normal or if problems occur with the incisions, a DLAR
veterinarian will be asked to examine the animal and recommend treatment (or
euthanasia if needed).
Wound Closure: Surgical wounds will be closed with 5.0 Vicryl (Ethicon)
absorbable sutures, or wound clips.
Will post-operative analgesics be administered? Yes
Indicate Post-Operative Medications and Describe Postop Care:
1. Post-operative animals, will be given buprenorphine (opioid) analgesia
0.1mg/kg by IP every 12 hours for 48 hours.
2. A pink DLAR Surgery Card with the date the procedure was performed will be
used to mark cages after surgery. Animals that have had surgery will be
observed daily (5-7 days) by the PI, or a member of the research team, and
the results of observations recorded (e.g. back of pink card). The animals will
be observed with regard to normal activity, inquisitiveness, condition of hair
coat, eating, drinking, defecation, urination, appearance of eyes, breathing
rate, gait, and body condition. The animals will also be evaluated for
vocalization, dehydration, and appearance of the surgical wound (e.g. red
edges, swelling, or exudates), and suture/wound clip displacement. The
cards will be removed after suture/staple removal.
3. Mice will be observed twice weekly for tumor growth and size. Endpoints
requiring sacrifice include decreased range of motion, poor oral intake,
tumors > 2 cm, lethargy, or signs of animal discomfort. Tumors greater than
10% animal body weight will require humane euthanasia.
4. If abnormal conditions are observed, the PI or a co-investigator will consult
with a DLAR veterinarian.
When will sutures/staples be removed? Absorbable sutures. Not
applicable. 10-14 days for wound.
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APPENDIX C: Center for Clinical and Translational Sciences Seed Grant
The metabolomic effects of Metformin on colon cancer in human colon
tissues
Applicant:
Jennifer W. Harris, MD
741 S. Limestone Street, BBSRB
Lexington, KY 40505
Post-doctoral Fellow, Markey Cancer Center
University of Kentucky College of Medicine
(859) 330-0777
jenn.whittington@uky.edu
Immediate Supervisor:
B. Mark Evers, MD
Primary Mentor:
Tianyan Gao, PhD
741 S. Limestone Street
B367 BBSRB
Lexington, KY 40505
Core Support, Markey Cancer Center
University of Kentucky, Department of Molecular and Cellular Biochemistry
(859) 323-3454
Tianyan.gao@uky.edu
Amount requested:
$5,000
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Budget and Budget Justification
Metfomin Metabolomic Study Budget
Incubation and Laboratory Supplies

Cost

Laboratory computer for research nurse

$700

13

$500

C labeled media and supplies

Total cost

Tissue analysis fees
NMR/MS analysis

$2,640

Computational fees

$600

Medication costs
Metformin Hydrochloride

$560

$5,000

Overview:
Funding for this project is requested for 1) equipment to assist in the
record keeping for the clinical research nurse and supplies for tissue
preparation, 2) partial cost of nuclear magnetic resonance imaging (NMR) and
mass spectrometry (MS) for tissue analysis and 3) study drug purchase. This
project will continue enrollment until a maximum of 33 subjects complete one
experiment.
Incubation and Laboratory Supplies:
We are requesting a laptop PC ($700) for the clinical research nurse to
keep all data with patient health information in a secure, password protected
location. We anticipate one year lab costs for basic supplies including 13C
labeled media and tissue preparation supplies to cost ($500). This will result in
$1,200 in cost.
These supplies will be necessary to process tissues collected from the
subjects in our study. The PC will be a one-time purchase and the cost of the
supplies from our current providers has remained static for the past three years.
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Tissue analysis fees:
NMR and MS sample analysis costs forty dollars per hour of sample
analysis. The pair based approach of tissue incubation will result in sixty six total
samples from thirty three patients will result in a cost of $2,640 dollars.
Computational data analysis will cost an additional $600, resulting in a total cost
of $3,240.
Medication costs: The Markey Cancer Center laboratory will purchase all
study medications from a United States retailer, and study medication will be of
pharmaceutical grade and quality as defined by the FDA. Cost of Metformin for
tissue incubation is $76 for 100 gram. We anticipate medication costs for patient
sample incubation to be approximately $560 over the course of the study for
thirty three patients.
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Abstract:
Colon cancer is the third leading cause of cancer mortality worldwide and
is associated with obesity and Type II diabetes (110) (111). Metformin is an FDA
approved oral antidiabetic drug which has also been shown to have anti-cancer
effects (11, 18). The primary anti-tumor molecular target of Metformin is AMPactivated protein kinase (AMPK), a serine/threonine protein kinase (113). AMPK
plays a crucial role in monitoring systemic and cellular energy status and crucial
cellular functions under energy-restricted conditions such as metabolic stress, i.e.
tumor development . Specific downstream mechanisms proposed to be affected
by Metformin’s action on AMPK in colon cancers are i)protein metabolism by the
mammalian target of rapamycin (mTOR) pathway and ii) acetyl co-enzyme A
(ACC) pathway in lipid metabolism (45, 114). Previous studies have shown the
anti-tumor effects of Metformin in breast, prostate, gastric, and pancreatic
cancers (83, 124-126). However, a trial studying the specific metabolic effects of
Metformin in colon cancer has yet to be performed. We propose a novel,
innovative approach studying the metabolic effects of Metformin in colon
cancer tissues using a prospective patient matched tissue pilot study. Our
proposed project is fundamentally different from previous studies using
Metformin since we will use human tissues as opposed to in vitro cell lines or
animal tissues to examine this drug’s anti-oncogenic effects. Furthermore, we will
determine the specific metabolic effects of the drug which contribute to its ability
to target colon cancer cells. This innovative study will provide insight into further
understanding of colon cancer metabolism and novel strategies for targeted
therapies.
Study Personnel:
Jennifer W. Harris, M.D., Principal Investigator, is currently a postdoctoral fellow recipient of a T32 training grant and general surgery resident at
the University of Kentucky. Dr. Harris has considerable experience in human
tissue collection and tissue processing and analysis, as well as treatment of
clinical diseases such as metabolic syndrome and colon and rectal cancers. The
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proposed project is an extension of metabolic studies performed at the University
of Kentucky Markey Cancer Center exploring tumor microenvironment and
signaling in human colon cancers. Dr. Harris’ responsibilities will be to
coordinate clinical study and perform metabolic studies in collaboration with Dr.
Gao and Dr. Fan.
Mark Evers, M.D., Consultant, is currently the director of the Markey
Cancer Center and surgeon at the University of Kentucky. Dr. Evers has an
extensive background in conducting clinical trials and is an expert in cancers of
the gastrointestinal tract. He will serve as a mentor and provide guidance to
assist in coordinating the progression of the study and collaboration of the group
as a whole.
Tianyan Gao, PhD, Co-Investigator, is currently an Associate Professor
in the Department of Cellular and Molecular Biology at the University of
Kentucky. Dr. Gao has an extensive background in conducting protein and
ribonucleic acid analysis which will be necessary for the analysis of patient
samples and cellular data collection. Dr. Gao will assist with specimen analysis
and data interpretation.
Tersea Fan, PhD, Co-Investigator, has a longstanding history in quality
human tissue collection and analysis, and is considering an expert in the field of
isotope labeling of human tissues for metabolic study using nuclear magnetic
resonance imaging and mass spectrometry. Dr. Fan will share her expertise in
our proposed study by assisting us with the use of this state of the art technology
and interpretation of data and results.
Clinical Research Nurse, R.N, B.S.N. required, will be responsible for
ethical registering and consenting patients for the study, obtaining and labeling
study medications for the patients, being on call for patient questions, blinding
the treatment arms to the care providers and patients, and collecting clinical data
on study patients. We plan to interview several clinical research nurses all of
whom have a strong background in human trials at the University of Kentucky for
this position which will offer a stipend to their additional pay.
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Heidi Weiss, PhD, Consultant, is a Professor of Biostatistics at the
University of Kentucky. Dr. Weiss will conduct the data analysis with her
statistical expertise both during and at the conclusion of our proposed study.
Resources and Environment:
Utilizing a multidisciplinary approach with significant surgical and clinical
experience from the Colorectal Surgery Division of General Surgery at University
of Kentucky (Beck, Hourigan, Patel), metabolism and obesity (Fan, Lane,
Higashi), colon cancer treatment/study design (Gao, Evers), and
biostatistics/computational biology (Weiss/Moseley) we plan to develop a patient
matched tissue human pilot study using Metformin as a metabolic
chemotherapeutic agent against colon cancer. Comparing patient matched
samples incubated with and without Metformin we will determine the short-term
effects of Metformin treatment by comparing protein expression of effectors
involved in protein synthesis, tumor cell migration, and tumor metabolism. We will
also use isotope labeling to determine protein and fatty acid metabolism
differences between the pre-treatment and post-treatment samples.
The Markey Cancer Center at the University of Kentucky Medical Center
is a NCI (National Cancer Institute) designated center that provides cutting edge
surgical and medical cancer care to Kentucky and surrounding states. The
endoscopy and surgical services provided at this center have the expertise and
surgical volume to support this trial. A clinical research nurse will be designated
to enroll patients and organize and record of data to ensure the success of this
trial. We have worked closely with the Markey Cancer Center Biospecimen Core
to collect gastrointestinal tissues from surgical patients. Over the past six months
we have enrolled over seventy five percent of patients from whom we requested
consent for tissue collection. We do plan to financially compensate participants
as we are requesting that patients in this study reliably take a study drug for two
weeks. Plasma samples to confirm Metformin use will be drawn in the
preoperative area to ensure usage of drug and study cooperation.
Our laboratory is located in the Biomedical/Biological Sciences Research
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Building and has all of the necessary equipment and supplies we need for tissue
storage, culture, and preparation. We have spent the last year refining our tissue
collection and preparation techniques with assistance from the Markey Cancer
Center Biospecimen Core and lab personnel from the Fan lab to ensure the
appropriate protocol is followed and those samples are ready for metabolomics
analysis. We will work with the Fan lab using state of the art metabolomics
analysis to perform 1D nuclear magnetic resonance (NMR) and gas
chromatography mass spectrometry (GC-MS) to assess the difference between
patient matched samples collected from our study population.
Finally, we plan to work closely with our biostatistician colleagues Heidi
Weiss, PhD and Hunter Moseley, PhD to analyze and interpret the data we
collect for our outlined experiments. Dr. Weiss has an extensive background in
development and data analysis of clinical trials, and Dr. Moseley is an expert in
the analysis and interpretation of metabolomics data.
Specific Aims: Metformin is a safe, low cost, FDA approved drug for the
treatment of type II diabetes mellitus, but has also been shown to have potential
anti-cancer effects (11, 18). Epidemiologic data in human colon cancers
suggests patients taking Metformin for the treatment of diabetes have better
outcomes than their non-diabetic counterparts, which seems counterintuitive as
these patients often have other comorbidities such as obesity which contribute to
less optimal outcomes (67, 121). Both in vitro and in vivo animal data in colon
cancer also suggest Metformin does have an anti-tumor effect, but the direct
metabolic implications of the drug have yet to be determined (122, 123). Thus far
the only human clinical trials have been performed on patients with benign colon
diseases and not colon cancer (154). We are proposing a novel human tissue
pilot study to determine the underlying metabolic effects of Metformin in colon
cancer.
Our central hypothesis is that the predominant role of Metformin in colon
cancer cells is to activate AMPK which has downstream impacts on decreasing
protein metabolism through its effect on Akt/mTOR pathway, and decreasing
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fatty acid metabolism through decreasing ACC and its targeted impact on fatty
acid metabolism. Moreover, we speculate that Metformin’s impact on these
molecular growth factors will inhibit colon cancer cell growth and proliferation,
and may even offer a therapeutic option for patients whom cannot tolerate
aggressive traditional chemotherapy agents. To examine our hypothesis and
achiever our long term goal of better defining the metabolic impact of Metformin
in human colon cancers, we have planned experiments with the following.
Aim 1: To determine the role of Metformin on protein metabolism and
tumor cell proliferation in colon cancer tissues.
Hypothesis: Patient colon cancer tissues treated with Metformin will have
decreased expression of markers indicative of protein metabolism and tumor cell
proliferation compared to samples treated with the placebo condition.
Approach: Surgically resected patient colon cancer tissues will be treated
ex vivo with Metformin. We will use the well-established techniques of Western
blotting and immunohistochemistry staining to evaluate protein metabolism
markers AMPK, Akt, mTOR, and phosphor-S6 ribosomal protein and cell
proliferation marker Ki-67 and markers of fatty acid metabolism such as fatty
acid synthase (FASN).
Impact: This study will establish that tumors in patient tissue samples
treated with Metformin have less growth potential due to a decrease in protein
metabolism and ability to grow and proliferate secondary to the targeted
molecular effects of Metformin.
Aim 2: To delineate the effect of Metformin on cellular metabolism in
human colon cancer tissues.
Hypothesis: Patient tissues treated with Metformin will have altered
cellular metabolism and particularly decreased fatty acid synthesis in evaluated
colon cancer tissues compared to patients treated with the placebo condition.
Approach: We will utilize state of the art metabolomic techniques 13Clabeled NMR and GC-MS to study specific metabolic pathways in patient derived
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colon cancer tissues.
Impact: This patient matched human tissue study will establish that tumors
in patients treated with Metformin are indeed less metabolically active compared
to tissues of patient tissues incubated without Metformin.
To achieve our aims, we have assembled a multidisciplinary team with
significant expertise in colon cancer physiology and function (Harris, Evers,
Gao), metabolism and obesity (Evers, Fan), and biostatistics/computational
biology (Weiss, Moseley). Our highly collaborative team has the requisite
expertise, novel model systems and state-of-the art technology to make rapid
progress that will significantly advance the fields of colon cancer physiology,
endocrinology, and metabolism. Ultimately, our findings will provide insight into
the specific mechanisms by which Metformin acts on human colon cancer
tissues could provide other insights into other novel avenues of research for drug
development in the treatment and control of this devastating disease.
Research Strategy
Significance: Colon cancer is the third leading cause of cancer mortality
worldwide has become increasingly prevalent in Western populations (111). This
devastating disease was the second leading cause of cancer mortality in the
United States in 2008, and is projected to increase in prevalence given its
association a sedentary lifestyle and a high/ low fiber diet (155-157). Obesity and
its associated comorbid conditions have become an increasingly difficult
challenge for healthcare providers worldwide, and in the U.S. adult obesity rates
rose from 14% in 1978 to over 30% in 2000 with over 50% of Americans
projected to be obese in 2030 (158). Obesity and its associated comorbid
conditions, namely Type II diabetes mellitus, are suggested as culprits for
increasing the risk of developing colon cancer, as well as increasing both the
morbidity and mortality of patients who fall victim to this disease (41, 159, 160).
Metformin is an oral antidiabetic drug in the biguanide class and is FDA
approved as the first line drug of choice for the treatment of DMII, but has also
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be shown to have an anti-tumor effect on colon cancer cells in in vitro and animal
studies (123, 161, 162).
Metformin acts through both insulin dependent and insulin independent
pathways and this makes it an attractive option for targeted molecular therapy as
it has the potential to inhibit multiple pathways involved in cancer cell metabolism
(40) The consensus of the published literature agrees that the main effect of
Metformin on tumorigenic cells occurs at the convergence of multiple metabolic
pathways, namely at the molecular activator AMPK which is of paramount
importance as it plays a significant role in how cells respond under metabolic
stress conditions (36, 70, 163, 164). AMPK acts on protein metabolism through
the Akt/mTOR pathway and on fatty acid metabolism through mechanisms
involving ACC (47, 135). Little is known regarding the effect of Metformin on the
nuclear and mitochondrial changes which occur downstream from these
molecular pathways.
Our proposal is significant as we intend to discover these downstream
mechanisms which profoundly affect tumor growth and cancer cell proliferation.
Innovation: Our innovative approach to determine the metabolic impact of
Metformin will involve the analysis of patient tissues using state-of-the-art
approaches. This system combines the use of stable isotope tracers with mass
spectrometry (MS) and nuclear magnetic resonance imaging (NMR) analyses, to
enable robust and global mapping of Metformin’s impact on fatty acid
metabolism, lipid absorption, metabolism, and storage. All of these factors
contribute to a cancer cell’s ability to acquire nutrition and survive under
metabolic stress conditions.
Another novel and innovative detail to our proposal is the design of our
study. Patients will undergo surgical resection of all or part of their colon.
Multiple tissue samples of the tumor will be collected and a portion of the sample
will be incubated in growth media with Metformin while another portion of the
sample will be incubated in growth media without Metformin. We will be able to
create a human tissue pilot study using Metformin in which we compare the
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metabolic effects of the drug on patient matched samples. This approach offers
an innovative qualitative as well as quantitative analysis of the differences in both
patient matched samples as well as samples from patient tissues receiving the
two different study conditions.
Approach: Our work on the in vitro effects of Metformin on colon cancer
cell lines was initially funded by the T32 funding mechanism (Trainee Grant
5T32CA160003-03). We found that there is a considerable difference in the
cellular growth and metabolism of colon cancer cell lines HT29, HCT116,
SW480, and KM20, all of which are colon cancer cell lines derived from human
colon cancers. We also successfully submitted a human gastrointestinal tissue
collection protocol to the University of Kentucky IRB which aims to collect colon
cancer tissues from human patients (IRB# 13-0753-P2H). We were strongly
advised to seek additional funding to explore performing protein analysis and
metabolomic studies on tissues acquired from patients who have colon cancer.
Human tissue pilot study design: Patients seeking treatment at the Markey
Cancer Center who have been recently diagnosed with Stage I- Stage IV colon
cancer will discuss study involvement with the clinical research nurse designated
to the study. Pre-clinical data will be reviewed to determine if the patient has any
of the excluding criteria that would make them ineligible for the study. Exclusion
criteria for the study include the following:
•

Ages < 21 or > 90 years old

•

Stage 0 (carcinoma in situ)

•

Metformin treatment within the past 6 months for any other condition

•

BMI < 18 or > 40

•

Previous malignancies treated with chemotherapy or radiation

•

Surgical intervention at another institution for treatment of colorectal
cancer prior to being treated at University of Kentucky

•

Current pregnancy or breast feeding. If patient becomes pregnant during
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their time in the study they will be removed from the study.
The patient will be enrolled in the study if they agree to informed consent
to provide tissues for analysis. After surgical resection, the patient samples will
be retrieved immediately and either cultured under different conditions ex vivo in
medium or cryopreserved directly in liquid nitrogen. Our lab as well as our
collaborators lab (Fan), have an extensive background in tissue collection,
cryopreservation, processing, and storage (92, 94, 97). According to our power
analysis we need to have a total of thirty three patients in order to adequately be
able to ascertain statistical significance, if any, between the patient matched
samples. The specific analysis of these tissues and the approaches in which we
will successfully complete our proposed aims are discussed in further detail
below.
Specific Aim 1: To determine the role of Metformin on protein metabolism
and tumor cell proliferation in colon cancer tissues.
Metformin acts through insulin dependent mechanisms mainly in the liver,
and this contributes to increased systemic glucose by means of
gluconeogenesis in the liver which releases glucose into the blood stream
(Figure A.1). This effect increases the amount of circulating insulin and
subsequent binding of insulin the insulin receptors on cells in the body. This
cellular stimulation results in increased cellular catabolism and downstream
protein synthesis and cell growth. However, the insulin independent mechanism
of Metformin acts intracellularly and increases the effects of AMPK.
Intracellularly AMPK decreases the cells ability to participate in protein synthesis
in two ways: i) it increases the activity of TSC2 which is a tumor suppressor of
the mTOR complex, and also directly decreases the activity of the mTOR
complex. Increased AMPK activity also decreases the activity of ACC which is
the first gateway of the cell to participate in fatty acid metabolism.
Metformin acts on this pathway in an insulin dependent manner and
results in decreased fatty acid production and subsequent storage. Our intended
experiments after collection of surgical specimen human tissues will use
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Figure A.1. Metformin is an oral antihypoglycemic drug that plays an
important role in regulating cellular metabolism via AMPK and mTOR.
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biochemical and immunological techniques to measure protein expression of
protein synthesis and fatty acid metabolism. Freshly collected tissues will be
incubated in Metformin containing or control medium and cellular lysis will be
performed to isolate protein samples for Western blotting. After cell lysate and
protein isolation, Western blotting will be performed and we will probe for
markers for cell energy utilization such as AMPK, protein synthesis including
mTOR and phospho-S6, as well as markers of fatty acid metabolism such as
ACC and fatty acid synthase (FASN) (44, 165). Alternatively, the treated tissues
can be fixed and prepared as paraffin-embedded tissue blocks. To measure cell
proliferation we will use the standard technique of immunohistochemistry (IHC)
tissue staining which is routinely performed in our lab (Harris, Gao). We will only
evaluate the surgical specimens with IHC as the biopsy samples will not provide
enough tissue to perform the paraffin preparation step required for IHC. We will
probe for a well-known marker of cell proliferation Ki-67, as well as FASN (43).
Statistical considerations for the endpoints of protein metabolism will include
comparisons of pre- and post-treatment tissues, and also comparison of tissues
from patients in the different treatment conditions using both descriptive and
graphical presentations. Similar comparisons comparing qualitative data for IHC
will include a comparison of patient tissues after different treatment conditions to
asses for changes in markers indicating decreased cell proliferation. We will
quantify the number of cells stained with the respective markers and perform a
two tailed t-test comparing the expression of cell proliferation markers in the two
groups (Weiss).
Anticipated results, potential problems, and alternative solutions:
There will be a decrease in protein synthesis and fatty acid metabolism
markers in the Metformin treated tissues compared to those not treated with
Metformin.
Potential problems could include loss of sample due to inappropriate
tissue preparation or errors in performing Western blotting. To prevent either of
these problems we will only allow experience technicians to process samples
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and perform Western blotting. We anticipate IHC staining results will show that
post treatment samples will have a decreased expression of Ki67 and FASN.
One potential limitation is that the surgically resected tissues may undergo
apoptosis during the ex vivo treatment period. We will monitor the level of
apoptosis by analyzing the expression of apoptosis markers such as cleaved
caspase 3 to make sure that tissues are mostly viable after the control treatment.
We are currently conducting pilot experiments using mouse colon tissues to
determine the optimal incubation time needed. Our experiments with human
tissues will be adjusted accordingly.
Specific Aim 2: To delineate the effect of Metformin on cellular metabolism
in human colon cancer tissues.
It is well established in the colon cancer literature that an increase in fatty
acid metabolism and fatty acid production promotes the growth of colon cancer
cells by increasing the activity of ACC and its downstream effectors (166-168).
Previous authors have also shown Metformin impacts fatty acid
metabolism in vitro and in animal models, but the literature lacks evidence of
these effects actually being present in humans and there have only been
analyses to evaluate protein and nuclear markers (23, 50, 169). We are also
interested in detecting any global alteration in cellular metabolism (e.g. Increased
TCA cycle activity) upon Metformin treatment. Our intended experiments after
collection of the surgical specimen human tissues will use similar techniques to
measure protein expression of protein synthesis and fatty acid metabolism. To
label freshly collected tissues, mucosal slices will be incubated with 13C-glucose
containing medium for 24 hours and processed as described previously. SIRM
analysis will be performed by a combination of NMR, Gas chromatography-mass
spectrometry (GC-MS), and Fourier transform mass spectrometry (FT-MS) (92).
Our co-investigator has over twenty years of experience with this technique and
equipment (Fan). The extent of 13C-labeling lipid precursors in both treatment
groups of patient matched samples, including glycerol-3-phosphate and citrate,
will be obtained from GS-MS analysis while intact triglycerides, phospholipids,
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and fatty acids will be acquired from FT-MS analysis (Figure A.2). Based on
these

13

C-labeled enrichment patterns of lipids in Metformin treated and non-

treated human patient matched colon cancer samples and their precursors, the
dynamics of colon cancer cells and their de novo fatty acid and lipid synthesis
pathways in the two treatment groups will be compared, thus delineating if
Metformin treatment does indeed affect de novo fatty acid and lipid synthesis.
Labeling the tissues and using this advanced technology will tell us exactly when
and where in the Krebs cycle these metabolic changes are taking place.
Statistical analysis will include using two sample t-tests with Hochberg’s pvalue adjustment due to the simultaneous testing of multiple metabolites.
Software simulation will be performed 1000 times to determine the sample size
that will provide adequate statistical power to detect the hypothesized difference
between treatment groups with control of family-wise error rate. Statistical
analysis for the processed endpoints from the fatty acid synthesis and fatty acid
oxidation studies will involve pairwise comparisons for each treatment condition,
each pair matched sample, and time points of software analysis. Linear and
mixed models to evaluate metabolic kinetics will be measured. Multivariate
statistical analyses will be used for the discovery of non-targeted metabolic
changes.
Anticipated results, potential problems, and alternative solutions:
We anticipate that there will be a decrease in fatty acid synthesis in
Metformin treated patient tissues compared to their matched non-treated
specimens. In addition, we expect to detect various metabolic alterations
associated with metformin treatment. We do not anticipate problems with tissue
collection or processing, nor do we anticipate problems with profiling the lipid
and polar metabolites including their 13C-labeling patterns using in-house tools
established in the metabolomics center at the University of Kentucky through
collaboration with Dr. Fan. Dr. Weiss, our biostatistics collaborator will perform
multivariate statistical analysis for discerning non-targeted metabolic changes
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A

B

Figure A.2. NMR and GC-MS analyses.
(A) NMR analysis. Expected 13C-positional isotopomer patterns of glycolytic and
Krebs cycle metabolites synthesized from [U-13C]-Glc by mammalian cells (Fan
et al.); (B) GC-MS analysis. Each 1H peak arose from protons directly attached
to 13C and the peak assignment denotes the 13C-carbon. Thus, the peak intensity
reflects 13C abundance of the attached carbon (Fan et al.).
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from the very large metabolomics datasets for any unexpected but meaningful
metabolic signature associated with AMPK or ACC manipulation. This is the
value of the metabolomics approach for discovery of new functional links for
signaling pathways.
Training Plan:
1. Training expectations associated with research
The funds we are requesting through the CCTS Seed grant will be applied
to this study by providing materials for data collection and analysis, as well as
tissue sample analysis and study medication. These funds will specifically cover
the expenses of the most translational aspects of this novel and innovative
study. As post-doctoral fellow/surgical resident who is interested in oncology this
project literally takes a novel idea from the bench to the bedside, involves patient
intervention in the clinical, pre-operative, and surgical setting, and brings the
tissues they generously provide for bedside to bench research. This approach
embodies the heart of clinical and translational science and the use of NMR and
GC-MS metabolomics analysis is an elegant method of elucidating information
that will significant advance this topic in the surgical and oncology literature.
2. Plan for meeting these expectations
We will obtain both IRB approval as well as approval from the Markey
Cancer Center Clinical Trial Board to conduct this project. We anticipate starting
patient enrollment and tissue collection in October 2014 and concluding
enrollment and tissue collection in April 2015. Funds provided by the CCTS
Seed grant will be applied to the project as outlined in the proposal by funding
supplies for tissue collection and preparation, a computer for the clinical
research nurse, and human patient sample analysis. We plan to complete tissue
and data analysis in May 2015 and begin work on our findings and a manuscript
in June 2015.
3. Objective criteria for meeting these criteria
The data and safety monitoring board will meet monthly and discuss data
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collection, monitoring, and any adverse events. At these bi-monthly meetings the
board will confirm the following criteria:
•

patient enrollment is meeting its proposed trajectory and is documented
correctly

•

patient data is satisfactorily being collected and protected by the clinical
research nurse

•

tissues are being collected in a timely manner and being appropriately
prepared for analysis

•

data and data analysis is shared with the board as it is collected at each
meeting

4. Schedule of meetings with applicant and primary mentor
The applicant already has scheduled weekly meetings with the primary
mentor, Dr. Gao and scheduled bi-weekly meetings with the immediate
supervisor, Dr. Evers. These meetings can be recorded and all parties can sign
a document that can be copied and recorded for the records of the data and
safety monitoring board, as well as the CCTS.
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